

# NHS Greater Glasgow and Clyde: New Medicines Decisions

## January 2016 to present

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHS Scotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and preferences.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultation with healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines included and these are consistent across the health board.

## How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

### What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland
  - how well the medicine works,
  - which patients might benefit from it,
  - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
  - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence (NICE) Medicines Topic Appraisals (NICE MTAs) are applicable in Scotland.

### What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

### Why is a particular medicine not routinely available in NHSGG&C?

- This is usually because the medicine is not recommended for use in NHS Scotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.

| Medicine                                                                       | Condition being treated                                                                                                                                                                      | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Fenfluramine</b><br><br>Fintepla<br><br>SMC2569                             | For the treatment of seizures associated with Dravet syndrome as an add-on to other anti-epileptic medicines for patients 2 years of age and older.                                          | Routinely available in line with local or regional guidance       | 09/10/2023       |
| <b>5-aminolaevulinic acid</b><br><br>Ameluz®<br><br>1260/17                    | Treatment of superficial and / or nodular basal cell carcinoma (BCC) unsuitable for surgical treatment due to possible treatment-related morbidity and / or poor cosmetic outcome in adults. | Not routinely available as not recommended for use in NHSScotland | 28/08/2017       |
| <b>5-aminolaevulinic acid (as hydrochloride)</b><br><br>Ameluz®<br><br>1260/17 | Treatment of superficial and / or nodular basal cell carcinoma (BCC) unsuitable for surgical treatment due to possible treatment-related morbidity and / or poor cosmetic outcome in adults. | Routinely available in line with national guidance                | 26/02/2018       |
| <b>5-aminolevulinic acid</b><br><br>Alacare®<br><br>SMC2353                    | Single use treatment of mild actinic keratoses lesions with a maximum diameter of 1.8 cm on the face and scalp (hairless areas).                                                             | Routinely available in line with national guidance                | 14/06/2021       |

| Medicine                                                           | Condition being treated                                                                                                                                                                                                                                                                                                          | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>abaloparatide</b><br><br>Eladynos®<br><br>SMC2764               | Treatment of osteoporosis in postmenopausal women at increased risk of fracture.                                                                                                                                                                                                                                                 | Routinely available in line with national guidance                | 18/08/2025       |
| <b>Abatacept</b><br><br>Orencia®<br><br>1287/17                    | Alone or in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy including methotrexate has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required. | Not routinely available as not recommended for use in NHSScotland | 11/12/2017       |
| <b>Abatacept</b><br><br>Orencia®<br><br>1230/17                    | Treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.                                                                                                                                                                                         | Not routinely available as not recommended for use in NHSScotland | 24/04/2017       |
| <b>Abatacept, Adalimumab, Etanercept, Tocilizumab</b><br><br>TA373 | Juvenile idiopathic arthritis - various licences with differing age limits                                                                                                                                                                                                                                                       | Routinely available in line with national guidance                | 22/02/2016       |

| Medicine                                            | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                          | NHSGGC Decision                                                | Date of decision |
|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------------------|
| <b>Abemaciclib</b><br><br>Verzenios®<br><br>SMC2494 | in combination with endocrine therapy for the<br>0 adjuvant treatment of adult patients with hormone<br>receptor (HR)-positive, human epidermal growth<br>factor receptor 2 (HER2)-negative, node-positive<br>early breast cancer at high risk of recurrence. In<br>pre- or perimenopausal women, aromatase<br>inhibitor endocrine therapy should be combined<br>with a luteinising hormone-releasing hormone<br>(LHRH) agonist. | Routinely available in line with local<br>or regional guidance | 12/12/2022       |
| <b>Abemaciclib</b><br><br>Verzenios®<br><br>SMC2135 | Treatment of women with hormone receptor (HR)<br>0 positive, human epidermal growth factor receptor 2<br>(HER2) negative locally advanced or metastatic<br>breast cancer in combination with an aromatase<br>inhibitor* as initial endocrine-based therapy, or in<br>women who have received prior endocrine therapy.                                                                                                            | Routinely available in line with local<br>or regional guidance | 10/06/2019       |
| <b>Abemaciclib</b><br><br>Verzenios®<br><br>SMC2179 | Treatment of women with hormone receptor (HR)<br>0 positive, human epidermal growth factor receptor 2<br>(HER2) negative locally advanced or metastatic<br>breast cancer in combination with fulvestrant* as<br>initial endocrine-based therapy or in women who<br>have received prior endocrine therapy.                                                                                                                        | Routinely available in line with local<br>or regional guidance | 10/06/2019       |
| <b>Abiraterone</b><br><br><br>NCMAG110              | Abiraterone acetate plus prednisolone in<br>0 combination with androgen deprivation therapy for<br>the treatment for newly diagnosed low-risk<br>metastatic hormone-sensitive prostate cancer<br>patients who are not suitable for currently<br>accessible on-label alternatives.                                                                                                                                                | Routinely available in line with local<br>or regional guidance | 21/08/2023       |

| Medicine                                                 | Condition being treated                                                                                                                                                                                        | NHSGGC Decision                                                               | Date of decision |
|----------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|------------------|
| <b>Abiraterone</b><br><br>Zytiga<br><br>NCMAG101         | Proposed off-label use: High-risk hormone-sensitive non-metastatic cancer: 2 years of abiraterone with radical radiotherapy to the prostate and 3 years of androgen deprivation therapy (ADT)                  | Not routinely available as not recommended for use in NHSScotland             | 15/08/2022       |
| <b>Abiraterone</b><br><br>NCMAG102                       | Abiraterone acetate plus prednisolone in combination with androgen deprivation therapy for the treatment of high-risk hormone-sensitive non-metastatic prostate cancer (off-label use)                         | Routinely available in line with local or regional guidance<br><br>21/08/2023 | 24/04/2023       |
| <b>Abiraterone acetate</b><br><br>Zytiga®<br><br>SMC2215 | Abiraterone acetate with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer in adult men in combination with androgen deprivation therapy. | Routinely available in line with local or regional guidance                   | 24/02/2020       |
| <b>Abrocitinib</b><br><br>Cibinqo®<br><br>SMC2431        | Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.                                                                        | Routinely available in line with national guidance                            | 13/06/2022       |

| Medicine                                                                                                                                                                                                                                        | Condition being treated                                                                                                                                                                                                                             | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Acalabrutinib</b><br><br>Calquence®<br><br>SMC2348                                                                                                                                                                                           | 0 Monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.                                                                                                            | Routinely available in line with local or regional guidance       | 19/04/2021       |
| <b>Acalabrutinib</b><br><br>Calquence®<br><br>SMC2346                                                                                                                                                                                           | 0 Monotherapy or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).                                                                                                | Routinely available in line with local or regional guidance       | 19/04/2021       |
| <b>Acalabrutinib</b><br><br>Calquence®<br><br>SMC2347                                                                                                                                                                                           | 0 Monotherapy or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).                                                                                                | Routinely available in line with local or regional guidance       | 14/06/2021       |
| <b>Adalimumab</b><br><br>Humira®<br><br>1209/16                                                                                                                                                                                                 | 0 Treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. | Not routinely available as not recommended for use in NHSScotland | 12/12/2016       |
| <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1209_16_adalimumab_Humira/adalimumab_Humira_Non_submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1209_16_adalimumab_Humira/adalimumab_Humira_Non_submission</a> |                                                                                                                                                                                                                                                     |                                                                   |                  |

| Medicine                                        | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Adalimumab</b><br><br>Humira®<br><br>1143/16 | 0 Treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy.                                                                                                                                                                                                                                                                                                                                                                                                   | Routinely available in line with national guidance                | 13/06/2016       |
| <b>Adalimumab</b><br><br>Humira®<br><br>1208/16 | 0 Treatment of moderately active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1208_16_adalimumab_Humira/adalimumab_Humira_Non-submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1208_16_adalimumab_Humira/adalimumab_Humira_Non-submission</a> | Not routinely available as not recommended for use in NHSScotland | 12/12/2016       |
| <b>Adalimumab</b><br><br>Humira®<br><br>1243/17 | 0 Treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/adalimumab_Humira_Abbreviated_FINAL_May_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/adalimumab_Humira_Abbreviated_FINAL_May_2017_for_website.pdf</a>                                                                                                                                | Routinely available in line with national guidance                | 23/10/2017       |
| <b>Adalimumab</b><br><br>Humira®<br><br>1305/18 | 0 Treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/adalimumab_Humira_Non_Sub_FINAL_Dec_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/adalimumab_Humira_Non_Sub_FINAL_Dec_2017_for_website.pdf</a>                                                                                             | Not routinely available as not recommended for use in NHSScotland | 26/02/2018       |

| Medicine                                                                      | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                            | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Adalimumab</b><br><br>Humira®<br><br>1173/16                               | 0<br>Treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. (This licence extension relates to previous SMC advice (468/08).<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1173_16_adalimumab_Humira/adalimumab_Humira">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1173_16_adalimumab_Humira/adalimumab_Humira</a> | Not routinely available as not recommended for use in NHSScotland | 22/08/2016       |
| <b>Adalimumab, dexamethasone intravitreal implant</b><br><br>0<br><br>MTA 460 | 0<br>Non-infectious uveitis<br><br><a href="https://www.nice.org.uk/Guidance/TA460">https://www.nice.org.uk/Guidance/TA460</a>                                                                                                                                                                                                                                                                                     | Routinely available in line with national guidance                | 23/10/2017       |
| <b>Adalimumab, Etanercept, Infliximab, Abatacept</b><br><br>NICE TA715        | 0<br>Treatment of moderate arthritis after conventional DMARDs have failed.                                                                                                                                                                                                                                                                                                                                        | Routinely available in line with national guidance                | 13/12/2021       |



| Medicine                                   | Condition being treated                                                                                                                                                                                                                                                                                 | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Adalimumab, Etanercept, Ustekinumab</b> | plaque psoriasis in children and young people<br>0                                                                                                                                                                                                                                                      | Routinely available in line with national guidance                | 23/10/2017       |
| MTA 455                                    | <a href="https://www.nice.org.uk/guidance/ta455/resources/adalimumab-etanercept-and-ustekinumab-for-treating-plaque-psoriasis-in-children-and-young-p">https://www.nice.org.uk/guidance/ta455/resources/adalimumab-etanercept-and-ustekinumab-for-treating-plaque-psoriasis-in-children-and-young-p</a> |                                                                   |                  |
| <b>Afamelanotide</b>                       | Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).<br>0                                                                                                                                                                                                            | Routinely available in line with national guidance                | 19/04/2021       |
| Scenesse®                                  |                                                                                                                                                                                                                                                                                                         |                                                                   |                  |
| 1251/17                                    |                                                                                                                                                                                                                                                                                                         |                                                                   |                  |
| <b>Afatinib</b>                            | As monotherapy for the treatment of locally advanced or metastatic non small cell lung cancer of squamous histology progressing on or after platinum-based chemotherapy.<br>0                                                                                                                           | Not routinely available as not recommended for use in NHSScotland | 22/08/2016       |
| Giotrif®                                   |                                                                                                                                                                                                                                                                                                         |                                                                   |                  |
| 1174/16                                    | <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1174_16_afatinib_Giotrif/afatinib_Giotrif">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1174_16_afatinib_Giotrif/afatinib_Giotrif</a>                                                                                           |                                                                   |                  |
| <b>Aflibercept</b>                         | In preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease.<br>0                                                                                                               | Not routinely available as not recommended for use in NHSScotland | 21/08/2023       |
| Eylea®                                     |                                                                                                                                                                                                                                                                                                         |                                                                   |                  |
| SMC2612                                    |                                                                                                                                                                                                                                                                                                         |                                                                   |                  |

| Medicine           | Condition being treated                                                                                                                                                                                                                                     | NHSGGC Decision                                             | Date of decision |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Aflibercept</b> | For adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV).                                                                                                                                                  | Routinely available in line with national guidance          | 10/10/2016       |
| Eylea®             |                                                                                                                                                                                                                                                             |                                                             |                  |
| 1186/16            |                                                                                                                                                                                                                                                             |                                                             |                  |
|                    | <a href="http://www.scottishmedicines.org.uk/files/advice/aflibercept_Eylea_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/aflibercept_Eylea_FINAL_Sept_2016_for_website.pdf</a>                                         |                                                             |                  |
| <b>Abiglutide</b>  | Treatment of type 2 diabetes mellitus in adults to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. | Routinely available in line with national guidance          | 22/02/2016       |
| Eperzan®           |                                                                                                                                                                                                                                                             |                                                             |                  |
| 1024/15            |                                                                                                                                                                                                                                                             |                                                             |                  |
| <b>Alectinib</b>   | As monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).                                                                                                   | Routinely available in line with local or regional guidance | 13/08/2018       |
| Alecensa®          |                                                                                                                                                                                                                                                             |                                                             |                  |
| 2012               |                                                                                                                                                                                                                                                             |                                                             |                  |
|                    | <a href="https://www.scottishmedicines.org.uk/media/3645/alectinib-hydrochloride-alecensa-final-july-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3645/alectinib-hydrochloride-alecensa-final-july-2018-for-website.pdf</a>             |                                                             |                  |
| <b>alectinib</b>   | Monotherapy as adjuvant treatment for adult patients with Stage IB (tumours ≥ 4 cm) to IIIA (7th edition of the UICC/AJCC-staging system) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) following complete tumour resection. | Routinely available in line with local or regional guidance | 18/08/2025       |
| Alecensa®          |                                                                                                                                                                                                                                                             |                                                             |                  |
| SMC2749            |                                                                                                                                                                                                                                                             |                                                             |                  |



| Medicine                                          | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | NHSGGC Decision                                                               | Date of decision |
|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|------------------|
| <b>Alirocumab</b><br><br>Praluent®<br><br>SMC2201 | In adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:<br>- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or, alone<br>- or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.                                                                                                                                                                                                                                 | Not routinely available as not recommended for use in NHSScotland             | 10/06/2019       |
| <b>Alirocumab</b><br><br>Praluent®<br><br>1147/16 | adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1147_16_alirocumab_Praluent/alirocumab_Praluent">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1147_16_alirocumab_Praluent/alirocumab_Praluent</a> | Routinely available in line with local or regional guidance<br><br>10/10/2016 | 12/12/2016       |
| <b>Alpelisib</b><br><br>Piqray®<br><br>SMC2481    | In combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine-based therapy.                                                                                                                                                                                                                                                                                                                                                              | Not routinely available as not recommended for use in NHSScotland             | 12/12/2022       |

| Medicine                                            | Condition being treated                                                                                                                                                                                                                                                                                                      | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Alpelisib</b><br><br>Piqray®<br><br>SMC2339      | In combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy. | Not routinely available as not recommended for use in NHSScotland | 19/04/2021       |
| <b>Amikacin</b><br><br>Arikayce®<br><br>SMC2432     | Treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.                                                                                                                                       | Routinely available in line with national guidance                | 13/12/2021       |
| <b>Amikacin</b><br><br>Arikayce®<br><br>SMC2369     | Treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.                                                                                                                                       | Not routinely available as not recommended for use in NHSScotland | 18/10/2021       |
| <b>amivantamab</b><br><br>Rybrevant®<br><br>SMC2758 | In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon20 insertion mutations.                                                                                           | Not routinely available as not recommended for use in NHSScotland | 18/08/2025       |

| Medicine                                            | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>amivantamab</b><br><br>Rybrevant®<br><br>SMC2368 | 0 Monotherapy for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.                                                                                                                                                                                                                                                                                                                                | Not routinely available as not recommended for use in NHSScotland | 11/12/2023       |
| <b>amivantamab</b><br><br>Rybrevant®<br><br>SMC2768 | 0 In combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).                                                                                                                                                                                                                                                                                                                    | Not routinely available as not recommended for use in NHSScotland | 28/04/2025       |
| <b>Anakinra</b><br><br>Kineret®<br><br>SMC2104      | 0 In adults, adolescents, children and infants aged eight months and older with a body weight of 10kg or above for the treatment of Still's disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. Anakinra can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying anti-rheumatic drugs (DMARDs). | Routinely available in line with national guidance                | 08/10/2018       |

| Medicine                                              | Condition being treated                                                                                                                                                                     | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|-------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Anakinra</b><br><br>Kineret®<br><br>SMC2449        | Treatment of Familial Mediterranean Fever (FMF).<br>0 Kineret should be given in combination with colchicine, if appropriate.                                                               | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 13/12/2021       |
| <b>anastrozole</b><br><br>NCMAG113                    | 0 primary prevention of breast cancer in post-menopausal people at moderate or high risk                                                                                                    | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>25/08/2025 | 28/04/2025       |
| <b>Andexanet alfa</b><br><br>Ondexxya®<br><br>SMC2273 | 0 For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. | Routinely available in line with local or regional guidance                                                                                                                           | 31/08/2020       |
| <b>Apalutamide</b><br><br>Erleada®<br><br>SMC2472     | 0 Treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).                                                     | Routinely available in line with local or regional guidance                                                                                                                           | 10/10/2022       |

| Medicine                                          | Condition being treated                                                                                                                                | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>apalutamide</b><br><br>Erleada®<br><br>SMC2579 | In adults for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.     | Routinely available in line with local or regional guidance       | 21/08/2023       |
| <b>Apalutamide</b><br><br>Erleada®<br><br>SMC2268 | In adult men for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC) who are at high risk of developing metastatic disease. | Not routinely available as not recommended for use in NHSScotland | 24/02/2020       |
| <b>Apalutamide</b><br><br>Erleada®<br><br>SMC2323 | In adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy.               | Not routinely available as not recommended for use in NHSScotland | 19/04/2021       |
| <b>Apremilast</b><br><br>Otezla®<br><br>SMC2340   | Treatment of adult patients with oral ulcers associated with Behçet's disease who are candidates for systemic therapy                                  | Not routinely available as not recommended for use in NHSScotland | 19/04/2021       |



| Medicine                                                | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | NHSGGC Decision                                             | Date of decision |
|---------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Aprepitant</b><br><br>Emend<br><br>1252/17           | As part of combination therapy, for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy in children, toddlers and infants from the age of six months to <12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules).<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/aprepitant_Emend_Abbreviated_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/aprepitant_Emend_Abbreviated_FINAL_June_2017_for_website.pdf</a>                                                                     | Routinely available in line with local or regional guidance | 23/10/2017       |
| <b>Aprepitant</b><br><br>Emend®<br><br>1241/17          | As part of combination therapy, for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in infants, toddlers and children from the age of six months to less than 12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules). Aprepitant is given as part of combination therapy<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/aprepitant_Emend_FINAL_May_2017_Amended_060617_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/aprepitant_Emend_FINAL_May_2017_Amended_060617_for_website.pdf</a> | Routinely available in line with local or regional guidance | 23/10/2017       |
| <b>Arsenic trioxide</b><br><br>Trisenox®<br><br>SMC2181 | In combination with all-trans-retinoic acid (ATRA [tretinoin]) for the induction of remission, and consolidation in adult patients with newly diagnosed, low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count $\leq 10 \times 10^3/\mu\text{l}$ ), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene.                                                                                                                                                                             | Routinely available in line with local or regional guidance | 12/08/2019       |

| Medicine                                                | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Arsenic trioxide</b><br><br>Trisenox®<br><br>SMC2025 | In combination with all-trans-retinoic acid (ATRA [tretinoin]) for the induction of remission, and consolidation in adult patients with newly diagnosed, low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, $\leq 10 \times 10^3/\mu\text{l}$ ), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene. | Not routinely available as not recommended for use in NHSScotland | 25/02/2019       |
| <b>Asciminib</b><br><br>Scemblix®<br><br>SMC2482        | Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibitors (TKIs), and without a known T315I mutation.                                                                                                                                                                                                                  | Routinely available in line with local or regional guidance       | 12/12/2022       |
| <b>Asfotase alfa</b><br><br>Strensiq®<br><br>SMC2433    | Long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease                                                                                                                                                                                                                                                                                                                | Not routinely available as not recommended for use in NHSScotland | 13/12/2021       |

| Medicine                                                                               | Condition being treated                                                                                                                                                                                                                                                                                                                                                | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Asparaginase (Recombinant E.coli asparaginase)</b><br><br>Spectrila®<br><br>1319/18 | As a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults.                                                                                                                                                                                                | Routinely available in line with local or regional guidance       | 23/04/2018       |
|                                                                                        | <a href="https://www.scottishmedicines.org.uk/medicines-advice/asparaginase-spectrila-abbreviatedsubmission-131918/">https://www.scottishmedicines.org.uk/medicines-advice/asparaginase-spectrila-abbreviatedsubmission-131918/</a>                                                                                                                                    |                                                                   |                  |
| <b>Ataluren</b><br><br>Translarna®<br><br>1131/16                                      | Treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 5 years and older.                                                                                                                                                                                                                     | Not routinely available as not recommended for use in NHSScotland | 18/04/2016       |
|                                                                                        | <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a>                                                                                                                                                                                                    |                                                                   |                  |
| <b>Ataluren</b><br><br>Translarna®<br><br>SMC2327                                      | Treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older.                                                                                                                                                                                                                     | Routinely available in line with national guidance                | 15/08/2022       |
| <b>Atezolizumab</b><br><br>Tecentriq®<br><br>1336/18                                   | As monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK)-positive tumour mutations should also have received targeted therapy before receiving atezolizumab. | Routinely available in line with local or regional guidance       | 13/08/2018       |
|                                                                                        | <a href="https://www.scottishmedicines.org.uk/media/3554/atezolizumab-tecentriq-final-june-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3554/atezolizumab-tecentriq-final-june-2018-for-website.pdf</a>                                                                                                                                            |                                                                   |                  |

| Medicine                                             | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                          | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Atezolizumab</b><br><br>Tecentriq®<br><br>1297/18 | 0 Monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy or who are considered cisplatin ineligible.<br><br><a href="https://www.scottishmedicines.org.uk/medicines-advice/atezolizumab-tecentriq-fullsubmission-129718/">https://www.scottishmedicines.org.uk/medicines-advice/atezolizumab-tecentriq-fullsubmission-129718/</a> | Not routinely available as not recommended for use in NHSScotland | 23/04/2018       |
| <b>atezolizumab</b><br><br>Tecentriq®<br><br>SMC2769 | 0 Monotherapy for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy                                                                                                                                                                                                                                                                                                   | Not routinely available as not recommended for use in NHSScotland | 28/04/2025       |
| <b>Atezolizumab</b><br><br>Tecentriq<br><br>SMC2103  | 0 As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy.                                                                                                                                                                                                                                                                      | Not routinely available as not recommended for use in NHSScotland | 10/12/2018       |
| <b>Atezolizumab</b><br><br>Tecentriq®<br><br>SMC2254 | 0 In combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.                                                                                                                                                                                                           | Not routinely available as not recommended for use in NHSScotland | 09/12/2019       |

| Medicine                                             | Condition being treated                                                                                                                                                                                                                                                                                                                                           | NHSGGC Decision                                                | Date of decision |
|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------------------|
| <b>Atezolizumab</b><br><br>Tecentriq®<br><br>SMC2349 | In combination with bevacizumab for the treatment<br>of adult patients with advanced or unresectable<br>hepatocellular carcinoma (HCC) who have not<br>received prior systemic therapy.                                                                                                                                                                           | Routinely available in line with local<br>or regional guidance | 09/08/2021       |
| <b>Atezolizumab</b><br><br>Tecentriq®<br><br>SMC2492 | as monotherapy as adjuvant treatment following<br>complete resection for adult patients with Stage II<br>to IIIA (7th edition of the UICC/AJCC staging<br>system) non-small cell lung cancer (NSCLC)<br>whose tumours have PD-L1 expression on ≥50% of<br>tumour cells and whose disease has not<br>progressed following platinum-based adjuvant<br>chemotherapy. | Routinely available in line with local<br>or regional guidance | 15/08/2022       |
| <b>Atezolizumab</b><br><br>Tecentriq®<br><br>SMC2279 | In combination with carboplatin and etoposide, is<br>indicated for the first-line treatment of adult<br>patients with extensive-stage small cell lung cancer<br>(ES-SCLC).                                                                                                                                                                                        | Routinely available in line with local<br>or regional guidance | 14/12/2020       |
| <b>Atezolizumab</b><br><br>Tecentriq®<br><br>SMC2267 | In combination with nab-paclitaxel is indicated for<br>the treatment of adult patients with unresectable<br>locally advanced or metastatic triple-negative<br>breast cancer (TNBC) whose tumours have<br>programmed death-ligand 1 [PD-L1] expression<br>≥1% and who have not received prior<br>chemotherapy for metastatic disease.                              | Routinely available in line with local<br>or regional guidance | 14/12/2020       |

| Medicine                                                       | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Atezolizumab</b><br><br>Tecentriq®<br><br>SMC2379           | 0 <p>Monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression <math>\geq 50\%</math> tumour cells (TC) or <math>\geq 10\%</math> tumour-infiltrating immune cells (IC) and who do not have epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK)-positive NSCLC.</p>                                                                                                                                                             | Routinely available in line with local or regional guidance       | 13/12/2021       |
| <b>Atezolizumab</b><br><br>Tecentriq®<br><br>SMC2208           | 0 <p>In combination with bevacizumab, paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK)-positive NSCLC, atezolizumab in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.</p>                                                                                                   | Not routinely available as not recommended for use in NHSScotland | 09/12/2019       |
| <b>Atidarsagene autotemcel</b><br><br>Libmeldy®<br><br>SMC2413 | 0 <p>treatment of metachromatic leukodystrophy (MLD) characterized by biallelic mutations in the arylsulfatase A (ARSA) gene leading to a reduction of the ARSA enzymatic activity:</p> <ul style="list-style-type: none"> <li>- in children with late infantile or early juvenile forms, without clinical manifestations of the disease,</li> <li>- in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.</li> </ul> | Routinely available in line with national guidance                | 11/12/2023       |

| Medicine                                                                               | Condition being treated                                                                                                                                                                                    | NHSGGC Decision                                                | Date of decision |
|----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------------------|
| <b>Atogepant</b><br><br>AQUIPTA®)<br><br>SMC2599                                       | For the prophylaxis of migraine in adults who have<br>at least 4 migraine days per month.                                                                                                                  | Routinely available in line with local<br>or regional guidance | 09/10/2023       |
| <b>Autologous anti-CD19-<br/>transduced CD3+ cells</b><br><br>TECARTUS®<br><br>SMC2351 | Treatment of adult patients with relapsed or<br>refractory mantle cell lymphoma (MCL) after two or<br>more lines of systemic therapy including a Bruton's<br>tyrosine kinase (BTK) inhibitor.              | Routinely available in line with<br>national guidance          | 09/08/2021       |
| <b>avacopan</b><br><br>TAVNEOS®<br><br>SMC2578                                         | In combination with a rituximab or<br>cyclophosphamide regimen, for the treatment of<br>adult patients with severe, active granulomatosis<br>with polyangiitis (GPA) or microscopic polyangiitis<br>(MPA). | Routinely available in line with local<br>or regional guidance | 11/12/2023       |
| <b>avalglucosidase alfa</b><br><br>NEXVIADYME®<br><br>SMC2546                          | Long-term enzyme replacement therapy for the<br>treatment of patients with Pompe disease (acid $\alpha$ -<br>glucosidase deficiency)                                                                       | Routinely available in line with<br>national guidance          | 21/08/2023       |

| Medicine                                            | Condition being treated                                                                                                                                                                                         | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Avapritinib</b><br><br>Ayvakyt®<br><br>SMC2424   | 0 Monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation. | Not routinely available as not recommended for use in NHSScotland | 18/10/2021       |
| <b>Avatrombopag</b><br><br>Doptelet®<br><br>SMC2345 | 0 Treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids or immunoglobulins).                                                | Routinely available in line with national guidance                | 09/08/2021       |
| <b>Avatrombopag</b><br><br>Doptelet®<br><br>SMC2296 | 0 Treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.                                                                         | Routinely available in line with national guidance                | 14/12/2020       |
| <b>Avelumab</b><br><br>Bavencio®<br><br>SMC2248     | 0 in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).                                                                                         | Routinely available in line with local or regional guidance       | 26/10/2020       |



| Medicine                                                           | Condition being treated                                                                                                                                                                           | NHSGGC Decision                                             | Date of decision |
|--------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Avelumab</b><br><br>Bavencio®<br><br>1315/18                    | As monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (mMCC).                                                                                                  | Routinely available in line with local or regional guidance | 11/06/2018       |
| <b>Avelumab</b><br><br>Bavencio®<br><br>SMC2359                    | Monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy.   | Routinely available in line with local or regional guidance | 09/08/2021       |
| <b>Aviptadil with Phentolamine</b><br><br>Invicorp®<br><br>1284/17 | For the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology.                                                            | Routinely available in line with national guidance          | 11/12/2017       |
| <b>Axicabtagene ciloleucel</b><br><br>Yescarta®<br><br>SMC2189     | Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy. | Routinely available in line with local or regional guidance | 07/10/2019       |

| Medicine                                                       | Condition being treated                                                                                                                                                                                             | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|----------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>axicabtagene ciloleucel</b><br><br>Yescarta®<br><br>SMC2628 | Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 22/04/2024       |
| <b>axicabtagene ciloleucel</b><br><br>Yescarta®<br><br>SMC2695 | Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>16/02/2026 | 06/10/2025       |
| <b>Axicabtagene ciloleucel</b><br><br>Yescarta®<br><br>SMC2114 | Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.                   | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 25/02/2019       |
| <b>axicabtagene ciloleucel</b><br><br>Yescarta®<br><br>SMC2646 | Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.                                                                                     | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 19/02/2024       |

| Medicine                                           | Condition being treated                                                                                                                                                                                                                                                                                                                                   | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Azacitidine</b><br><br>Vidaza®<br><br>1175/16   | Treatment of adult patients aged 65 years or older who are not eligible for haematopoietic stem cell transplantation (HSCT) with acute myeloid leukaemia (AML) with >30% marrow blasts according to the World Health Organisation (WHO) classification.                                                                                                   | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 22/08/2016       |
|                                                    | <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1175_16_azacitidine_Vidaza/azacitidine_Vidaza">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1175_16_azacitidine_Vidaza/azacitidine_Vidaza</a>                                                                                                                                     |                                                                                                                                                                                       |                  |
| <b>azacitidine</b><br><br>Onureg®<br><br>SMC2533   | Maintenance therapy in adult patients with acute myeloid leukaemia who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, haematopoietic stem cell transplantation. | Routinely available in line with local or regional guidance                                                                                                                           | 21/08/2023       |
| <b>Baricitinib</b><br><br>Olumiant®<br><br>SMC2337 | Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy                                                                                                                                                                                                                                               | Routinely available in line with national guidance                                                                                                                                    | 14/06/2021       |
| <b>Baricitinib</b><br><br>Olumiant®<br><br>1265/17 | Treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Baricitinib may be used as monotherapy or in combination with methotrexate.                                                                  | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>16/04/2017 | 23/10/2017       |
|                                                    | <a href="http://www.scottishmedicines.org.uk/files/advice/baricitinib_Olumiant_FINAL_August_2017_Amended_03.09.16_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/baricitinib_Olumiant_FINAL_August_2017_Amended_03.09.16_for_website.pdf</a>                                                                                           |                                                                                                                                                                                       |                  |

| Medicine                                                                                                                                                                                                                                                        | Condition being treated                                                                                                                                                                                                                                                                           | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>baricitinib</b><br><br>Olumiant®<br><br>SMC2572                                                                                                                                                                                                              | For the treatment of severe alopecia areata in adult patients.<br><br>0                                                                                                                                                                                                                           | Not routinely available as not recommended for use in NHSScotland | 21/08/2023       |
| <b>Baricitinib</b><br><br>Olumiant®<br><br>1265/17                                                                                                                                                                                                              | Treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Baricitinib may be used as monotherapy or in combination with methotrexate.<br><br>0 | Routinely available in line with local or regional guidance       | 26/02/2018       |
| <a href="http://www.scottishmedicines.org.uk/files/advice/baricitinib_Olumiant_FINAL_August_2017_Amended_03.09.16_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/baricitinib_Olumiant_FINAL_August_2017_Amended_03.09.16_for_website.pdf</a> |                                                                                                                                                                                                                                                                                                   |                                                                   |                  |
| <b>Beclometasone, Formoterol and Glycopyrronium</b><br><br>Trimbow®<br><br>SMC2334                                                                                                                                                                              | maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year<br><br>0                                    | Routinely available in line with national guidance                | 15/08/2022       |
| <b>Beclomethasone, formoterol, glycopyrronium</b><br><br>Trimbow®<br><br>1274/17                                                                                                                                                                                | Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.<br><br>0                                                               | Routinely available in line with national guidance                | 23/10/2017       |
| <a href="http://www.scottishmedicines.org.uk/files/advice/beclometasone_Trimbow_Abbreviated_FINAL_Sept_2107_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/beclometasone_Trimbow_Abbreviated_FINAL_Sept_2107_for_website.pdf</a>             |                                                                                                                                                                                                                                                                                                   |                                                                   |                  |

| Medicine                                                                              | Condition being treated                                                                                                                                                                                                                                                                                                         | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Beclomethasone/<br/>Formoterol/ Glycopyrronium</b><br><br>Trimbrow®<br><br>SMC2335 | Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.                                                                        | Routinely available in line with national guidance                                                                                                                                    | 19/04/2021       |
| <b>belantamab mafodotin</b><br><br>Blenrep®<br><br>SMC2597                            | Monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 19/02/2024       |
| <b>belantamab mafodotin</b><br><br>Blenrep<br><br>SMC2747                             | in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy including lenalidomide.                                                                                                                                               | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 06/10/2025       |
| <b>belantamab mafodotin</b><br><br>Blenrep<br><br>SMC2727                             | in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.                                                                                                                                                                        | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>08/12/2025 | 06/10/2025       |

| Medicine                                                                                                                                                                                                                            | Condition being treated                                                                                                                                                                                                                               | NHSGGC Decision                                                         | Date of decision |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|------------------|
| <b>Belimumab</b><br><br>injection in pre-filled pen<br><br>SMC2483                                                                                                                                                                  | In combination with background<br>0 immunosuppressive therapies for the treatment of<br>adult patients with active lupus nephritis.                                                                                                                   | Not routinely available as not<br>recommended for use in<br>NHSScotland | 13/06/2022       |
| <b>Belimumab</b><br><br>Benlysta®<br><br>SMC2477                                                                                                                                                                                    | Add-on therapy in patients aged 5 years and older<br>0 with active, autoantibody-positive systemic lupus<br>erythematosus (SLE) with a high degree of disease<br>activity (e.g., positive anti-dsDNA and low<br>complement) despite standard therapy. | Routinely available in line with<br>national guidance                   | 12/12/2022       |
| <b>Belimumab</b><br><br>Benlysta®<br><br>SMC2530                                                                                                                                                                                    | Add-on therapy in adult patients with active,<br>0 autoantibody-positive systemic lupus<br>erythematosus (SLE) with a high degree of disease<br>activity (e.g. positive anti-dsDNA and low<br>complement) despite standard therapy.                   | Routinely available in line with<br>national guidance                   | 12/12/2022       |
| <b>Belimumab</b><br><br>Benlysta®<br><br>775/12                                                                                                                                                                                     | Add-on therapy in adult patients with active,<br>0 autoantibody-positive systemic lupus<br>erythematosus (SLE) with a high degree of disease<br>activity (e.g. positive anti-dsDNA and low<br>complement) despite standard therapy.                   | Routinely available in line with<br>national guidance                   | 19/06/2017       |
| <a href="http://www.scottishmedicines.org.uk/files/advice/belimumab_Benlysta_Resub_FINAL_April_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/belimumab_Benlysta_Resub_FINAL_April_2017_for_website.pdf</a> |                                                                                                                                                                                                                                                       |                                                                         |                  |

| Medicine                                           | Condition being treated                                                                                                                                                                                                                                                                             | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>belumosudil</b><br><br>Rezurock®<br><br>SMC2583 | 0 Treatment of patients aged 12 years and older with chronic graft-versus-host disease (chronic GvHD) who have received at least two prior lines of systemic therapy.                                                                                                                               | Routinely available in line with national guidance                | 21/08/2023       |
| <b>belzutifan</b><br><br>Welireg®<br><br>SMC2864   | 0 Treatment of adult patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with a programmed death receptor-1 (PD-1) / programmed death ligand (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).      | Not routinely available as not recommended for use in NHSScotland | 06/10/2025       |
| <b>Belzutifan</b><br><br>Welireg®<br><br>SMC2587   | 0 Treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable. | Routinely available in line with local or regional guidance       | 09/10/2023       |

| Medicine                                             | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | NHSGGC Decision                                                         | Date of decision |
|------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|------------------|
| <b>bempedoic acid</b><br><br>Nilemdo®<br><br>SMC2740 | in adults with established or at high risk for<br>0 atherosclerotic cardiovascular disease to reduce<br>cardiovascular risk by lowering LDL-C levels, as an<br>adjunct to correction of other risk factors:<br>- in patients on a maximum tolerated dose of a<br>statin with or without ezetimibe or,<br>- alone or in combination with ezetimibe in patients<br>who are statin-intolerant, or for whom a statin is<br>contraindicated                                                                                    | Not routinely available as not<br>recommended for use in<br>NHSScotland | 16/06/2025       |
| <b>Bempedoic acid</b><br><br>Nilemdo®<br><br>SMC2363 | Adults with primary hypercholesterolaemia<br>0 (heterozygous familial and non-familial) or mixed<br>dyslipidaemia, as an adjunct to diet:<br>- In combination with a statin, or a statin with other<br>lipid-lowering therapies in patients unable to reach<br>low-density lipoprotein cholesterol (LDL-C) goals<br>with the maximum tolerated dose of a statin or<br>-Alone or in combination with other lipid-lowering<br>therapies in patients who are statin-intolerant, or<br>for whom a statin is contra-indicated. | Routinely available in line with local<br>or regional guidance          | 13/06/2022       |
| <b>Bempedoic acid</b><br><br>Nilemdo®<br><br>SMC2292 | in adults with primary hypercholesterolaemia<br>0 (heterozygous familial and non-familial) or mixed<br>dyslipidaemia, as an adjunct to diet:<br>- In combination with a statin, or a statin with other<br>lipid-lowering therapies in patients unable to reach<br>LDL-C goals with the maximum tolerated dose of a<br>statin or<br>- Alone or in combination with other lipid-lowering<br>therapies in patients who are statin-intolerant, or<br>for whom a statin is contra-indicated.                                   | Not routinely available as not<br>recommended for use in<br>NHSScotland | 14/12/2020       |



| Medicine                                                             | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | NHSGGC Decision                                                          | Date of decision  |
|----------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|-------------------|
| <b>bempedoic acid , ezetimibe</b><br><br>Nustendi®<br><br>SMC2741    | <p>Treatment of adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:</p> <ul style="list-style-type: none"> <li>- in patients on a maximum tolerated dose of a statin and not adequately controlled with additional ezetimibe treatment or,</li> <li>- in patients who are either statin-intolerant, or for whom a statin is contraindicated, and not adequately controlled with ezetimibe treatment or,</li> <li>- in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets.</li> </ul> | <p>Not routinely available as not recommended for use in NHSScotland</p> | <p>16/06/2025</p> |
| <b>Bempedoic acid with Ezetimibe</b><br><br>Nustendi®<br><br>SMC2406 | <p>Treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:</p> <ul style="list-style-type: none"> <li>- in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe,</li> <li>- alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone</li> <li>- in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin.</li> </ul>                  | <p>Routinely available in line with local or regional guidance</p>       | <p>13/06/2022</p> |

| Medicine                                                                                                                                                                                                                                    | Condition being treated                                                                                                                                                                                                                          | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Benralizumab</b><br><br>Fasenra®<br><br>SMC2155                                                                                                                                                                                          | As an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting $\beta$ -agonists.                                                       | Routinely available in line with national guidance                | 10/06/2019       |
| <b>Berotrastat</b><br><br>Orladeyo®<br><br>SMC2405                                                                                                                                                                                          | Routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.                                                                                                                 | Routinely available in line with national guidance                | 13/06/2022       |
| <b>Bevacizumab</b><br><br>Avastin®<br><br>1135/16                                                                                                                                                                                           | In combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. | Routinely available in line with local or regional guidance       | 13/06/2016       |
| <b>Bevacizumab</b><br><br>Avastin®<br><br>1190/16                                                                                                                                                                                           | In combination with erlotinib for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.          | Not routinely available as not recommended for use in NHSScotland | 10/10/2016       |
| <a href="http://www.scottishmedicines.org.uk/files/advice/bevacizumab_Avastin_Non_Sub_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/bevacizumab_Avastin_Non_Sub_FINAL_August_2016_for_website.pdf</a> |                                                                                                                                                                                                                                                  |                                                                   |                  |

| Medicine                                                                     | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | NHSGGC Decision                                                                                                                                                            | Date of decision |
|------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Bevacizumab</b><br><br>Avastin®<br><br>1275/17                            | In combination with carboplatin and paclitaxel for the treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/bevacizumab_Avastin_Non_Sub_FINAL_August_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/bevacizumab_Avastin_Non_Sub_FINAL_August_2017_for_website.pdf</a> | Not routinely available as not recommended for use in NHSScotland                                                                                                          | 23/10/2017       |
| <b>bevacizumab gamma</b><br><br>Lytenava<br><br>SMC2744                      | In adults for treatment of neovascular (wet) age-related macular degeneration (nAMD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s) | 18/08/2025       |
| <b>Bezlotoxumab</b><br><br>Zinplava®<br><br>1293/17                          | Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Not routinely available as not recommended for use in NHSScotland                                                                                                          | 11/12/2017       |
| <b>Bictegravir, Emtricitabine, Tenofovir</b><br><br>Biktarvy®<br><br>SMC2093 | Treatment of adults infected with human immunodeficiency virus 1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.                                                                                                                                                                                                                                                                                                                                                                       | Routinely available in line with national guidance                                                                                                                         | 08/10/2018       |

| Medicine                                                                                 | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>bictegravir, emtricitabine, tenofovir alafenamide</b><br><br>Biktarvy®<br><br>SMC2760 | treatment of human immunodeficiency virus-1 (HIV-1) infection in paediatric patients at least 2 years of age and weighing at least 14 kg to less than 25 kg without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.                                                                                                                                                                                                                 | Not routinely available as not recommended for use in NHSScotland | 17/02/2025       |
| <b>bimekizumab</b><br><br>Bimzelx®<br><br>SMC2616                                        | axial spondyloarthritis<br>•For the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).<br>•For the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy. | Routinely available in line with local or regional guidance       | 11/12/2023       |
| <b>bimekizumab</b><br><br>Bimzelx®<br><br>SMC2698                                        | Treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.                                                                                                                                                                                                                                                                                                                                 | Routinely available in line with local or regional guidance       | 28/04/2025       |

| Medicine                                          | Condition being treated                                                                                                                                                                                                                                       | NHSGGC Decision                                             | Date of decision |
|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>bimekizumab</b><br><br>Bimzelx®<br><br>SMC2605 | 0 <p>Alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).</p>                  | Routinely available in line with local or regional guidance | 11/12/2023       |
| <b>Bimekizumab</b><br><br>Bimzelx®<br><br>SMC2410 | 0 <p>Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy</p>                                                                                                                                                   | Routinely available in line with national guidance          | 13/12/2021       |
| <b>Biologic agents (See below)</b><br><br>MTA 383 | 0 <p>Ankylosing spondylitis and axial spondyloarthritis (non-radiographic) : medicines are adalimumab, certolizumab, etanercept, infliximab, golimumab</p> <p><a href="https://www.nice.org.uk/guidance/ta383">https://www.nice.org.uk/guidance/ta383</a></p> | Routinely available in line with national guidance          | 18/04/2016       |
| <b>Biologic agents (see below)</b><br><br>MTA 375 | 0 <p>Rheumatoid arthritis (medicines are adalimumab, etanercept, infliximab, certolizumab, golimumab, abatacept, tocilizumab)</p> <p><a href="https://www.nice.org.uk/guidance/ta375">https://www.nice.org.uk/guidance/ta375</a></p>                          | Routinely available in line with national guidance          | 18/04/2016       |

| Medicine                                                                  | Condition being treated                                                                                                                                                                                                                                                                                                     | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>birch bark extract</b><br><br>Filsuvez®<br><br>SMC2651                 | treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older                                                                                                                                                                                   | Routinely available in line with local or regional guidance       | 09/12/2024       |
| <b>bismuth, metronidazole, tetracycline</b><br><br>Pylera®<br><br>SMC2701 | In combination with omeprazole, for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers in patients with active or a history of H. pylori associated ulcers.                                                                                                                                  | Routinely available in line with local or regional guidance       | 09/12/2024       |
| <b>Blinatumomab</b><br><br>Blinicyto®<br><br>SMC2234                      | Monotherapy for the treatment of adults with Philadelphia chromosome negative, CD19 positive, B-precursor acute lymphoblastic leukaemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.                                                                      | Routinely available in line with local or regional guidance       | 06/07/2020       |
| <b>Blinatumomab</b><br><br>Blinicyto®<br><br>SMC2468                      | Monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options. | Not routinely available as not recommended for use in NHSScotland | 13/06/2022       |

| Medicine                                                                                                                                                                                                      | Condition being treated                                                                                                                                                                                                                                                                                                                                | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Blinatumomab</b><br><br>Blincyto®<br><br>1145/16                                                                                                                                                           | The treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).                                                                                                                                                                                                                  | Routinely available in line with local or regional guidance                                                                                                                           | 13/06/2016       |
| <b>Blinatumomab</b><br><br>Blincyto®<br><br>SMC2148                                                                                                                                                           | As monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukaemia which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation. | Routinely available in line with national guidance                                                                                                                                    | 29/04/2019       |
| <b>blinatumomab</b><br><br>Blincyto®<br><br>SMC2808                                                                                                                                                           | Treatment of adult patients with Philadelphia chromosome negative CD19-positive B-cell precursor acute lymphoblastic leukaemia (ALL) in the consolidation phase.                                                                                                                                                                                       | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>08/12/2025 | 06/10/2025       |
| <b>Bosutinib</b><br><br>Bosulif®<br><br>2109                                                                                                                                                                  | Treatment of adult patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia.                                                                                                                                                                                                                         | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 13/08/2018       |
| <a href="https://www.scottishmedicines.org.uk/medicines-advice/bosutinib-bosulif-non-submission-smc2109/">https://www.scottishmedicines.org.uk/medicines-advice/bosutinib-bosulif-non-submission-smc2109/</a> |                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                       |                  |

| Medicine                                                                                                                                                                                                                                                                                                                        | Condition being treated                                                                                                                                              | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Botulinum toxin A</b><br><br>Botox®<br><br>692/11<br><br><a href="http://www.scottishmedicines.org.uk/SMCAdvice/Advice/692_11_botulinum_toxin_type_a_BOTOX/botulinum_toxin_A_Botox_2nd_Resub">http://www.scottishmedicines.org.uk/SMCAdvice/Advice/692_11_botulinum_toxin_type_a_BOTOX/botulinum_toxin_A_Botox_2nd_Resub</a> | Prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).                       | Routinely available in line with local or regional guidance       | 20/02/2017       |
| <b>Brentuximab</b><br><br>Adcetris®<br><br>SMC2310                                                                                                                                                                                                                                                                              | In combination with cyclophosphamide, doxorubicin and prednisone (CHP) for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). | Routinely available in line with local or regional guidance       | 19/04/2021       |
| <b>Brentuximab</b><br><br>Adcetris®<br><br>SMC2098                                                                                                                                                                                                                                                                              | Treatment of adult patients with CD30+ cutaneous T-cell lymphoma after at least one prior systemic therapy.                                                          | Not routinely available as not recommended for use in NHSScotland | 13/08/2018       |
| <b>Brentuximab vedotin</b><br><br>Adcetris®<br><br>SMC2202                                                                                                                                                                                                                                                                      | Treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with doxorubicin, vinblastine and dacarbazine.                  | Not routinely available as not recommended for use in NHSScotland | 10/06/2019       |



| Medicine                                                         | Condition being treated                                                                                                                                           | NHSGGC Decision                                                         | Date of decision |
|------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|------------------|
| <b>brentuximab vedotin</b><br><br>Adcetris®<br><br>SMC2762       | Adult patients with previously untreated CD30+<br>Stage III or IV Hodgkin lymphoma (HL) in<br>combination with doxorubicin, vinblastine and<br>dacarbazine (AVD). | Routinely available in line with local<br>or regional guidance          | 06/10/2025       |
| <b>Brentuximab Vedotin</b><br><br>Adcetris®<br><br>SMC2229       | Treatment of adult patients with CD30+ cutaneous<br>T-cell lymphoma (CTCL) after at least one prior<br>systemic therapy.                                          | Routinely available in line with local<br>or regional guidance          | 24/02/2020       |
| <b>Brentuximab vedotin</b><br><br>Adcetris ®<br><br>SMC2025      | Treatment of adult patients with CD30+ Hodgkin<br>lymphoma at increased risk of relapse or<br>progression following autologous stem cell<br>transplant.           | Not routinely available as not<br>recommended for use in<br>NHSScotland | 11/06/2018       |
| <b>Brexucabtagene autoleucel</b><br><br>Tecartus®<br><br>SMC2548 | Treatment of adult patients 26 years of age and<br>above with relapsed or refractory B-cell precursor<br>acute lymphoblastic leukaemia (ALL).                     | Routinely available in line with<br>national guidance                   | 19/02/2024       |

| Medicine                                            | Condition being treated                                                                                                                                                                                | NHSGGC Decision                                                                                                                                                                                                                                                                             | Date of decision |
|-----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Brigatinib</b><br><br>Alunbrig®<br><br>SMC2314   | As monotherapy for the treatment of adult patients<br>0 with anaplastic lymphoma kinase (ALK)-positive<br>advanced non-small cell lung cancer (NSCLC)<br>previously not treated with an ALK inhibitor. | Routinely available in line with local or regional guidance                                                                                                                                                                                                                                 | 19/04/2021       |
| <b>Brigatinib</b><br><br>Alunbrig®<br><br>SMC2147   | as monotherapy for the treatment of adult patients<br>0 with anaplastic lymphoma kinase (ALK) positive<br>advanced non-small cell lung cancer (NSCLC)<br>previously treated with crizotinib            | Routinely available in line with local or regional guidance                                                                                                                                                                                                                                 | 10/06/2019       |
| <b>Brivaracetam</b><br><br>Briviact®<br><br>1160/16 | Adjunctive therapy in the treatment of partial-onset<br>0 seizures with or without secondary generalisation<br>in adult and adolescent patients from 16 years of<br>age with epilepsy.                 | Routinely available in line with national guidance                                                                                                                                                                                                                                          | 22/08/2016       |
| <b>Brivaracetam</b><br><br>Briviact®<br><br>SMC2113 | Adjunctive therapy in the treatment of partial-onset<br>0 seizures with or without secondary generalisation<br>in children from 4 years to ≤15 years of age with<br>epilepsy.                          | Routinely available in line with national guidance<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1160_16_brivaracetam_Briviact/brivaracetam_Briviact">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1160_16_brivaracetam_Briviact/brivaracetam_Briviact</a> | 25/02/2019       |

| Medicine                                          | Condition being treated                                                                                             | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Brodalumab</b><br><br>Kyntheum®<br><br>1283/17 | Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.         | Routinely available in line with local or regional guidance       | 09/12/2019       |
|                                                   |                                                                                                                     | 31/12/2018                                                        |                  |
| <b>Brodalumab</b><br><br>Kyntheum®<br><br>1283/17 | for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. | Not routinely available as not recommended for use in NHSScotland | 11/12/2017       |
| <b>Brolucizumab</b><br><br>Beovu®<br><br>SMC2272  | In adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).                            | Routinely available in line with local or regional guidance       | 31/08/2020       |
| <b>Brolucizumab</b><br><br>Beovu®<br><br>SMC2508  | In adults for the treatment of visual impairment due to diabetic macular oedema.                                    | Routinely available in line with local or regional guidance       | 12/12/2022       |
|                                                   |                                                                                                                     | 12/12/2022                                                        |                  |

| Medicine          | Condition being treated                                                                                                                                                                                                               | NHSGGC Decision                                    | Date of decision |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|------------------|
| <b>Budesonide</b> | Treatment of active ulcerative colitis that is limited to the rectum and the sigmoid colon.                                                                                                                                           | Routinely available in line with national guidance | 23/10/2017       |
| Budenofalk®       |                                                                                                                                                                                                                                       |                                                    |                  |
| 409/07            |                                                                                                                                                                                                                                       |                                                    |                  |
|                   | <a href="http://www.scottishmedicines.org.uk/files/409_07_budesonide_Budenofalk_Abb_Sept07.pdf">http://www.scottishmedicines.org.uk/files/409_07_budesonide_Budenofalk_Abb_Sept07.pdf</a>                                             |                                                    |                  |
| <b>Budesonide</b> | Treatment of eosinophilic oesophagitis (EoE) in adults (older than 18 years of age).                                                                                                                                                  | Routinely available in line with national guidance | 26/10/2020       |
| Jorveza®          |                                                                                                                                                                                                                                       |                                                    |                  |
| SMC2158           |                                                                                                                                                                                                                                       |                                                    |                  |
| <b>Budesonide</b> | In adults for induction of remission in patients with mild to moderate active ulcerative colitis (UC) where aminosalicylate (5-ASA) treatment is not sufficient.                                                                      | Routinely available in line with national guidance | 10/10/2016       |
| Cortiment®        |                                                                                                                                                                                                                                       |                                                    |                  |
| 1093/15           |                                                                                                                                                                                                                                       |                                                    |                  |
|                   | <a href="http://www.scottishmedicines.org.uk/files/advice/budesonide_Cortiment_Resub_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/budesonide_Cortiment_Resub_FINAL_Sept_2016_for_website.pdf</a> |                                                    |                  |
| <b>Budesonide</b> | Induction of remission in patients with active microscopic colitis                                                                                                                                                                    | Routinely available in line with national guidance | 21/02/2022       |
| Cortiment®        |                                                                                                                                                                                                                                       |                                                    |                  |
| SMC 2448          |                                                                                                                                                                                                                                       |                                                    |                  |

| Medicine                                                                  | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Budesonide/formoterol</b><br><br>Symbicort® SMART®<br><br>1244/17      | The regular treatment of asthma where use of a combination (inhaled corticosteroid and a long-acting $\beta$ 2 adrenoceptor agonist is appropriate: patients not adequately controlled with inhaled corticosteroids and as needed short-acting $\beta$ 2 adrenoceptor agonists, or patients already adequately controlled on both inhaled corticosteroids and long-acting $\beta$ 2 adrenoceptor agonists<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/budesonide-formoterol_Symbicort_SMART_Abb_FINAL_May_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/budesonide-formoterol_Symbicort_SMART_Abb_FINAL_May_2017_for_website.pdf</a> | Routinely available in line with national guidance                | 23/10/2017       |
| <b>budesonide/formoterol</b><br><br>Symbicort® Turbohaler®<br><br>SMC2622 | As reliever therapy for adults and adolescents (12 years and older) with mild asthma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Routinely available in line with local or regional guidance       | 17/06/2024       |
| <b>Budesonide/Formoterol</b><br><br>Symbicort®<br><br>1198/16             | Treatment of patients with chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) 50% to 70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/budesonide_formoterol_Symbicort_Non_Sub_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/budesonide_formoterol_Symbicort_Non_Sub_FINAL_Sept_2016_for_website.pdf</a>                                                                                                                                                              | Not routinely available as not recommended for use in NHSScotland | 10/10/2016       |
| <b>Bulevirtide</b><br><br>Hepcludex®<br><br>SMC2520                       | Treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult patients with compensated liver disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Routinely available in line with local or regional guidance       | 24/04/2023       |

| Medicine                                             | Condition being treated                                                                                                                                                                                                                                                                       | NHSGGC Decision                                                                                                                                                            | Date of decision |
|------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Buprenorphine</b><br><br>Espranor®<br><br>1245/17 | Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. Treatment with buprenorphine oral lyophilisate is intended for use in adults and adolescents aged 15 years or over who have agreed to be treated for addiction.         | Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s) | 19/06/2017       |
|                                                      | <a href="http://www.scottishmedicines.org.uk/files/advice/buprenorphine_oral_lyophilisate_Espranor_Abb_FINAL_May_2017_amended_050617_for_website">http://www.scottishmedicines.org.uk/files/advice/buprenorphine_oral_lyophilisate_Espranor_Abb_FINAL_May_2017_amended_050617_for_website</a> |                                                                                                                                                                            |                  |
| <b>Buprenorphine</b><br><br>Sixmo®<br><br>SMC2372    | for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.                                                                        | Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s) | 13/12/2021       |
| <b>Buprenorphine</b><br><br>Butec®<br><br>1213/17    | In adults, for the treatment of chronic non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia.                                                                                                                                                | Routinely available in line with local or regional guidance                                                                                                                | 20/02/2017       |
|                                                      | <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1213_17_buprenorphine_transdermal_patch_Butec/buprenorphine_transdermal_patch">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1213_17_buprenorphine_transdermal_patch_Butec/buprenorphine_transdermal_patch</a>         |                                                                                                                                                                            |                  |
| <b>Buprenorphine</b><br><br>Buvidal®<br><br>SMC2169  | Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.                                                                                                              | Routinely available in line with national guidance                                                                                                                         | 12/08/2019       |

| Medicine                                                           | Condition being treated                                                                                                                                                                                                                                                                                                                | NHSGGC Decision                                                                                                                                                            | Date of decision |
|--------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Buprenorphine with Naloxone</b><br><br>Suboxone®                | Substitution treatment for opioid drug dependence<br><br>0                                                                                                                                                                                                                                                                             | Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s) | 11/12/2017       |
| <b>Buprenorphine with Naloxone</b><br><br>Zubsolv®<br><br>SMC2123  | Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.<br><br>0                                                                               | Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s) | 12/12/2022       |
| <b>Buprenorphine with Naloxone</b><br><br>Suboxone®<br><br>SMC2316 | Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Buprenorphine/naloxone is indicated in adults and adolescents over 15 years of age who have agreed to be treated for addiction.<br><br>0 | Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s) | 19/04/2021       |
| <b>Burosumab</b><br><br>Crysvita®<br><br>SMC2514                   | X-linked hypophosphataemia<br><br>0                                                                                                                                                                                                                                                                                                    | Routinely available in line with national guidance                                                                                                                         | 24/04/2023       |

| Medicine                                            | Condition being treated                                                                                                                                                                                                                                                                                                                                                           | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>burosumab</b><br><br>Crysvita®<br><br>SMC2588    | Treatment of X-linked hypophosphataemia in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease.                                                                                                                                                                                                                                                | Routinely available in line with national guidance                | 19/02/2024       |
| <b>Cabazitaxel</b><br><br>Jevtana®<br><br>735/11    | In combination with prednisone or prednisolone, is indicated for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.                                                                                                                                                                             | Not routinely available as not recommended for use in NHSScotland | 13/06/2016       |
| <b>Cabazitaxel</b><br><br>Jevtana®<br><br>735/11    | In combination with prednisone or prednisolone is indicated for the treatment of adult patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.                                                                                                                                                                        | Routinely available in line with local or regional guidance       | 12/12/2016       |
| <b>Cabotegravir</b><br><br>Vocabria®<br><br>SMC2376 | In combination with rilpivirine prolonged-release injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class. | Routinely available in line with national guidance                | 15/08/2022       |

[http://www.scottishmedicines.org.uk/SMC\\_Advice/Advice/735\\_11\\_cabazitaxel\\_Jevtana/cabazitaxel\\_Jevtana\\_2nd\\_Resub](http://www.scottishmedicines.org.uk/SMC_Advice/Advice/735_11_cabazitaxel_Jevtana/cabazitaxel_Jevtana_2nd_Resub)



| Medicine                                                                                                                                                                                                                    | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>cabotegravir</b><br><br>Apretude®<br><br>SMC2718                                                                                                                                                                         | 0 injection: in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg.<br>tablets: in combination with safer sex practices for short term pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg. Cabotegravir tablets may be used as:<br>- oral lead-in to assess tolerability of cabotegravir prior to administration of long acting cabotegravir injection.<br>- oral PrEP for individuals who will miss planned dosing with cabotegravir injection. | Routinely available in line with national guidance                | 17/02/2025       |
| <b>Cabozantinib</b><br><br>Cabometyx®<br><br>SMC2095                                                                                                                                                                        | 0 Advanced renal cell carcinoma (RCC) in treatment-naïve adults with intermediate or poor risk.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Not routinely available as not recommended for use in NHSScotland | 08/10/2018       |
| <b>Cabozantinib</b><br><br>Cabometyx®<br><br>1234/17                                                                                                                                                                        | 0 For the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Routinely available in line with local or regional guidance       | 19/06/2017       |
| <a href="http://www.scottishmedicines.org.uk/files/advice/cabozantinib_Cabometyx_FINAL_May_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/cabozantinib_Cabometyx_FINAL_May_2017_for_website.pdf</a> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                   |                  |

| Medicine                                             | Condition being treated                                                                                                                                                                                                                       | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Cabozantinib</b><br><br>Cabometyx®<br><br>SMC2136 | Advanced renal cell carcinoma (RCC) in treatment-naïve adults with intermediate or poor risk.                                                                                                                                                 | Not routinely available as not recommended for use in NHSScotland | 25/02/2019       |
| <b>Cabozantinib</b><br><br>Cabometyx®<br><br>SMC2160 | Monotherapy for the treatment of hepatocellular carcinoma in adults who have previously been treated with sorafenib.                                                                                                                          | Not routinely available as not recommended for use in NHSScotland | 25/02/2019       |
| <b>cabozantinib</b><br><br>Cabometyx®<br><br>SMC2590 | Monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy | Not routinely available as not recommended for use in NHSScotland | 19/02/2024       |
| <b>Cabozantinib</b><br><br>Cabometyx®<br><br>SMC2386 | In combination with nivolumab for the first-line treatment of advanced renal cell carcinoma in adults.                                                                                                                                        | Routinely available in line with local or regional guidance       | 18/10/2021       |

| Medicine                                                                  | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                         | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>cabozantinib</b><br><br>SMC2754                                        | 0 Monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.                                                                                                                                                                                                                                                                                                                                                    | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>08/12/2025 | 06/10/2025       |
| <b>Calcipotriol, betamethasone</b><br><br>Enstilar®<br><br>1182/16        | 0 Topical treatment of psoriasis vulgaris in adults<br><br><br><br><a href="http://www.scottishmedicines.org.uk/files/advice/calcipotriol_betamethasone_Enstilar_Abb_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/calcipotriol_betamethasone_Enstilar_Abb_FINAL_August_2016_for_website.pdf</a>                                                                                                                                          | Routinely available in line with national guidance                                                                                                                                    | 10/10/2016       |
| <b>Camellia sinensis (green tea) leaf</b><br><br>Catephen®<br><br>1133/16 | 0 Cutaneous treatment of external genital and perianal warts (condylomata acuminata) in immunocompetent patients from the age of 18 years.                                                                                                                                                                                                                                                                                                                                      | Routinely available in line with national guidance                                                                                                                                    | 18/04/2016       |
| <b>Canagliflozin, dapagliflozin, empagliflozin</b><br><br>MTA 390         | 0 <a href="http://http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a><br>as monotherapy for type 2 diabetes in adults for whom use of metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control<br><br><a href="https://www.nice.org.uk/guidance/ta390">https://www.nice.org.uk/guidance/ta390</a> | Routinely available in line with national guidance                                                                                                                                    | 22/08/2016       |

| Medicine                                            | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | NHSGGC Decision                                                                   | Date of decision |
|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|------------------|
| <b>Canakinumab</b><br><br>Ilaris®<br><br>1210/16    | Treatment of active Still's disease including Adult-Onset Still's Disease who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1210_16_canakinumab_Ilaris/canakinumab_Ilaris_non_submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1210_16_canakinumab_Ilaris/canakinumab_Ilaris_non_submission</a>   | Not routinely available as not recommended for use in NHSScotland                 | 12/12/2016       |
| <b>Canakinumab</b><br><br>Ilaris®<br><br>1268/17    | Treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:<br>- tumour necrosis factor receptor associated periodic syndrome<br>- hyperimmunoglobulin D syndrome / mevalonate kinase deficiency<br>- Familial Mediterranean Fever<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/canakinumab_Ilaris_Non_Sub_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/canakinumab_Ilaris_Non_Sub_FINAL_July_2017_for_website.pdf</a> | Not routinely available as not recommended for use in NHSScotland                 | 28/08/2017       |
| <b>Cannabidiol</b><br><br>Epidyolex®<br><br>SMC2402 | Use as adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older.                                                                                                                                                                                                                                                                                                                                                                                                                        | Routinely available in line with national guidance                                | 21/02/2022       |
| <b>Cannabidiol</b><br><br>Epidyolex®<br><br>SMC2262 | For use as adjunctive therapy of seizures associated with Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older.                                                                                                                                                                                                                                                                                                                                                                                                      | Routinely available in line with local or regional guidance<br><br><br>30/04/2021 | 19/04/2021       |

| Medicine                                            | Condition being treated                                                                                                                                                                                                                                                                                                                                                           | NHSGGC Decision                                                                   | Date of decision |
|-----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|------------------|
| <b>Cannabidiol</b><br><br>Epidyolex®<br><br>SMC2263 | For use as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome, in conjunction with clobazam, for patients 2 years of age and older.                                                                                                                                                                                                                           | Routinely available in line with local or regional guidance<br><br><br>30/04/2021 | 19/04/2021       |
| <b>capivasertib</b><br><br>Truqap<br><br>SMC2823    | in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0 or 1+, or IHC 2+/ISH-) locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. | Not routinely available as not recommended for use in NHSScotland                 | 06/10/2025       |
| <b>Caplacizumab</b><br><br>Cablivi®<br><br>SMC2266  | Treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.                                                                                                                                                                                                                    | Routinely available in line with local or regional guidance                       | 31/08/2020       |
| <b>Capsaicin</b><br><br>Qutenza®<br><br>1140/16     | Treatment of peripheral neuropathic pain in diabetic adults either alone or in combination with other medicinal products for pain.                                                                                                                                                                                                                                                | Not routinely available as not recommended for use in NHSScotland                 | 18/04/2016       |

| Medicine           | Condition being treated                                                                                                                                                                                                   | NHSGGC Decision                                                   | Date of decision |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Carbetocin</b>  | For the prevention of uterine atony following delivery of the infant by Caesarean section under epidural or spinal anaesthesia                                                                                            | Not routinely available as not recommended for use in NHSScotland | 26/02/2018       |
| Pabal®             |                                                                                                                                                                                                                           |                                                                   |                  |
| 309/06             |                                                                                                                                                                                                                           |                                                                   |                  |
|                    | <a href="http://www.scottishmedicines.org.uk/files/advice/carbetocin_Pabal_FINAL_Dec_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/carbetocin_Pabal_FINAL_Dec_2017_for_website.pdf</a>           |                                                                   |                  |
| <b>Carfilzomib</b> | in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.                                                                | Routinely available in line with local or regional guidance       | 26/10/2020       |
| Kyprolis®          |                                                                                                                                                                                                                           |                                                                   |                  |
| SMC2290            |                                                                                                                                                                                                                           |                                                                   |                  |
| <b>Carfilzomib</b> | In combination with dexamethasone alone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.                                                                           | Routinely available in line with local or regional guidance       | 28/08/2017       |
| Kyprolis®          |                                                                                                                                                                                                                           |                                                                   |                  |
| 1242/17            |                                                                                                                                                                                                                           |                                                                   |                  |
|                    | <a href="http://www.scottishmedicines.org.uk/files/advice/carfilzomib_Kyprolis_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/carfilzomib_Kyprolis_FINAL_July_2017_for_website.pdf</a> |                                                                   |                  |
| <b>Carfilzomib</b> | In combination with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.                                                                 | Not routinely available as not recommended for use in NHSScotland | 13/06/2022       |
| Kyprolis®          |                                                                                                                                                                                                                           |                                                                   |                  |
| SMC2484            |                                                                                                                                                                                                                           |                                                                   |                  |

| Medicine                                           | Condition being treated                                                                                                                                                                                                                                     | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Carfilzomib</b><br><br>Kyprolis®<br><br>1171/16 | In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.                                                                                                  | Not routinely available as not recommended for use in NHSScotland | 20/02/2017       |
|                                                    | <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1171_16_carfilzomib_Kyprolis/carfilzomib_Kyprolis_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1171_16_carfilzomib_Kyprolis/carfilzomib_Kyprolis_Resub</a>                   |                                                                   |                  |
| <b>Carfilzomib</b><br><br>Kyprolis®<br><br>1171/16 | In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.                                                                                                  | Not routinely available as not recommended for use in NHSScotland | 10/10/2016       |
|                                                    | <a href="http://www.scottishmedicines.org.uk/files/advice/carfilzomib_Kyprolis_FINAL_August_2016_revised_080916_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/carfilzomib_Kyprolis_FINAL_August_2016_revised_080916_for_website.pdf</a> |                                                                   |                  |
| <b>Carfilzomib</b><br><br>NCMAG104                 | Carfilzomib once-weekly regimen in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (off-label use)                                                                    | Routinely available in line with local or regional guidance       | 20/02/2023       |
| <b>Cariprazine</b><br><br>Reagila®<br><br>SMC2137  | Treatment of schizophrenia in adult patients.                                                                                                                                                                                                               | Routinely available in line with national guidance                | 10/06/2019       |

| Medicine                                                                                                                                                                                                                                                      | Condition being treated                                                                                                                                                                                                                                                                                                                                                         | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Casirivimab, Imdevimab</b><br><br>Ronapreve®<br><br>SMC2553                                                                                                                                                                                                | Treatment of acute COVID-19 infection<br><br>0                                                                                                                                                                                                                                                                                                                                  | Not routinely available as not recommended for use in NHSScotland | 24/04/2023       |
| <b>Ceftaroline fosamil</b><br><br>Zinforo®<br><br>1306/18                                                                                                                                                                                                     | treatment of:<br>0 - complicated skin and soft tissue infections in children from the age of 2 months<br>- community-acquired pneumonia in children from the age of 2 months                                                                                                                                                                                                    | Not routinely available as not recommended for use in NHSScotland | 26/02/2018       |
| <a href="http://www.scottishmedicines.org.uk/files/advice/ceftaroline_fosamil_Zinforo_Non_Sub_FINAL_Dec_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/ceftaroline_fosamil_Zinforo_Non_Sub_FINAL_Dec_2017_for_website.pdf</a>         |                                                                                                                                                                                                                                                                                                                                                                                 |                                                                   |                  |
| <b>Ceftazadime with Avibactam</b><br><br>Zavicefta<br><br>1307/18                                                                                                                                                                                             | Treatment of the following infections in adults: 1)<br>0 complicated intra-abdominal Infection (cIAI); 2)<br>complicated urinary tract infection (cUTI), including pyelonephritis; 3) hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP); 4) infections due to aerobic Gram-negative organisms in adult patients with limited treatment options | Not routinely available as not recommended for use in NHSScotland | 26/02/2018       |
| <a href="http://www.scottishmedicines.org.uk/files/advice/ceftazidime_avibactam_Zavicefta_Non_Sub_FINAL_Dec_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/ceftazidime_avibactam_Zavicefta_Non_Sub_FINAL_Dec_2017_for_website.pdf</a> |                                                                                                                                                                                                                                                                                                                                                                                 |                                                                   |                  |
| <b>Ceftolozane with Tazobactam</b><br><br>Zerbaxa®<br><br>1146/16                                                                                                                                                                                             | Treatment of the following infections in adults:<br>0 - Complicated intra-abdominal infections<br>- Acute pyelonephritis<br>- Complicated urinary tract infections                                                                                                                                                                                                              | Not routinely available as not recommended for use in NHSScotland | 13/06/2016       |



| Medicine                                                     | Condition being treated                                                                                                                                                                            | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Ceftolozane/Tazobactam</b><br><br>Zerbaxa®<br><br>SMC2256 | In adults for the treatment of hospital acquired pneumonia, including ventilator-associated pneumonia.                                                                                             | Not routinely available as not recommended for use in NHSScotland | 09/12/2019       |
| <b>Cefuroxime</b><br><br>Aprokam®<br><br>932/13              | Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery.                                                                                                                    | Routinely available in line with national guidance                | 12/12/2016       |
| <b>Cemiplimab</b><br><br>Libtayo®<br><br>SMC2216             | As monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. | Routinely available in line with local or regional guidance       | 24/02/2020       |
| <b>cemiplimab</b><br><br>Libtayo®<br><br>SMC2584             | Monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation.    | Routinely available in line with local or regional guidance       | 11/12/2023       |

[http://www.scottishmedicines.org.uk/SMC\\_Advice/Advice/932\\_13\\_cefuroxime\\_sodium\\_Aprokam/cefuroxime\\_Aprokam\\_Abbreviated](http://www.scottishmedicines.org.uk/SMC_Advice/Advice/932_13_cefuroxime_sodium_Aprokam/cefuroxime_Aprokam_Abbreviated)

| Medicine                                           | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                  | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>cemiplimab</b><br><br>Libtayo®<br><br>SMC2719   | monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.                                                                                                                                                                                                                                            | Routinely available in line with local or regional guidance       | 28/04/2025       |
| <b>Cemiplimab</b><br><br>Libtayo<br><br>SMC 2724   | In combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in $\geq 1\%$ of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have: <ul style="list-style-type: none"> <li>•locally advanced NSCLC who are not candidates for definitive chemoradiation, or</li> <li>•metastatic NSCLC.</li> </ul> | Not routinely available as not recommended for use in NHSScotland | 07/10/2024       |
| <b>Cemiplimab</b><br><br>Libtayo®<br><br>SMC2489   | As monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in $\geq 50\%$ tumour cells), with no EGFR, ALK or ROS1 aberrations, who have: <ul style="list-style-type: none"> <li>- locally advanced NSCLC who are not candidates for definitive chemoradiation, or</li> <li>- metastatic NSCLC</li> </ul>                                   | Not routinely available as not recommended for use in NHSScotland | 13/06/2022       |
| <b>Cenegermine</b><br><br>Oxervate®<br><br>SMC2124 | Treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.                                                                                                                                                                                                                                                                                         | Not routinely available as not recommended for use in NHSScotland | 08/10/2018       |

| Medicine                                                | Condition being treated                                                                                                                                                                                                            | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Cenobamate</b><br><br>Ontozry®<br><br>SMC2408        | Adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti-epileptic medicinal products. | Routinely available in line with national guidance                | 21/02/2022       |
| <b>Ceritinib</b><br><br>Zykadia ®<br><br>1333/18        | As monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer.                                                                                  | Not routinely available as not recommended for use in NHSScotland | 23/04/2018       |
| <b>Certolizumab and Secukinumab</b><br><br>TA445        | Active psoriatic arthritis after inadequate response to DMARDs                                                                                                                                                                     | Routinely available in line with national guidance                | 28/08/2017       |
| <b>Certolizumab pegol</b><br><br>Cimzia®<br><br>1155/16 | Treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.                                                                                                                          | Not routinely available as not recommended for use in NHSScotland | 13/06/2016       |

| Medicine                                                                          | Condition being treated                                                                                                                                                                                                    | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Certolizumab Pegol</b><br><br>Cimzia®<br><br>SMC2132                           | Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy                                                                                                                         | Routinely available in line with national guidance                | 09/12/2019       |
| <b>Chenodeoxycholic acid</b><br><br>Chenodeoxycholic acid<br>Leadiant®<br>SMC2190 | Treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis) in infants, children and adolescents aged 1 month to 18 years and adults. | Not routinely available as not recommended for use in NHSScotland | 10/06/2019       |
| <b>Chlormethine hydrochloride</b><br><br>Ledaga®<br><br>SMC2318                   | for the topical treatment of mycosis fungoides-type cutaneous Tcell lymphoma (MF-type CTCL) in adult patients                                                                                                              | Routinely available in line with local or regional guidance       | 14/06/2021       |
| <b>Chloroprocaine hydrochloride</b><br><br>Ampres®<br><br>SMC2373                 | Spinal anaesthesia in adults where the planned surgical procedure should not exceed 40 minutes.                                                                                                                            | Routinely available in line with national guidance                | 18/10/2021       |

| Medicine                                           | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>ciclosporin</b><br><br>Cequa®<br><br>SMC2739    | 0 Treatment of moderate-to-severe Dry Eye Disease (keratoconjunctivitis sicca) in adult patients who have not responded adequately to artificial tears.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Routinely available in line with local or regional guidance       | 17/02/2025       |
| <b>Ciclosporin</b><br><br>Verkazia®<br><br>SMC2111 | 0 Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Routinely available in line with national guidance                | 25/02/2019       |
| <b>Cinacalcet</b><br><br>Mimpara®<br><br>SMC2275   | 0 Secondary hyperparathyroidism (HPT):<br>- Treatment of secondary HPT in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.<br>- Treatment of secondary HPT in children aged 3 years and older with ESRD on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy<br>Parathyroid carcinoma and primary HPT in adults<br>- Reduction of hypercalcaemia in adult patients with:<br>- parathyroid carcinoma.<br>- primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but in whom parathyroidectomy is not clinically appropriate or is contraindicated | Not routinely available as not recommended for use in NHSScotland | 06/07/2020       |

| Medicine                                                               | Condition being treated                                                                                                                                                                        | NHSGGC Decision                                             | Date of decision |
|------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>cipaglucosidase alfa</b><br><br>Pombiliti®<br><br>SMC2606           | Long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency). | Routinely available in line with national guidance          | 11/12/2023       |
| <b>Ciprofloxacin</b><br><br>Cetraxal®<br><br>1320/18                   | Treatment of acute otitis externa in adults and children older than 1 year with an intact tympanic membrane, caused by ciprofloxacin susceptible microorganisms.                               | Routinely available in line with national guidance          | 23/04/2018       |
| <b>Ciprofloxacin with Dexamethasone</b><br><br>Cilodex®<br><br>1256/17 | Treatment of the following infections in adults and children:<br>- Acute otitis media in patients with tympanostomy tubes (AOMT)<br>- Acute otitis externa                                     | Routinely available in line with national guidance          | 28/08/2017       |
| <b>Cladribine</b><br><br>Mavenclad®<br><br>1300/18                     | Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.                                                                   | Routinely available in line with local or regional guidance | 26/02/2018       |

<https://www.scottishmedicines.org.uk/medicines-advice/ciprofloxacin-hydrochloride-cetraxal-abbreviatedsubmission-132018/>

[http://www.scottishmedicines.org.uk/files/advice/ciprofloxacin-dexamethasone\\_Cilodex\\_Abbreviated\\_FINAL\\_June\\_2017\\_for\\_website.pdf](http://www.scottishmedicines.org.uk/files/advice/ciprofloxacin-dexamethasone_Cilodex_Abbreviated_FINAL_June_2017_for_website.pdf)

[http://www.scottishmedicines.org.uk/files/advice/cladribine\\_Mavenclad\\_FINAL\\_Jan\\_2018\\_Amended\\_07.02.18\\_for\\_website.pdf](http://www.scottishmedicines.org.uk/files/advice/cladribine_Mavenclad_FINAL_Jan_2018_Amended_07.02.18_for_website.pdf)

| Medicine                                                                     | Condition being treated                                                                                                                           | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>cladribine</b><br><br>Mavenclad®<br><br>SMC2751                           | Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease as defined by clinical or imaging features.<br>0 | Routinely available in line with local or regional guidance       | 16/06/2025       |
| <b>clostridium botulinum neurotoxin type A</b><br><br>Xeomin®<br><br>SMC2680 | Focal spasticity of the lower limb affecting the ankle joint<br>0                                                                                 | Not routinely available as not recommended for use in NHSScotland | 17/06/2024       |
| <b>Clostridium botulinum neurotoxin type A</b><br><br>Xeomin®<br><br>SMC2212 | Symptomatic treatment of chronic sialorrhoea due to neurological disorders in adults.<br>0                                                        | Routinely available in line with national guidance                | 09/12/2019       |
| <b>Clostridium botulinum type A toxin</b><br><br>Dysport®<br><br>1321/18     | Symptomatic treatment of focal spasticity of lower limbs in adults affecting the ankle joint due to stroke or traumatic brain injury.<br>0        | Not routinely available as not recommended for use in NHSScotland | 23/04/2018       |

<https://www.scottishmedicines.org.uk/medicines-advice/clostridium-botulinum-type-a-toxin-haemagglutinin-complex-300-and-500-units-dysport-no>

| Medicine                                                                  | Condition being treated                                                                                                                                                                                                                       | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Cobimetinib</b><br><br>Cotellic®<br><br>1191/16                        | In combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.                                                                                                       | Not routinely available as not recommended for use in NHSScotland | 10/10/2016       |
|                                                                           | <a href="http://www.scottishmedicines.org.uk/files/advice/cobimetinib_Cotellic_Non_Sub_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/cobimetinib_Cotellic_Non_Sub_FINAL_August_2016_for_website.pdf</a> |                                                                   |                  |
| <b>Co-careldopa</b><br><br>Duodopa®<br><br>316/06                         | Treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.                           | Routinely available in line with national guidance                | 13/06/2016       |
| <b>Collagenase clostridium histolyticum</b><br><br>Xiapex®<br><br>MTA 459 | Dupuytren's contracture                                                                                                                                                                                                                       | Routinely available in line with national guidance                | 23/10/2017       |
|                                                                           | <a href="https://www.nice.org.uk/Guidance/TA459">https://www.nice.org.uk/Guidance/TA459</a>                                                                                                                                                   |                                                                   |                  |
| <b>Conestat Alfa</b><br><br>Ruconest®<br><br>745/11                       | For treatment of acute angioedema attacks in adults and adolescents with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency                                                                                                  | Routinely available in line with national guidance                | 13/08/2018       |
|                                                                           | <a href="https://www.scottishmedicines.org.uk/media/3647/conestat-alfa-ruconest-final-20180808-for-website.pdf">https://www.scottishmedicines.org.uk/media/3647/conestat-alfa-ruconest-final-20180808-for-website.pdf</a>                     |                                                                   |                  |



| Medicine                                            | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Crizanlizumab</b><br><br>Adakveo®<br><br>SMC2438 | Prevention of recurrent vaso-occlusive crises in sickle cell disease patients aged 16 years and older. It can be given as an add-on therapy to hydroxycarbamide or as monotherapy in patients for whom hydroxycarbamide is inappropriate or inadequate.                                                                                                                                                                                                                                                                                                              | Routinely available in line with national guidance                | 15/08/2022       |
| <b>Crizotinib</b><br><br>Xalkori®<br><br>1152/16    | First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).                                                                                                                                                                                                                                                                                                                                                                                                                                           | Routinely available in line with local or regional guidance       | 22/08/2016       |
| <b>Crizotinib</b><br><br>Xalkori®<br><br>SMC2621    | <p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1152_16_crizotinib_Xalkori/crizotinib_Xalkori">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1152_16_crizotinib_Xalkori/crizotinib_Xalkori</a></p> As monotherapy for the treatment of paediatric patients (age ≥6 to <18 years) with:<br>- relapsed or refractory systemic anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL)<br>- recurrent or refractory anaplastic lymphoma kinase (ALK) positive unresectable inflammatory myofibroblastic tumour (IMT). | Not routinely available as not recommended for use in NHSScotland | 09/10/2023       |
| <b>Crizotinib</b><br><br>Xalkori®<br><br>1329/18    | Treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Routinely available in line with local or regional guidance       | 11/06/2018       |

| Medicine                                         | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                | NHSGGC Decision                                             | Date of decision |
|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>crovalimab</b><br><br>Piasky®<br><br>SMC2728  | <p>Monotherapy for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH):</p> <ul style="list-style-type: none"> <li>- In patients with haemolysis with clinical symptom(s) indicative of high disease activity.</li> <li>- In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.</li> </ul> | Routinely available in line with national guidance          | 28/04/2025       |
| <b>Cyanocobalamin</b>                            | Vitamin B12 deficiency (Short-term diagnostic use - refer to Formulary for full details)                                                                                                                                                                                                                                                                                                                                                                                               | Routinely available in line with local or regional guidance | 11/12/2017       |
| <b>Dabrafenib</b><br><br>capsules<br><br>SMC2131 | In combination with trametinib for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.                                                                                                                                                                                                                                                                                                                           | Routinely available in line with local or regional guidance | 25/02/2019       |

| Medicine                                                                                                                                                                                                                  | Condition being treated                                                                                                                                                                               | NHSGGC Decision                                             | Date of decision |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Dabrafenib (caps) and trametinib (tabs) combination</b>                                                                                                                                                                | The treatment of adult patients with locally advanced or metastatic anaplastic thyroid cancer with evidence of a BRAF V600E mutation and with no satisfactory locoregional treatment options.         | Routinely available in line with local or regional guidance | 11/12/2023       |
| NCMAG107                                                                                                                                                                                                                  |                                                                                                                                                                                                       |                                                             |                  |
| <b>Daclizumab</b>                                                                                                                                                                                                         | In adult patients for the treatment of relapsing forms of multiple sclerosis.                                                                                                                         | Routinely available in line with national guidance          | 24/04/2017       |
| Zinbryta®                                                                                                                                                                                                                 |                                                                                                                                                                                                       |                                                             |                  |
| 1216/17                                                                                                                                                                                                                   |                                                                                                                                                                                                       |                                                             |                  |
| <b>Dacomitinib</b>                                                                                                                                                                                                        | Monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. | Routinely available in line with local or regional guidance | 07/10/2019       |
| Vizimpro®                                                                                                                                                                                                                 |                                                                                                                                                                                                       |                                                             |                  |
| SMC2184                                                                                                                                                                                                                   |                                                                                                                                                                                                       |                                                             |                  |
| <b>Dalbavancin</b>                                                                                                                                                                                                        | Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.                                                                                                                   | Routinely available in line with local or regional guidance | 20/02/2017       |
| Xydalba®                                                                                                                                                                                                                  |                                                                                                                                                                                                       |                                                             |                  |
| 1105/15                                                                                                                                                                                                                   |                                                                                                                                                                                                       |                                                             |                  |
| <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1105_15_dalbavancin_Xydalba/dalbavancin_Xydalba">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1105_15_dalbavancin_Xydalba/dalbavancin_Xydalba</a> |                                                                                                                                                                                                       |                                                             |                  |

| Medicine                                            | Condition being treated                                                                                                                                                                                                                                 | NHSGGC Decision                                    | Date of decision |
|-----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|------------------|
| <b>danicopan</b><br><br>Voydeya®<br><br>SMC2675     | Add-on to ravulizumab or eculizumab for the<br>0 treatment of adult patients with paroxysmal<br>nocturnal haemoglobinuria (PNH) who have<br>residual haemolytic anaemia.                                                                                | Routinely available in line with national guidance | 28/04/2025       |
| <b>Dapagliflozin</b><br><br>Forxiga®<br><br>SMC2322 | The treatment of symptomatic chronic heart failure<br>0 with reduced ejection fraction in adult patients.                                                                                                                                               | Routinely available in line with national guidance | 19/04/2021       |
| <b>dapagliflozin</b><br><br>Forxiga®<br><br>SMC2577 | In adults for the treatment of symptomatic chronic<br>0 heart failure with left ventricular ejection fraction<br>(LVEF) >40%.                                                                                                                           | Routinely available in line with national guidance | 21/08/2023       |
| <b>Dapagliflozin</b><br><br>Forxiga®<br><br>SMC2185 | In adults for the treatment of insufficiently<br>0 controlled type 1 diabetes mellitus as an adjunct to<br>insulin in patients with BMI ≥27kg/m2, when insulin<br>alone does not provide adequate glycaemic control<br>despite optimal insulin therapy. | Routinely available in line with national guidance | 07/10/2019       |

| Medicine                                            | Condition being treated                                                                                                                                                                                                                                                                                                                               | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>dapagliflozin</b><br><br>Forxiga®<br><br>SMC2763 | Treatment of chronic kidney disease (CKD).<br>0                                                                                                                                                                                                                                                                                                       | Routinely available in line with local or regional guidance       | 28/04/2025       |
| <b>Dapagliflozin</b><br><br>Forxiga®<br><br>SMC2428 | In adults for the treatment of chronic kidney disease.<br>0                                                                                                                                                                                                                                                                                           | Routinely available in line with national guidance                | 13/06/2022       |
| <b>Daptomycin</b><br><br>Cubicin®<br><br>1309/18    | Treatment of paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia associated with complicated skin and soft-tissue infections.<br>0                                                                                                                                                                                      | Not routinely available as not recommended for use in NHSScotland | 26/02/2018       |
| <b>Daptomycin</b><br><br>Cubicin®<br><br>1141/16    | <a href="http://www.scottishmedicines.org.uk/files/advice/daptomycin_Cubicin_Non_Sub_FINAL_Jan_2018_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/daptomycin_Cubicin_Non_Sub_FINAL_Jan_2018_for_website.pdf</a><br>Treatment of paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections.<br>0 | Not routinely available as not recommended for use in NHSScotland | 18/04/2016       |

| Medicine                                           | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | NHSGGC Decision                                             | Date of decision |
|----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Daratumumab</b><br><br>Darzalex®<br><br>1205/17 | As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/daratumumab_Darzalex_Resubmission_FINAL_Sept_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/daratumumab_Darzalex_Resubmission_FINAL_Sept_2017_for_website.pdf</a> | Routinely available in line with local or regional guidance | 23/10/2017       |
| <b>Daratumumab</b><br><br>Darzalex®<br><br>SMC2536 | In combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).                                                                                                                                                                                                                                                                                                                       | Routinely available in line with local or regional guidance | 09/10/2023       |
| <b>Daratumumab</b><br><br>Darzalex®<br><br>SMC2447 | In combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis.                                                                                                                                                                                                                                                                                                                                                | Routinely available in line with local or regional guidance | 15/08/2022       |
| <b>Daratumumab</b><br><br>Darzalex®<br><br>SMC2301 | in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.                                                                                                                                                                                                                                                                                                                      | Routinely available in line with local or regional guidance | 26/10/2020       |

| Medicine                                           | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Daratumumab</b><br><br>Darzalex®<br><br>1205/17 | 0 Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1205_17_daratumumab_Darzalex/daratumumab_Darzalex">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1205_17_daratumumab_Darzalex/daratumumab_Darzalex</a> | Not routinely available as not recommended for use in NHSScotland | 20/02/2017       |
| <b>Daratumumab</b><br><br>Darzalex®<br><br>SMC2180 | 0 In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.                                                                                                                                                                                                                                                                                             | Routinely available in line with local or regional guidance       | 12/08/2019       |
| <b>Daratumumab</b><br><br>Darzalex®<br><br>SMC2326 | 0 In combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant                                                                                                                                                                                                                                                                                             | Routinely available in line with local or regional guidance       | 19/04/2021       |
| <b>Daratumumab</b><br><br>Darzalex®<br><br>SMC2416 | 0 In combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.                                                                                                                                                                                                                                                                                               | Not routinely available as not recommended for use in NHSScotland | 13/06/2022       |

| Medicine                                           | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                            | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Daratumumab</b><br><br>Darzalex®<br><br>SMC2269 | In combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.                                                                                                                                                                                                                               | Not routinely available as not recommended for use in NHSScotland | 24/02/2020       |
| <b>Daratumumab</b><br><br>Darzalex®<br><br>SMC2469 | Combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy. | Not routinely available as not recommended for use in NHSScotland | 13/06/2022       |
| <b>Daratumumab</b><br><br>Darzalex®<br><br>SMC2302 | In combination with bortezomib, thalidomide and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.                                                                                                                                                                                                                     | Routinely available in line with local or regional guidance       | 19/04/2021       |
| <b>Daratumumab</b><br><br>Darzalex®<br><br>SMC2191 | In combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.                                                                                                                                                                                                                         | Not routinely available as not recommended for use in NHSScotland | 10/06/2019       |



| Medicine                                                           | Condition being treated                                                                                                                                                                                                                                | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Daratumumab</b><br><br><a href="#">Darzalex®</a><br><br>SMC2304 | as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. | Routinely available in line with local or regional guidance       | 26/10/2020       |
| <b>daridorexant</b><br><br><a href="#">Quviviq®</a><br><br>SMC2611 | Treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.                                                                                                      | Routinely available in line with national guidance                | 22/04/2024       |
| <b>Darolutamide</b><br><br><a href="#">Nubeqa®</a><br><br>SMC2544  | Treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.                                                                                                                                           | Not routinely available as not recommended for use in NHSScotland | 24/04/2023       |
| <b>Darolutamide</b><br><br><a href="#">Nubeqa®</a><br><br>SMC2297  | Treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.                                                                                                        | Routinely available in line with local or regional guidance       | 14/12/2020       |

| Medicine                                                                                                                                                                                                                                                              | Condition being treated                                                                                                                                                                                             | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Darolutamide</b><br><br>Nubeqa®<br><br>SMC2604                                                                                                                                                                                                                     | Treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.                                                                                                        | Routinely available in line with local or regional guidance       | 09/10/2023       |
| <b>Darunavir, Cobicistat, Emtricitabine, Tenofovir</b><br><br>Symtuza®<br><br>1290/18                                                                                                                                                                                 | the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40kg).                                                          | Routinely available in line with national guidance                | 26/02/2018       |
| <b>Darvadstrocel</b><br><br>Alofisel®<br><br>SMC2115                                                                                                                                                                                                                  | treatment of complex perianal fistulas in adult patients with non-active / mildly active luminal Crohn's disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. | Not routinely available as not recommended for use in NHSScotland | 12/08/2019       |
| <b>Dasatinib</b><br><br>Sprycel®<br><br>370/07                                                                                                                                                                                                                        | The treatment of adult patients with chronic, accelerated or blast phase chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate                            | Routinely available in line with local or regional guidance       | 10/10/2016       |
| <a href="http://www.scottishmedicines.org.uk/files/advice/darunavir_Symtuza_Abbreviated_FINAL_Dec_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/darunavir Symtuza Abbreviated FINAL Dec 2017 for website.pdf</a>                             |                                                                                                                                                                                                                     |                                                                   |                  |
| <a href="http://www.scottishmedicines.org.uk/files/advice/dasatinib_Sprycel_Resub_FINAL_August_2016_Amended_06.09.16_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/dasatinib Sprycel Resub FINAL August 2016 Amended 06.09.16 for website.pdf</a> |                                                                                                                                                                                                                     |                                                                   |                  |

| Medicine                                        | Condition being treated                                                                                                                                                                                                                         | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Dasatinib</b><br><br>Sprycel®<br><br>SMC2142 | The treatment of paediatric patients with newly<br>0 diagnosed Philadelphia chromosome positive<br>chronic myelogenous leukaemia in chronic phase<br>(Ph+ CML-CP) or Ph+ CML-CP resistant or<br>intolerant to prior therapy including imatinib. | Routinely available in line with national guidance                | 29/04/2019       |
| <b>dasatinib</b><br><br><br><br>NCMAG117        | Dasatinib for the treatment of adult patients with<br>0 Philadelphia chromosome positive (Ph+) acute<br>lymphoblastic leukaemia (ALL) with resistance or<br>intolerance to prior therapy                                                        | Routinely available in line with local or regional guidance       | 17/02/2025       |
| <b>Dasatinib</b><br><br>Sprycel®<br><br>SMC2192 | Treatment of paediatric patients with newly<br>0 diagnosed Philadelphia chromosome positive acute<br>lymphoblastic leukaemia in combination with<br>chemotherapy.                                                                               | Not routinely available as not recommended for use in NHSScotland | 10/06/2019       |
| <b>dasatinib</b><br><br><br><br>NCMAG116        | Treatment of adult patients with newly diagnosed<br>0 Philadelphia chromosome positive (Ph+) acute<br>lymphoblastic leukaemia (ALL) integrated with<br>chemotherapy                                                                             | Routinely available in line with local or regional guidance       | 17/02/2025       |

| Medicine                                                             | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Dasatinib</b><br><br>Sprycel®<br><br>1170/16                      | The treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/dasatinib_Sprycel_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/dasatinib_Sprycel_FINAL_August_2016_for_website.pdf</a>                                                                                                                                                                                                                                    | Routinely available in line with local or regional guidance       | 10/10/2016       |
| <b>decitabine , cedazuridine</b><br><br>Inaqovi®<br><br>SMC2681      | Monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Not routinely available as not recommended for use in NHSScotland | 17/06/2024       |
| <b>Defatted Arachis hypogaea L.</b><br><br>Palforzia®<br><br>SMC2487 | treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. Palforzia® may be continued in patients 18 years of age and older. Palforzia® should be used in conjunction with a peanut-avoidant diet.                                                                                                                                                                                                                                                                                                                                                                                        | Not routinely available as not recommended for use in NHSScotland | 10/10/2022       |
| <b>Deferasirox</b><br><br>Exjade®<br><br>1246/17                     | Treatment of chronic iron overload due to frequent blood transfusions in patients with beta thalassaemia major aged 6 years and older and treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in specific patient groups as outlined in full in the SMC advice.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/deferiasirox_Exjade_Abbreviated_FINAL_May_2017_Amended_050617_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/deferiasirox_Exjade_Abbreviated_FINAL_May_2017_Amended_050617_for_website.pdf</a> | Routinely available in line with national guidance                | 19/06/2017       |

| Medicine                                            | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                           | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Deferasirox</b><br><br>Exjade®<br><br>347/07     | Treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate, in adult and paediatric patients aged 2 years and older with rare acquired or inherited anaemias.<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/347_07_deferasirox_Exjade/deferasirox_Exjade_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/347_07_deferasirox_Exjade/deferasirox_Exjade_Resub</a> | Routinely available in line with local or regional guidance       | 20/02/2017       |
| <b>degarelix</b><br><br>Firmagon®<br><br>SMC2625    | •for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.<br>•as neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.                                                                                                                                                                                     | Routinely available in line with local or regional guidance       | 11/12/2023       |
| <b>Delafloxacin</b><br><br>Quofenix®<br><br>SMC2453 | Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of this infection.                                                                                                                                                                                                                               | Routinely available in line with national guidance                | 15/08/2022       |
| <b>Delafloxacin</b><br><br>Quofenix®<br><br>SMC2393 | Treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections. Consideration should be given to official guidance on the appropriate use of antibacterial agents.                                                                                                                                                   | Not routinely available as not recommended for use in NHSScotland | 09/08/2021       |

| Medicine                                                                                                                                                                                                                                                                                                                                                                                                                                           | Condition being treated                                                                                                                                                                                                                                                                                               | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Delta-9-tetrahydrocannabinol, cannabidiol</b><br><br>Sativex®<br><br>SMC2473                                                                                                                                                                                                                                                                                                                                                                    | treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy. | Routinely available in line with national guidance                | 10/10/2022       |
| <b>Denosumab</b><br><br>Xgeva®<br><br>2110                                                                                                                                                                                                                                                                                                                                                                                                         | Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with haematological malignancies involving bone.                                                                                                                               | Not routinely available as not recommended for use in NHSScotland | 13/08/2018       |
| <b>Denosumab</b><br><br>Prolia ®<br><br>SMC2017                                                                                                                                                                                                                                                                                                                                                                                                    | Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.                                                                                                                                                                                     | Not routinely available as not recommended for use in NHSScotland | 08/10/2018       |
| <b>Dequalinium chloride</b><br><br>Floumizin®<br><br>1194/16                                                                                                                                                                                                                                                                                                                                                                                       | Treatment of bacterial vaginosis.                                                                                                                                                                                                                                                                                     | Routinely available in line with national guidance                | 12/12/2016       |
| <a href="https://www.scottishmedicines.org.uk/medicines-advice/denosumab-xgeva-non-submission-smc2110/">https://www.scottishmedicines.org.uk/medicines-advice/denosumab-xgeva-non-submission-smc2110/</a><br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1194_16_dequalinium_Floumizin/dequalinium_Floumizin">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1194_16_dequalinium_Floumizin/dequalinium_Floumizin</a> |                                                                                                                                                                                                                                                                                                                       |                                                                   |                  |

| Medicine                                                                                                                                                                                                                          | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Dermatophagoides pteronyssinus and Dermatophagoides farina</b><br><br>Acarizax<br><br>SMC2613                                                                                                                                  | <ul style="list-style-type: none"> <li>Adult patients (18-65 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with at least one of the following conditions: <ul style="list-style-type: none"> <li>- persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication</li> <li>- house dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment</li> <li>- Adolescents (12-17 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication.</li> </ul> </li> </ul> | Not routinely available as not recommended for use in NHSScotland | 21/08/2023       |
| <b>Desmopressin</b><br><br>Noqdirna®<br><br>1218/17                                                                                                                                                                               | Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Not routinely available as not recommended for use in NHSScotland | 20/02/2017       |
| <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1218_17_desmopressin_Noqdirna/desmopressin_Noqdirna">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1218_17_desmopressin_Noqdirna/desmopressin_Noqdirna</a> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                   |                  |

| Medicine               | Condition being treated                                                                                         | NHSGGC Decision                                                                                                                                                                                                                                       | Date of decision |
|------------------------|-----------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Desmopressin</b>    | Symptomatic treatment of nocturia due to<br>idiopathic nocturnal polyuria in adults                             | Not routinely available as local<br>implementation plans are being<br>developed or ADTC is waiting for<br>further advice from local clinical<br>experts - Decision expected by:                                                                       | 28/08/2017       |
| Noqdirna®              |                                                                                                                 | 19/02/2018                                                                                                                                                                                                                                            |                  |
| 1218/17                |                                                                                                                 | <a href="http://www.scottishmedicines.org.uk/files/advice/desmopressin_Noqdirna_Resubmission_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/desmopressin_Noqdirna_Resubmission_FINAL_July_2017_for_website.pdf</a> |                  |
| <b>Desmopressin</b>    | Symptomatic treatment of nocturia due to<br>idiopathic nocturnal polyuria in adults.                            | Routinely available in line with local<br>or regional guidance                                                                                                                                                                                        | 26/02/2018       |
| Noqdirna®              |                                                                                                                 |                                                                                                                                                                                                                                                       |                  |
| 1218/17                |                                                                                                                 | <a href="http://www.scottishmedicines.org.uk/files/advice/desmopressin_Noqdirna_Resubmission_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/desmopressin_Noqdirna_Resubmission_FINAL_July_2017_for_website.pdf</a> |                  |
| <b>deucravacitinib</b> | Treatment of moderate to severe plaque psoriasis<br>in adults who are candidates for systemic therapy.          | Routinely available in line with local<br>or regional guidance                                                                                                                                                                                        | 11/12/2023       |
| Sotyktu®               |                                                                                                                 |                                                                                                                                                                                                                                                       |                  |
| SMC2581                |                                                                                                                 |                                                                                                                                                                                                                                                       |                  |
| <b>Dexamethasone</b>   | In adults for the treatment of symptomatic multiple<br>myeloma in combination with other medicinal<br>products. | Not routinely available as not<br>recommended for use in<br>NHSScotland                                                                                                                                                                               | 23/04/2018       |
| Neofordex ®            |                                                                                                                 |                                                                                                                                                                                                                                                       |                  |
| 1322/18                |                                                                                                                 | <a href="https://www.scottishmedicines.org.uk/medicines-advice/dexamethasone-40mg-tablets-neofordex-non-submission-132218/">https://www.scottishmedicines.org.uk/medicines-advice/dexamethasone-40mg-tablets-neofordex-non-submission-132218/</a>     |                  |



| Medicine                                                       | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Dexmedetomidine</b><br><br>Dexdor®<br><br>SMC2161           | 0 Sedation of non-intubated adult patients prior to and/or during diagnostic or surgical procedures requiring sedation, i.e. procedural/awake sedation.                                                                                                                                                                                                                                                                                                                                                                                                                                         | Not routinely available as not recommended for use in NHSScotland | 25/02/2019       |
| <b>Diamorphine hydrochloride</b><br><br>Ayendi®<br><br>1172/16 | 0 Treatment of acute severe nociceptive pain in children and adolescents in a hospital setting. Diamorphine hydrochloride nasal spray (Ayendi®) should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with appropriate monitoring.<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1172_16_diamorphine_hydrochloride_Ayendi/diamorphine_hydrochloride_Ayendi">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1172_16_diamorphine_hydrochloride_Ayendi/diamorphine_hydrochloride_Ayendi</a> | Routinely available in line with national guidance                | 22/08/2016       |
| <b>difelikefalin</b><br><br>Kapruvia®<br><br>SMC2623           | 0 Treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Routinely available in line with national guidance                | 19/02/2024       |
| <b>Dimethyl fumarate</b><br><br>Skilarence®<br><br>1313/18     | 0 Treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.<br><br><a href="https://www.scottishmedicines.org.uk/medicines-advice/dimethyl-fumarate-skilarence-fullsubmission/">https://www.scottishmedicines.org.uk/medicines-advice/dimethyl-fumarate-skilarence-fullsubmission/</a>                                                                                                                                                                                                                                                                  | Routinely available in line with national guidance                | 23/04/2018       |

| Medicine                                                       | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | NHSGGC Decision                                    | Date of decision |
|----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|------------------|
| <b>Dinutuximab beta</b><br><br>Qarziba<br><br>SMC2105          | Treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease                                                                                                                                      | Routinely available in line with national guidance | 25/02/2019       |
| <b>Diroximel fumarate</b><br><br>Vumerity®<br><br>SMC2444      | Treatment of adult patients with relapsing remitting multiple sclerosis.                                                                                                                                                                                                                                                                                                                                                                                                                  | Routinely available in line with national guidance | 21/02/2022       |
| <b>Dolutegravir</b><br><br>Tivicay®<br><br>1253/17             | in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected children aged >6 to 12 years of age.                                                                                                                                                                                                                                                                                                                        | Routinely available in line with national guidance | 23/10/2017       |
| <b>Dolutegravir + lamivudine</b><br><br>Dovato®<br><br>SMC2205 | <p><a href="http://www.scottishmedicines.org.uk/files/advice/dolutegravir_Tivicay_Abbreviated_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/dolutegravir Tivicay Abbreviated FINAL June 2017 for website.pdf</a></p> treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine | Routinely available in line with national guidance | 07/10/2019       |

| Medicine                                                           | Condition being treated                                                                                                                                                                                                                                                                                                                                                 | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Dolutegravir with Rilpivirine</b><br><br>Juluca®<br><br>SMC2091 | The treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor | Routinely available in line with national guidance                | 08/10/2018       |
| <b>donanemab</b><br><br>Kisunla®<br><br>SMC2687                    | Treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers.                                                                                                                                                                                        | Not routinely available as not recommended for use in NHSScotland | 16/06/2025       |
| <b>Doravirine</b><br><br>Pifeltro®<br><br>SMC2332                  | In combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class.                                                                                                                                        | Routinely available in line with national guidance                | 19/04/2021       |
| <b>Doravirine</b><br><br>Pifeltro®<br><br>SMC2162                  | In combination with other antiretroviral medicinal products, for the treatment of adults infected with human immunodeficiency virus 1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor class.                                                                                                                       | Not routinely available as not recommended for use in NHSScotland | 25/02/2019       |

| Medicine                                                                  | Condition being treated                                                                                                                                                                                                                                              | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Doravirine, lamivudine, tenofovir</b><br><br>Delstrigo®<br><br>SMC2163 | Treatment of adults infected with human immunodeficiency virus 1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor class, lamivudine, or tenofovir.                                                               | Not routinely available as not recommended for use in NHSScotland | 25/02/2019       |
| <b>Doravirine/Lamivudine/Tenofovir</b><br><br>Delstrigo®<br><br>SMC2333   | Treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine, or tenofovir.                                                                                | Routinely available in line with national guidance                | 19/04/2021       |
| <b>Dostarlimab</b><br><br>Jemperli®<br><br>SMC2404                        | Monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.  | Routinely available in line with local or regional guidance       | 13/06/2022       |
| <b>dostarlimab</b><br><br>Jemperli®<br><br>SMC2635                        | In combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy. | Routinely available in line with local or regional guidance       | 19/08/2024       |

| Medicine                                                         | Condition being treated                                                                                                                                                                                                                                           | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Doxylamine &amp; Pyridoxine</b><br><br>Xonvea®<br><br>SMC2140 | 0 Treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.                                                                                                                                                           | Not routinely available as not recommended for use in NHSScotland | 10/06/2019       |
| <b>Drospirone</b><br><br>Slynd<br><br>SMC 2725                   | 0 Contraception                                                                                                                                                                                                                                                   | Not routinely available as not recommended for use in NHSScotland | 07/10/2024       |
| <b>Dulaglutide</b><br><br>Trulicity®<br><br>1110/15              | 0 In adults with type 2 diabetes mellitus to improve glycaemic control as add-on therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. | Routinely available in line with national guidance                | 22/02/2016       |
| <b>Dupilumab</b><br><br>Dupixent®<br><br>SMC2011                 | 0 The treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.                                                                                                                                                | Routinely available in line with local or regional guidance       | 25/02/2019       |

| Medicine                                         | Condition being treated                                                                                                                                                                                                                                                                                                                                         | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>dupilumab</b><br><br>Dupixent®<br><br>SMC2801 | In adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.  | Not routinely available as not recommended for use in NHSScotland | 18/08/2025       |
| <b>Dupilumab</b><br><br>Dupixent®<br><br>SMC2317 | In adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. | Routinely available in line with national guidance                | 19/04/2021       |
| <b>Dupilumab</b><br><br>Dupixent®<br><br>SMC2324 | As an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control                                                                                                                  | Not routinely available as not recommended for use in NHSScotland | 19/04/2021       |
| <b>dupilumab</b><br><br>Dupixent®<br><br>SMC2682 | Treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy                                                                                                                                | Not routinely available as not recommended for use in NHSScotland | 17/06/2024       |

| Medicine                                         | Condition being treated                                                                                                                                                                                                                                                                     | NHSGGC Decision                                             | Date of decision |
|--------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>dupilumab</b><br><br>Dupixent®<br><br>SMC2598 | 0 Treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.                                                                                                                                                                               | Routinely available in line with national guidance          | 19/02/2024       |
| <b>Durvalumab</b><br><br>Imfinzi®<br><br>SMC2156 | 0 As monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 [programmed cell death ligand 1] on ≥1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy. | Routinely available in line with local or regional guidance | 10/06/2019       |
| <b>durvalumab</b><br><br>Imfinzi®<br><br>SMC2734 | 0 In combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).                                                                                                                           | Routinely available in line with local or regional guidance | 16/06/2025       |
| <b>durvalumab</b><br><br>Imfinzi®<br><br>SMC2582 | 0 In combination with gemcitabine and cisplatin for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer.                                                                                                                             | Routinely available in line with local or regional guidance | 11/12/2023       |

| Medicine                                         | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>durvalumab</b><br><br>Imfinzi®<br><br>SMC2677 | In combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, is indicated for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known EGFR mutations or ALK rearrangements                                                                                                                     | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 09/12/2024       |
| <b>Durvalumab</b><br><br>Imfinzi®<br><br>SMC2434 | In combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer.                                                                                                                                                                                                                                                                                  | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 13/12/2021       |
| <b>durvalumab</b><br><br>Imfinzi<br><br>SMC2797  | in combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with:<br>•durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)<br>•durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR). | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>08/12/2025 | 06/10/2025       |



| Medicine                                         | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                     | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>durvalumab</b><br><br>Imfinzi®<br><br>SMC2735 | In combination with tremelimumab for the first-line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC)                                                                                                                                                                                                                                                                                                                        | Not routinely available as not recommended for use in NHSScotland | 16/06/2025       |
| <b>Eculizumab</b><br><br>Soliris®<br><br>1130/16 | In adults and children, for the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH). Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a> | Not routinely available as not recommended for use in NHSScotland | 18/04/2016       |
| <b>Eculizumab</b><br><br>Soliris®<br><br>767/12  | In adults and children for the treatment of patients with atypical haemolytic uraemic syndrome (aHUS)                                                                                                                                                                                                                                                                                                                                                       | Not routinely available as not recommended for use in NHSScotland | 22/02/2016       |
| <b>Eculizumab</b><br><br>Soliris®<br><br>SMC2456 | Treatment of adults with neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody-positive with a relapsing course of the disease                                                                                                                                                                                                                                                                                               | Not routinely available as not recommended for use in NHSScotland | 21/02/2022       |

| Medicine                                                      | Condition being treated                                                                                                                                                                            | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Eculizumab</b><br><br>Soliris®<br><br>SMC2236              | Treatment of adults with refractory generalised myasthenia gravis who are anti-acetylcholine receptor antibody-positive                                                                            | Not routinely available as not recommended for use in NHSScotland | 07/10/2019       |
| <b>efgartigimod alfa</b><br><br>Vyvgart®<br><br>SMC2561       | Add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.                              | Not routinely available as not recommended for use in NHSScotland | 11/12/2023       |
| <b>Eladocagene exuparvovec</b><br><br>Upstaza®<br><br>SMC2586 | Treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase (AADC) deficiency with a severe phenotype.   | Routinely available in line with national guidance                | 22/04/2024       |
| <b>elafibranor</b><br><br>Iqirvo®<br><br>SMC2714              | Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. | Routinely available in line with local or regional guidance       | 28/04/2025       |

| Medicine                                                        | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Elbasvir and grazoprevir</b><br><br>Zepatier®<br><br>1203/17 | Treatment of chronic hepatitis C (CHC) in adults.<br>0 (The efficacy of elbasvir-grazoprevir has not been demonstrated in genotypes 2, 3, 5 and 6. Elbasvir-grazoprevir is not recommended in patients infected with these genotypes).<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1203_17_elbasvir-grazoprevir_Zepatier/elbasvir-grazoprevir_Zepatier">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1203_17_elbasvir-grazoprevir_Zepatier/elbasvir-grazoprevir_Zepatier</a> | Routinely available in line with national guidance                | 20/02/2017       |
| <b>Eliglustat</b><br><br>Cerdelga®<br><br>1277/17               | Long-term treatment of adult patients with Gaucher<br>0 disease type 1 (GD1) who are CYP2D6 poor metabolisers, intermediate metabolisers or extensive metabolisers                                                                                                                                                                                                                                                                                                                                              | Routinely available in line with national guidance                | 11/12/2017       |
| <b>Elotuzumab</b><br><br>Empliciti®<br><br>SMC2407              | In combination with pomalidomide and<br>0 dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.                                                                                                                                                                                                       | Not routinely available as not recommended for use in NHSScotland | 09/08/2021       |
| <b>Elotuzumab</b><br><br>Empliciti®<br><br>1183/16              | Treatment of multiple myeloma in combination with<br>0 lenalidomide and dexamethasone in adult patients who have received at least one prior therapy.                                                                                                                                                                                                                                                                                                                                                           | Not routinely available as not recommended for use in NHSScotland | 22/08/2016       |
|                                                                 | <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1183_16_elotuzumab_Empliciti/elotuzumab_Empliciti">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1183_16_elotuzumab_Empliciti/elotuzumab_Empliciti</a>                                                                                                                                                                                                                                                                                   |                                                                   |                  |

| Medicine                                                                                                                                                                                                                                                                          | Condition being treated                                                                                                                                                                                                                                                                                  | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>elranatamab</b><br><br>Elrexio®<br><br>SMC2669                                                                                                                                                                                                                                 | 0 Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. | Routinely available in line with local or regional guidance                                                                                                                           | 28/04/2025       |
| <b>Eltrombopag</b><br><br>Revolade®<br><br>1206/17                                                                                                                                                                                                                                | 0 Chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year to 17 years who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).                                                                                                                            | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>24/04/2017 | 20/02/2017       |
| <b>Eltrombopag olamine</b><br><br>Revolade®<br><br>1164/16                                                                                                                                                                                                                        | 0 Treatment in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.                                                                           | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 13/06/2016       |
| <b>Eluxadoline</b><br><br>Truberzi®<br><br>1292/18                                                                                                                                                                                                                                | 0 in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D).                                                                                                                                                                                                                        | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 26/02/2018       |
| <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1164_16_eltrombopag_olamine_Revolade/eltrombopag_olamine_Revolade_Non_submi">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1164_16_eltrombopag_olamine_Revolade/eltrombopag_olamine_Revolade_Non_submi</a> |                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                       |                  |
| <a href="http://www.scottishmedicines.org.uk/files/advice/eluxadoline_Truberzi_FINAL_Dec_2017_Amended_14.12.17_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/eluxadoline_Truberzi_FINAL_Dec_2017_Amended_14.12.17_for_website.pdf</a>                         |                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                       |                  |

| Medicine                                                                                             | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Elvitegra/cobicistat/emtricitabine/tenofovir/raltegravir</b><br><br>Genvoya ®<br><br>1323/18      | Treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities.<br><br><a href="https://www.scottishmedicines.org.uk/medicines-advice/elvitegravir-150mg-cobicistat-150-mg-emtricitabine-200-mg-tenofovir-raltegravir-10-mg-">https://www.scottishmedicines.org.uk/medicines-advice/elvitegravir-150mg-cobicistat-150-mg-emtricitabine-200-mg-tenofovir-raltegravir-10-mg-</a> | Not routinely available as not recommended for use in NHSScotland | 23/04/2018       |
| <b>Elvitegravir, Cobicistat, Emtricitabine, Tenofovir</b><br><br>Stribild ®<br><br>1310/18           | Treatment of HIV-1 infection in adolescents aged 12 to <18 years weighing ≥35kg who are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild® and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil fumarate.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/elvit_cobic_emtric_Stribild_Non_Sub_FINAL_Jan_2018_with_website.pdf">http://www.scottishmedicines.org.uk/files/advice/elvit_cobic_emtric_Stribild_Non_Sub_FINAL_Jan_2018_with_website.pdf</a>               | Not routinely available as not recommended for use in NHSScotland | 26/02/2018       |
| <b>elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide</b><br><br>Genvoya®<br><br>SMC2809 | Treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in paediatric patients aged from 2 years and with body weight at least 14 kg to less than 25 kg.                                                                                                                                                                                                                                                                                                                                                 | Not routinely available as not recommended for use in NHSScotland | 16/06/2025       |

| Medicine                                                                  | Condition being treated                                                                                                                                                                                                                                                                                                     | NHSGGC Decision                                             | Date of decision |
|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Empagliflozin</b><br><br>Jardiance®<br><br>SMC2523                     | In adults for the treatment of symptomatic chronic heart failure with preserved ejection fraction (left ventricular ejection fraction [LVEF] >40%).                                                                                                                                                                         | Routinely available in line with national guidance          | 19/06/2023       |
| <b>Empagliflozin</b><br><br>Jardiance®<br><br>SMC2396                     | Treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction.                                                                                                                                                                                                                          | Routinely available in line with national guidance          | 18/10/2021       |
| <b>empagliflozin</b><br><br>Jardiance®<br><br>SMC2642                     | For the treatment of CKD in adults                                                                                                                                                                                                                                                                                          | Routinely available in line with local or regional guidance | 19/08/2024       |
| <b>Empagliflozin plus Linagliptin</b><br><br>Glyxambi®<br><br>SMC 1236/17 | in adults aged 18 years and older with type 2 diabetes mellitus:<br>- To improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi® do not provide adequate glycaemic control<br>- When already being treated with the free combination of empagliflozin and linagliptin | Routinely available in line with national guidance          | 12/08/2019       |

| Medicine                                                                     | Condition being treated                                                                                                                                                                                                                                                                             | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Emtricitabine with Tenofovir disoproxil</b><br><br>Truvada<br><br>1263/17 | Treatment of HIV-1 infected adolescents aged 12 to <18 years with nucleoside reverse transcriptase inhibitor resistance or toxicities precluding the use of first line agents                                                                                                                       | Not routinely available as not recommended for use in NHSScotland | 28/08/2017       |
|                                                                              | <a href="http://www.scottishmedicines.org.uk/files/advice/emtricitabine-tenofovir_disoproxil_Truvada_Non_Submission_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/emtricitabine-tenofovir_disoproxil_Truvada_Non_Submission_FINAL_June_2017_for_website.pdf</a> |                                                                   |                  |
| <b>Emtricitabine, tenofovir alafenamide</b><br><br>Descovy<br><br>N/A        | Pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in at-risk men who have sex with men, including adolescents (with body weight at least 35 kg)                                                                                                                      | Routinely available in line with local or regional guidance       | 13/06/2022       |
| <b>Emtricitabine/tenofovir alafenamide</b><br><br>Descovy®<br><br>1169/16    | In combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus type 1.                                                                                             | Routinely available in line with national guidance                | 22/08/2016       |
|                                                                              | <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1169_16_emtricitabine_tenofovir_alafenamide_Descovy/emtricitabine_tenofovir_alafena">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1169_16_emtricitabine_tenofovir_alafenamide_Descovy/emtricitabine_tenofovir_alafena</a>   |                                                                   |                  |

| Medicine                                                                 | Condition being treated                                                                                                                                                          | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Emtricitabine/tenofovir disoproxil</b><br><br>Truvada®<br><br>1225/17 | In combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.                             | Routinely available in line with national guidance                | 24/04/2017       |
| <b>Encorafenib</b><br><br>Braftovi®<br><br>SMC2145                       | In combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.                                          | Not routinely available as not recommended for use in NHSScotland | 12/08/2019       |
| <b>Encorafenib</b><br><br>Braftovi®<br><br>SMC2312                       | In combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy. | Routinely available in line with local or regional guidance       | 14/06/2021       |
| <b>encorafenib</b><br><br>Braftovi®<br><br>SMC2865                       | In combination with binimetinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.                                         | Not routinely available as not recommended for use in NHSScotland | 06/10/2025       |



| Medicine                                                            | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                    | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|---------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Encorafenib plus Binimetinib</b><br><br>Braftovi®<br><br>SMC2238 | In combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.                                                                                                                                                                                                                                                                                    | Routinely available in line with local or regional guidance                                                                                                                           | 24/02/2020       |
| <b>Enfortumab vedotin</b><br><br>Padcev®<br><br>SMC2505             | Monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor.                                                                                                                                                                            | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 15/08/2022       |
| <b>Entrectinib</b><br><br>Rozlytrek®<br><br>SMC2294                 | Monotherapy for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.                                                                                                                                                                                                                                                               | Routinely available in line with local or regional guidance                                                                                                                           | 19/04/2021       |
| <b>Entrectinib</b><br><br>Rozlytrek®<br><br>SMC2295                 | Monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion,<br>- who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and<br>- who have not received a prior NTRK inhibitor<br>- who have no satisfactory treatment options | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>31/08/2021 | 19/04/2021       |

| Medicine                                          | Condition being treated                                                                                                                                                                                                                            | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>enzalutamide</b><br><br>Xtandi®<br><br>SMC2742 | 0 Monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy. | Not routinely available as not recommended for use in NHSScotland | 09/12/2024       |
| <b>Enzalutamide</b><br><br>Xtandi®<br><br>SMC2400 | 0 Treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)                                                                                                             | Routinely available in line with local or regional guidance       | 21/02/2022       |
| <b>Enzalutamide</b><br><br>Xtandi<br><br>1066/15  | 0 Treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.               | Routinely available in line with local or regional guidance       | 18/04/2016       |
| <b>Enzalutamide</b><br><br>Xtandi®<br><br>SMC2195 | 0 The treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC).                                                                                                                                            | Not routinely available as not recommended for use in NHSScotland | 07/10/2019       |

[http://www.scottishmedicines.org.uk/SMC\\_Advice/Advice/1066\\_15\\_enzalutamide\\_Xtandi/Briefing\\_note\\_enzalutamide\\_Xtandi\\_IRP](http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1066_15_enzalutamide_Xtandi/Briefing_note_enzalutamide_Xtandi_IRP)

| Medicine                                           | Condition being treated                                                                                                                                                                                                               | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>epcoritamab</b><br><br>Tepkinly®<br><br>SMC2632 | 0 Monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.                                                                | Routinely available in line with local or regional guidance                                                                                                                           | 07/10/2024       |
| <b>eplontersen</b><br><br>Wainzua®<br><br>SMC2755  | 0 Treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with Stage 1 and 2 polyneuropathy.                                                                                                 | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>20/04/2026 | 06/10/2025       |
| <b>Epoetin Alfa</b><br><br>Eprex®<br><br>SMC2164   | 0 Treatment of symptomatic anaemia (haemoglobin concentration of $\leq 10\text{g/dL}$ ) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin ( $<200\text{ mU/mL}$ ). | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 29/04/2019       |
| <b>Eptinezumab</b><br><br>Vyepti®<br><br>SMC2547   | 0 Prophylaxis of migraine in adults who have at least 4 migraine days per month.                                                                                                                                                      | Routinely available in line with national guidance                                                                                                                                    | 20/02/2023       |

| Medicine                                                  | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>erdafitinib</b><br><br>Balversa®<br><br>SMC2738        | 0 Monotherapy for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.                                                                                                                                                                                                                                                                                              | Routinely available in line with local or regional guidance       | 16/06/2025       |
| <b>Erenumab</b><br><br>Aimovig®<br><br>SMC2134            | 0 The prophylaxis of migraine in adults who have at least four migraine days per month.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Routinely available in line with local or regional guidance       | 29/04/2019       |
| <b>Eribulin</b><br><br>Halaven®<br><br>SMC2231            | 0 Treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.                                                                                                                                                                                                                                                                                                                                                                                                                                   | Not routinely available as not recommended for use in NHSScotland | 07/10/2019       |
| <b>Eribulin (mesilate)</b><br><br>Halaven®<br><br>1065/15 | 0 Treatment of adults with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1065_15_eribulin_Halaven/Briefing_note_eribulin_Halaven_Resubmission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1065_15_eribulin_Halaven/Briefing_note_eribulin_Halaven_Resubmission</a> | Routinely available in line with local or regional guidance       | 18/04/2016       |

| Medicine                    | Condition being treated                                                                                                                                                                                                                                                                                                          | NHSGGC Decision                                                                                                                                                            | Date of decision |
|-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Erlotinib, Gefitinib</b> | Non-small cell lung cancer post chemotherapy                                                                                                                                                                                                                                                                                     | Routinely available in line with national guidance                                                                                                                         | 22/02/2016       |
| 0                           |                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                            |                  |
| TA374                       |                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                            |                  |
| <b>Ertugliflozin</b>        | In adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:                                                                                                                                                                                                 | Routinely available in line with national guidance                                                                                                                         | 25/02/2019       |
| 0                           |                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                            |                  |
| <b>Steglatro®</b>           | -As monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.                                                                                                                                                                                                   |                                                                                                                                                                            |                  |
| SMC2102                     | -In addition to other medicinal products for the treatment of diabetes.                                                                                                                                                                                                                                                          |                                                                                                                                                                            |                  |
| <b>Esketamine</b>           | Co-administered with oral antidepressant therapy, in adults with a moderate to severe episode of Major Depressive Disorder, as acute short-term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency.                                             | Not routinely available as not recommended for use in NHSScotland                                                                                                          | 12/12/2022       |
| 0                           |                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                            |                  |
| <b>Spravato®</b>            |                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                            |                  |
| SMC2539                     |                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                            |                  |
| <b>Esketamine</b>           | In combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI), for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode. | Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s) | 19/08/2024       |
| 0                           |                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                            |                  |
| <b>Spravato®</b>            |                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                            |                  |
| SMC2258                     |                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                            |                  |

| Medicine                                                                | Condition being treated                                                                                                                                                                                                                               | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Eslicarbazepine acetate</b><br><br>Zebinix ®<br><br>SMC2090          | 0 As monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy.                                                                                                       | Not routinely available as not recommended for use in NHSScotland | 11/06/2018       |
| <b>Eslicarbazepine acetate</b><br><br>Zebinix®<br><br>SMC2087           | 0 Adjunctive therapy in adolescents and children aged above 6 years with partial-onset seizures with or without secondary generalisation.                                                                                                             | Routinely available in line with national guidance                | 29/04/2019       |
| <b>Estetrol</b><br><br>Drovelis®<br><br>SMC2564                         | 0 Oral contraception                                                                                                                                                                                                                                  | Not routinely available as not recommended for use in NHSScotland | 20/02/2023       |
| <b>Estradiol, micronised progesterone</b><br><br>Bijuve®<br><br>SMC2502 | 0 : continuous combined hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses. The experience in treating women older than 65 years is limited. | Routinely available in line with national guidance                | 10/10/2022       |

| Medicine                         | Condition being treated                                                                                                                                                                                                                                         | NHSGGC Decision                                                   | Date of decision |
|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Etelcalcetide</b>             | Treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.                                                                                                                                  | Not routinely available as not recommended for use in NHSScotland | 23/10/2017       |
| <b>Parsabiv®</b>                 |                                                                                                                                                                                                                                                                 |                                                                   |                  |
| 1262/17                          |                                                                                                                                                                                                                                                                 |                                                                   |                  |
|                                  | <a href="http://www.scottishmedicines.org.uk/files/advice/etelcalcetide_Parsabiv_FINAL_August_2017_amended_030917_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/etelcalcetide_Parsabiv_FINAL_August_2017_amended_030917_for_website.pdf</a> |                                                                   |                  |
| <b>etranacogene dezaparvovec</b> | treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors.                                                                                                          | Routinely available in line with national guidance                | 18/08/2025       |
| <b>Hemgenix®</b>                 |                                                                                                                                                                                                                                                                 |                                                                   |                  |
| SMC2649                          |                                                                                                                                                                                                                                                                 |                                                                   |                  |
| <b>etrasimod</b>                 | Treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.                        | Routinely available in line with local or regional guidance       | 17/06/2024       |
| <b>Velsipity®</b>                |                                                                                                                                                                                                                                                                 |                                                                   |                  |
| SMC2655                          |                                                                                                                                                                                                                                                                 |                                                                   |                  |
| <b>Everolimus</b>                | Adjunctive treatment of patients aged two years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex (TSC).                                                              | Routinely available in line with national guidance                | 11/06/2018       |
| <b>Votubia®</b>                  |                                                                                                                                                                                                                                                                 |                                                                   |                  |
| 1331/18                          |                                                                                                                                                                                                                                                                 |                                                                   |                  |

| Medicine                                          | Condition being treated                                                                                                                                                                                                                                       | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Everolimus</b><br><br>Certican®<br><br>1288/17 | Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogenic renal transplant.                                                                                                                               | Not routinely available as not recommended for use in NHSScotland | 11/12/2017       |
| <b>Everolimus</b><br><br>Afinitor®<br><br>872/13  | Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor. | Routinely available in line with local or regional guidance       | 18/04/2016       |
| <b>Everolimus</b><br><br>Afinitor®<br><br>1215/17 | Treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.                                                                | Routinely available in line with local or regional guidance       | 20/02/2017       |
| <b>Everolimus and Sunitinib</b><br><br>MTA 449    | Unresectable or metastatic neuroendocrine tumours in people with progressive disease                                                                                                                                                                          | Routinely available in line with local or regional guidance       | 28/08/2017       |

[http://www.scottishmedicines.org.uk/SMC\\_Advice/Briefing\\_Note/Briefing\\_Note](http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note)

[http://www.scottishmedicines.org.uk/SMC\\_Advice/Advice/1215\\_17\\_everolimus\\_Afinitor/everolimus\\_Afinitor\\_NETs](http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1215_17_everolimus_Afinitor/everolimus_Afinitor_NETs)

<https://www.nice.org.uk/guidance/ta449>



| Medicine                                         | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Evolocumab</b><br><br>Repatha<br>SMC2133      | In adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:<br>- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,<br>- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.                                                                                                                                                                                                                                                  | Not routinely available as not recommended for use in NHSScotland | 10/12/2018       |
| <b>Evolocumab</b><br><br>Repatha®<br>1148/16     | In adults with primary hypercholesterolaemia (heterozygous familial hypercholesterolaemia and non-familial) or mixed dyslipidaemia, as an adjunct to diet: [1] in combination with a statin or statin with other lipid lowering therapies in patients unable to reach low density lipoprotein-cholesterol (LDL-C) goals with the maximum tolerated dose of a statin or, [2] alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1148_16_evolocumab_Repatha/evolocumab_Repatha_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1148_16_evolocumab_Repatha/evolocumab_Repatha_Resub</a> | Routinely available in line with local or regional guidance       | 20/02/2017       |
| <b>Evolocumab</b><br><br>Repatha® PFS<br>1148/16 | In adults with primary hypercholesterolaemia or mixed dyslipidaemia or in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia (see SMC advice for full details of indication)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Not routinely available as not recommended for use in NHSScotland | 13/06/2016       |

| Medicine                                                       | Condition being treated                                                                                                                                                                                                                                                                                                                                                    | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>exagamglogene autotemcel</b><br><br>Casgevy®<br><br>SMC2709 | Treatment of transfusion-dependent beta-thalassemia in patients 12 years of age and older for whom haematopoietic stem cell transplantation is appropriate and a human leukocyte antigen matched related haematopoietic stem cell donor is not available.                                                                                                                  | Routinely available in line with national guidance                | 18/08/2025       |
| <b>Fampridine</b><br><br>Fampyra®<br><br>SMC2253               | Improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS [expanded disability status scale] 4-7).                                                                                                                                                                                                                                    | Routinely available in line with local or regional guidance       | 09/08/2021       |
| <b>Fampridine</b><br><br>Fampyra®<br><br>789/12                | For the improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS [expanded disability status scale] 4 to 7).                                                                                                                                                                                                                    | Not routinely available as not recommended for use in NHSScotland | 12/12/2016       |
| <b>Fampridine</b><br><br>Fampyra<br><br>SMC2107                | <p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/789_12_fampridine_Fampyra/fampridine_Fampyra">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/789_12_fampridine_Fampyra/fampridine_Fampyra</a></p> For the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS [expanded disability status scale] 4-7). | Not routinely available as not recommended for use in NHSScotland | 10/12/2018       |

| Medicine                                          | Condition being treated                                                                                                                                                                  | NHSGGC Decision                                                | Date of decision |
|---------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------------------|
| <b>faricimab</b><br><br>Vabysmo<br><br>SMC 2685   | Treatment of adult patients with visual impairment<br>due to macular oedema secondary to retinal vein<br>occlusion (branch RVO or central RVO)                                           | Routinely available in line with local<br>or regional guidance | 09/12/2024       |
| <b>Faricimab</b><br><br>Vabysmo®<br><br>SMC2499   | Treatment of adult patients with visual impairment<br>due to diabetic macular oedema (DMO)                                                                                               | Routinely available in line with<br>national guidance          | 12/12/2022       |
| <b>Faricimab</b><br><br>Vabysmo®<br><br>SMC2512   | Treatment of adult patients with neovascular (wet)<br>age-related macular degeneration (nAMD).                                                                                           | Routinely available in line with<br>national guidance          | 12/12/2022       |
| <b>Febuxostat</b><br><br>Adenuric®<br><br>1153/16 | Prevention and treatment of hyperuricaemia in<br>adult patients undergoing chemotherapy for<br>haematologic malignancies at intermediate to high<br>risk of Tumour Lysis Syndrome (TLS). | Routinely available in line with<br>national guidance          | 13/06/2016       |

| Medicine                                             | Condition being treated                                                                                                                                                                                                                                                                                     | NHSGGC Decision                                                         | Date of decision |
|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|------------------|
| <b>Fedratinib</b><br><br>Inrebic®<br><br>SMC2462     | Treatment of disease-related splenomegaly or<br>0 symptoms in adult patients with primary<br>myelofibrosis, post polycythaemia vera<br>myelofibrosis or post essential thrombocythaemia<br>myelofibrosis who are Janus Associated Kinase<br>(JAK) inhibitor naïve or have been treated with<br>ruxolitinib. | Routinely available in line with local<br>or regional guidance          | 13/06/2022       |
| <b>fenfluramine</b><br><br>Fintepla®<br><br>SMC2723  | Treatment of seizures associated with Lennox-<br>0 Gastaut syndrome as an add-on therapy to other<br>anti-epileptic medicines for patients 2 years of age<br>and older.                                                                                                                                     | Routinely available in line with local<br>or regional guidance          | 17/02/2025       |
| <b>Fentanyl</b><br><br>lonsys®<br><br>1207/16        | Management of acute moderate to severe post-<br>0 operative pain in adult patients                                                                                                                                                                                                                          | Not routinely available as not<br>recommended for use in<br>NHSScotland | 12/12/2016       |
| <b>Ferric maltol</b><br><br>Feraccru®<br><br>SMC2500 | in adults for the treatment of iron deficiency [in<br>0 patients with IBD]                                                                                                                                                                                                                                  | Not routinely available as not<br>recommended for use in<br>NHSScotland | 20/02/2023       |

[http://www.scottishmedicines.org.uk/SMC\\_Advice/Advice/1207\\_16\\_fentanyl\\_lonsys/fentanyl\\_lonsys\\_Non\\_Submission](http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1207_16_fentanyl_lonsys/fentanyl_lonsys_Non_Submission)

| Medicine                                             | Condition being treated                                                                                                                                                                                                               | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Ferric maltol</b><br><br>Feraccru®<br><br>1202/16 | Treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD).                                                                                                                                   | Not routinely available as not recommended for use in NHSScotland | 12/12/2016       |
|                                                      | <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1202_16_ferric_maltol_Feraccru/ferric_maltol_Feraccru">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1202_16_ferric_maltol_Feraccru/ferric_maltol_Feraccru</a> |                                                                   |                  |
| <b>fezolinetant</b><br><br>Veoza®<br><br>SMC2798     | Treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.                                                                                                                                                   | Not routinely available as not recommended for use in NHSScotland | 18/08/2025       |
| <b>fezolinetant</b><br><br>Veoza®<br><br>SMC2702     | Treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.                                                                                                                                                   | Not routinely available as not recommended for use in NHSScotland | 19/08/2024       |
| <b>Filgotinib</b><br><br>Jyseleca®<br><br>SMC2467    | Treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.             | Routinely available in line with national guidance                | 13/06/2022       |

| Medicine                                                     | Condition being treated                                                                                                                                                                                                                                                                    | NHSGGC Decision                                             | Date of decision |
|--------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Filgotinib</b><br><br>Jyseleca®<br><br>SMC2365            | Treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Filgotinib may be used as monotherapy or in combination with methotrexate (MTX).   | Routinely available in line with national guidance          | 18/10/2021       |
| <b>Filgotinib</b><br><br>Jyseleca®<br><br>SMC2475            | for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Filgotinib may be used as monotherapy or in combination with methotrexate. | Routinely available in line with local or regional guidance | 10/10/2022       |
| <b>Finerenone</b><br><br>Kerendia®<br><br>SMC2486            | Treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.                                                                                                                                                                            | Routinely available in line with national guidance          | 12/12/2022       |
| <b>Fluocinolone acetonide</b><br><br>Iluvien®<br><br>SMC2260 | Prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.                                                                                                                                                                                      | Routinely available in line with national guidance          | 26/10/2020       |

| Medicine                                                                             | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | NHSGGC Decision                                                                                                                                                            | Date of decision |
|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Fluticasone and Formoterol</b><br><br>Flutiform k-haler®<br><br>SMC2016           | for the regular treatment of asthma where the use of a combination product [an inhaled corticosteroid (ICS) and a long-acting $\beta$ 2-agonist (LABA)] is appropriate:<br>- For patients not adequately controlled with ICS as 'as required' inhaled short-acting $\beta$ 2-agonist or<br>- For patients already adequately controlled on both ICS and a LABA<br><br><a href="https://www.scottishmedicines.org.uk/media/3468/fluticasone-propionate-flutiform-k-haler-abb-final-may-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3468/fluticasone-propionate-flutiform-k-haler-abb-final-may-2018-for-website.pdf</a> | Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s) | 11/06/2018       |
| <b>Fluticasone, Umeclidinium, Vilanterol</b><br><br>Trelegy® Ellipta®<br><br>1303/18 | Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting $\beta$ 2-agonist.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/fluticasone_furoate_Trelegy_Ellipta_Abbreviated_FINAL_Jan_2018_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/fluticasone_furoate_Trelegy_Ellipta_Abbreviated_FINAL_Jan_2018_for_website.pdf</a>                                                                                                                         | Routinely available in line with national guidance                                                                                                                         | 26/02/2018       |
| <b>Follitropin delta</b><br><br>Rekovele®<br><br>1269/17                             | Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies such as an in vitro fertilisation or intracytoplasmic sperm injection cycle.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/follitropin_Rekovele_Non_Sub_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/follitropin_Rekovele_Non_Sub_FINAL_July_2017_for_website.pdf</a>                                                                                                                                                                               | Not routinely available as not recommended for use in NHSScotland                                                                                                          | 28/08/2017       |
| <b>follitropin delta</b><br><br>Rekovele®<br><br>SMC2670                             | Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle.                                                                                                                                                                                                                                                                                                                                                                                                             | Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s) | 07/10/2024       |

| Medicine                                                                                                                                                                                                                                                            | Condition being treated                                                                                                                                                                                                                                                                                          | NHSGGC Decision                                             | Date of decision |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Formoterol/<br/>Glycopyrronium/ Budesonide</b><br><br>Triexo® Aerosphere<br><br>SMC2321                                                                                                                                                                          | Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist. | Routinely available in line with national guidance          | 19/04/2021       |
| <b>Fosaprepitant</b><br><br>Ivemend<br><br>SMC2108                                                                                                                                                                                                                  | prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in paediatric patients aged 6 months to 17 years.<br>Fosaprepitant is given as part of a combination therapy.                                                                                             | Routinely available in line with national guidance          | 25/02/2019       |
| <b>fosdenopterin</b><br><br>Nulibry®<br><br>SMC2624                                                                                                                                                                                                                 | Treatment of patients with molybdenum cofactor deficiency (MoCD) Type A                                                                                                                                                                                                                                          | Routinely available in line with national guidance          | 17/02/2025       |
| <b>Fosfomycin trometamol</b><br><br>Monuril®<br><br>1163/16                                                                                                                                                                                                         | Treatment of acute lower uncomplicated urinary tract infections, caused by pathogens sensitive to fosfomycin in adult and adolescent females and prophylaxis in diagnostic and surgical transurethral procedures.                                                                                                | Routinely available in line with local or regional guidance | 10/10/2016       |
| <a href="http://www.scottishmedicines.org.uk/files/advice/fosfomycin_trometamol_Monuril_Abbreviated_FINAL_June_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/fosfomycin_trometamol_Monuril_Abbreviated_FINAL_June_2016_for_website.pdf</a> |                                                                                                                                                                                                                                                                                                                  |                                                             |                  |



| Medicine                                                                 | Condition being treated                                                                                                                                                                                                                  | NHSGGC Decision                                                                      | Date of decision |
|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|------------------|
| <b>foslevodopa-foscarbidopa</b><br><br><b>Produodopa®</b><br><br>SMC2574 | Treatment of advanced levodopa-responsive<br>Parkinson's disease with severe motor fluctuations<br>and hyperkinesia or dyskinesia when available<br>combinations of Parkinson medicinal products<br>have not given satisfactory results. | Routinely available in line with<br>national guidance                                | 22/04/2024       |
| <b>Fostamatinib</b><br><br><b>Tavlesse®</b><br><br>SMC2300               | Treatment of chronic immune thrombocytopenia<br>(ITP) in adult patients who are refractory to other<br>treatments                                                                                                                        | Routinely available in line with<br>national guidance                                | 19/04/2021       |
| <b>Fostemsavir</b><br><br><b>Rukobia®</b><br><br>SMC2389                 | In combination with other antiretrovirals for the<br>treatment of adults with multidrug resistant HIV-1<br>infection for whom it is otherwise not possible to<br>construct a suppressive anti-viral regimen.                             | Not routinely available as not<br>recommended for use in<br>NHSScotland              | 09/08/2021       |
| <b>Fremanezumab</b><br><br><b>Ajovy®</b><br><br>SMC2226                  | Prophylaxis of migraine in adults who have at least<br>four migraine days per month.                                                                                                                                                     | Routinely available in line with local<br>or regional guidance<br><br><br>10/08/2020 | 14/12/2020       |

| Medicine                                            | Condition being treated                                                                                                                                                                                                                                                                                                  | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|-----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>fruquintinib</b><br><br>Fruzaqla®<br><br>SMC2748 | Treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and if RAS wildtype and medically appropriate, an anti-EGFR therapy. | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 16/06/2025       |
| <b>fruquintinib</b><br><br>Fruzaqla<br><br>SMC2858  | treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and if RAS wildtype and medically appropriate, an anti-EGFR therapy  | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>08/12/2025 | 06/10/2025       |
| <b>Fulvestrant</b><br><br>Faslodex®<br><br>1294/17  | Treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.                                                                                                                                                            | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 11/12/2017       |
| <b>Fulvestrant</b><br><br>Faslodex®<br><br>114/04   | Treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy, or disease progression on therapy with an anti-oestrogen.                                                                              | Routinely available in line with local or regional guidance                                                                                                                           | 22/02/2016       |

| Medicine                                                 | Condition being treated                                                                                                                                                                                                                                     | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|----------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>futibatinib</b><br><br>Lytgobi®<br>SMC2661            | 0 Monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>08/12/2025 | 06/10/2025       |
| <b>Galcanezumab</b><br><br>Emgality®<br>SMC23213         | 0 Prophylaxis of migraine in adults who have at least 4 migraine days per month.                                                                                                                                                                            | Routinely available in line with national guidance                                                                                                                                    | 19/04/2021       |
| <b>Gasdegib</b><br><br>Daurismo®<br>SMC2341              | 0 In combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.                                            | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 19/04/2021       |
| <b>Gemtuzumab ozogamicin</b><br><br>Mylotarg®<br>SMC2089 | 0 Combination therapy with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).                     | Routinely available in line with local or regional guidance                                                                                                                           | 08/10/2018       |

| Medicine                                                        | Condition being treated                                                                                                                                                                                                                                                | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Genvoya®</b><br><br>Genvoya®<br>1142/16                      | Treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus-1 (HIV-1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir. | Routinely available in line with national guidance                | 13/06/2016       |
| <b>Gilteritinib</b><br><br>Xospata®<br>SMC2252                  | as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia with a FLT3 mutation.                                                                                                                                       | Routinely available in line with local or regional guidance       | 31/08/2020       |
| <b>Givosiran</b><br><br>Givlaari®<br>SMC2470                    | Treatment of acute hepatic porphyria in adults and adolescents aged 12 years and older.                                                                                                                                                                                | Not routinely available as not recommended for use in NHSScotland | 13/06/2022       |
| <b>Glecaprevir with Pibrentasvir</b><br><br>Maviret®<br>1278/17 | Treatment of chronic hepatitis C virus (HCV) infection in adults                                                                                                                                                                                                       | Routinely available in line with national guidance                | 11/12/2017       |

| Medicine                                                      | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Glibenclamide</b><br><br>Amglidia®<br><br>SMC2237          | Treatment of neonatal diabetes mellitus, for use in newborns, infants and children.                                                                                                                                                                                                                                                                                                                                                                                                      | Not routinely available as not recommended for use in NHSScotland | 07/10/2019       |
| <b>glofitamab</b><br><br>Columvi®<br><br>SMC2614              | Monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.                                                                                                                                                                                                                                                                                                                    | Routinely available in line with local or regional guidance       | 07/10/2024       |
| <b>Glycerol Phenylbutyrate</b><br><br>Ravicti®<br><br>1342/18 | For use as adjunctive therapy for chronic management of adult and paediatric patients ≥2 months of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.<br><br><a href="https://www.scottishmedicines.org.uk/media/3649/glycerol-phenylbutyrate-ravict-final-july-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3649/glycerol-phenylbutyrate-ravict-final-july-2018-for-website.pdf</a> | Routinely available in line with national guidance                | 13/08/2018       |
| <b>Glycopyrronium</b><br><br>Sialanar®<br><br>1254/17         | Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/glycopyrronium_bromide_Sialanar_Abbreviated_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/glycopyrronium_bromide_Sialanar_Abbreviated_FINAL_June_2017_for_website.pdf</a>                                       | Routinely available in line with national guidance                | 23/10/2017       |

| Medicine                                                                                                                                                                                                                            | Condition being treated                                                                                                                                                                                                                                                                                                                | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Glycopyrronium / Formoterol fumarate</b><br><br>Bevespi Aerosphere®<br><br>SMC2377                                                                                                                                               | Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease                                                                                                                                                                                                                  | Not routinely available as not recommended for use in NHSScotland | 14/06/2021       |
| <b>glycopyrronium/formoterol fumarate</b><br><br>Bevespi Aerosphere®<br><br>SMC2652                                                                                                                                                 | As a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).                                                                                                                                                                                                     | Routinely available in line with local or regional guidance       | 22/04/2024       |
| <b>Golimumab</b><br><br>Simponi®<br><br>1124/16                                                                                                                                                                                     | Treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs). | Routinely available in line with national guidance                | 22/02/2016       |
| <b>Golimumab</b><br><br>Simponi®<br><br>1199/16                                                                                                                                                                                     | In combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children with a body weight of at least 40 kg, who have responded inadequately to previous therapy with methotrexate.                                                                                                             | Not routinely available as not recommended for use in NHSScotland | 10/10/2016       |
| <a href="http://www.scottishmedicines.org.uk/files/advice/golimumab_Simponi_Non_Sub_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/golimumab_Simponi_Non_Sub_FINAL_Sept_2016_for_website.pdf</a> |                                                                                                                                                                                                                                                                                                                                        |                                                                   |                  |

| Medicine                                         | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Golimumab</b><br><br>Simponi®<br><br>SMC2203  | In combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older who have responded inadequately to previous therapy with methotrexate                                                                                                                                                                                                                                                                                                                                                                                                                                                | Not routinely available as not recommended for use in NHSScotland | 10/06/2019       |
| <b>Guanfacine</b><br><br>Intuniv®<br><br>1123/16 | Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 yrs old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Treatment must be used as part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1123_16_guanfacine_hydrochloride_Intuniv/Briefing_note_guanfacine_hydrochloride_Int">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1123_16_guanfacine_hydrochloride_Intuniv/Briefing_note_guanfacine_hydrochloride_Int</a> | Routinely available in line with national guidance                | 18/04/2016       |
| <b>Guselkumab</b><br><br>Tremfya®<br><br>1340/18 | Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Routinely available in line with local or regional guidance       | 09/12/2019       |
| <b>Guselkumab</b><br><br>Tremfya®<br><br>SMC2360 | alone or in combination with methotrexate (MTX) for the Treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.                                                                                                                                                                                                                                                                                                                                                                                                          | Routinely available in line with national guidance                | 09/08/2021       |
|                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 31/12/2018                                                        |                  |

| Medicine                                                                                                                                                                                                                                                                                                                                                             | Condition being treated                                                                                                                                                                                                                                                                                                          | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Human alpha1-proteinase inhibitor</b><br><br>Respreeza®<br><br>1157/16<br><br><a href="http://www.scottishmedicines.org.uk/SMCAdvice/Advice/1157_16_human_alpha_1_proteinase_inhibitor_Respreeza/human_alpha_1_proteinase">http://www.scottishmedicines.org.uk/SMCAdvice/Advice/1157_16_human_alpha_1_proteinase_inhibitor_Respreeza/human_alpha_1_proteinase</a> | Maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor (A1-PI) deficiency.                                                                                                                                                                                     | Not routinely available as not recommended for use in NHSScotland | 22/08/2016       |
| <b>Human Corneal Epithelial Stem Cells</b><br><br>Holoclar®<br><br>SMC2261                                                                                                                                                                                                                                                                                           | Treatment of adult patients with moderate to severe limbal stem cell deficiency (defined by the presence of superficial corneal neovascularisation in at least two corneal quadrants, with central corneal involvement, and severely impaired visual acuity), unilateral or bilateral, due to physical or chemical ocular burns. | Routinely available in line with national guidance                | 26/10/2020       |
| <b>Hydrocortisone</b><br><br>Alkindi®<br><br>SMC2088                                                                                                                                                                                                                                                                                                                 | Replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to <18 years old).                                                                                                                                                                                                                 | Routinely available in line with national guidance                | 25/02/2019       |
| <b>Hydrocortisone</b><br><br>Plenadren®<br><br>848/12<br><br><a href="http://www.scottishmedicines.org.uk/SMCAdvice/Advice/848_12_hydrocortisone_Plenadren/hydrocortisone_Plenadren">http://www.scottishmedicines.org.uk/SMCAdvice/Advice/848_12_hydrocortisone_Plenadren/hydrocortisone_Plenadren</a>                                                               | Treatment of adrenal insufficiency in adults                                                                                                                                                                                                                                                                                     | Not routinely available as not recommended for use in NHSScotland | 12/12/2016       |



| Medicine                                            | Condition being treated                                                                                                                                                                                                                   | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Hydrocortisone</b><br><br>Efmody®<br><br>SMC2414 | Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.                                                                                                                                       | Not routinely available as not recommended for use in NHSScotland | 13/06/2022       |
| <b>Hyoscine hydrobromide</b><br><br>                | Antispasmodic for irritable bowel syndrome                                                                                                                                                                                                |                                                                   | 22/08/2016       |
| <b>Ibrutinib</b><br><br>Imbruvica®<br><br>1151/16   | Treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.      | Routinely available in line with local or regional guidance       | 22/08/2016       |
| <b>Ibrutinib</b><br><br>Imbruvica®<br><br>1150/16   | Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).                                                                                                                                                       | Routinely available in line with local or regional guidance       | 22/08/2016       |
|                                                     | <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1151_16_ibrutinib_Imbruvica_CLL/ibrutinib_Imbruvica_CLL">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1151_16_ibrutinib_Imbruvica_CLL/ibrutinib_Imbruvica_CLL</a> |                                                                   |                  |
|                                                     | <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1150_16_ibrutinib_Imbruvica_MCL/ibrutinib_Imbruvica_MCL">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1150_16_ibrutinib_Imbruvica_MCL/ibrutinib_Imbruvica_MCL</a> |                                                                   |                  |

| Medicine                                          | Condition being treated                                                                                                                                                                                               | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Ibrutinib</b><br><br>Imbruvica®<br><br>SMC2244 | In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.                                                                                         | Not routinely available as not recommended for use in NHSScotland | 09/12/2019       |
| <b>Ibrutinib</b><br><br>Imbruvica®<br><br>SMC2259 | in combination with rituximab for the treatment of adult patients with Waldenström's macroglobulinaemia.                                                                                                              | Routinely available in line with local or regional guidance       | 26/10/2020       |
| <b>Ibrutinib</b><br><br>Imbruvica®<br><br>SMC2245 | As a single agent for the treatment of adult patients with Waldenström's macroglobulinaemia who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. | Not routinely available as not recommended for use in NHSScotland | 09/12/2019       |
| <b>Ibrutinib</b><br><br>Imbruvica®<br><br>SMC2543 | In combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).                                                                                     | Routinely available in line with local or regional guidance       | 09/10/2023       |

| Medicine                                          | Condition being treated                                                                                                                                                                                                    | NHSGGC Decision                                                                                                                                                                                                                                                                                                              | Date of decision |
|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Ibrutinib</b><br><br>Imbruvica®<br><br>SMC2387 | As a single agent for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy. | Routinely available in line with local or regional guidance                                                                                                                                                                                                                                                                  | 13/12/2021       |
| <b>Ibrutinib</b><br><br>Imbruvica®<br><br>1289/17 | As a single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (who do not have 17p deletion or TP53 mutation).                                                             | Not routinely available as not recommended for use in NHSScotland                                                                                                                                                                                                                                                            | 11/12/2017       |
| <b>Ibrutinib</b><br><br>Imbruvica®<br><br>1258/17 | In combination with bendamustine and rituximab for the treatment of adult patients with chronic lymphocytic leukaemia who have received at least one prior therapy                                                         | Not routinely available as not recommended for use in NHSScotland                                                                                                                                                                                                                                                            | 19/06/2017       |
| <b>Ibrutinib</b><br><br>Imbruvica®<br><br>SMC2485 | In combination with rituximab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.                                                                                                 | <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1258_17_ibrutinib_Imbruvica/ibrutinib_Imbruvica_Non-submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1258_17_ibrutinib_Imbruvica/ibrutinib_Imbruvica_Non-submission</a><br>Not routinely available as not recommended for use in NHSScotland | 13/06/2022       |

| Medicine                                                | Condition being treated                                                                                                                                                                                                                                                                 | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|---------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Ibrutinib</b><br><br>Imbruvica®<br><br>1151/16       | Treatment of adult patients with chronic<br>0 lymphocytic leukaemia (CLL) who have received at least one prior therapy.                                                                                                                                                                 | Routinely available in line with local or regional guidance                                                                                                                           | 24/04/2017       |
| <b>Icatibant acetate</b><br><br>Firazyr®<br><br>1332/18 | Symptomatic treatment of acute attacks of<br>0 hereditary angioedema (HAE) in adolescents and children aged 2 years and older, with C1-esterase-inhibitor deficiency.                                                                                                                   | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>21/08/2018 | 11/06/2018       |
| <b>icosapent ethyl</b><br><br>Vazkepa®<br><br>SMC2602   | To reduce the risk of cardiovascular events in adult<br>0 statin-treated patients at high cardiovascular risk with elevated triglycerides ( $\geq 1.7\text{mmol/L}$ ) and established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor.           | Routinely available in line with national guidance                                                                                                                                    | 21/08/2023       |
| <b>Icosapent ethyl</b><br><br>Vazkepa®<br><br>SMC2531   | To reduce the risk of cardiovascular events in adult<br>0 statin-treated patients at high cardiovascular risk with elevated triglycerides ( $\geq 1.7\text{mmol/L}$ ) and<br>- established cardiovascular disease, or<br>- diabetes, and at least one other cardiovascular risk factor. | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 19/06/2023       |

| Medicine                                                                 | Condition being treated                                                                                                                                                                                                                                                                | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Idarucizumab</b><br><br>Praxbind®<br><br>1178/16                      | Reversal of anticoagulation effect of dabigatran in adults when rapid reversal is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding                                                                                                     | Routinely available in line with national guidance                | 10/10/2016       |
|                                                                          | <a href="http://www.scottishmedicines.org.uk/files/advice/idarucizumab_Praxbind_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/idarucizumab_Praxbind_FINAL_August_2016_for_website.pdf</a>                                                        |                                                                   |                  |
| <b>Idebenone</b><br><br>Raxone®<br><br>1226/17                           | Treatment of visual impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy (LHON).                                                                                                                                                                       | Routinely available in line with national guidance                | 19/06/2017       |
|                                                                          | <a href="http://www.scottishmedicines.org.uk/files/advice/idebenone_Raxone_FINAL_April_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/idebenone_Raxone_FINAL_April_2017_for_website.pdf</a>                                                                    |                                                                   |                  |
| <b>Idelalisib</b><br><br>Zydelig®<br><br>1212/16                         | In combination with ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia who have received at least one prior therapy, or first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies. | Not routinely available as not recommended for use in NHSScotland | 12/12/2016       |
|                                                                          | <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1212_16_idelalisib_Zydelig/idelalisib_Zydelig_Non_Submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1212_16_idelalisib_Zydelig/idelalisib_Zydelig_Non_Submission</a>                                    |                                                                   |                  |
| <b>Imipenem/ cilastatin/ relabactam</b><br><br>Recarbrio®<br><br>SMC2390 | Treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.                                                                                                                                                                               | Not routinely available as not recommended for use in NHSScotland | 09/08/2021       |

| Medicine                                                                 | Condition being treated                                                                                                                                                                                                                                                                                                                          | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Imipenem/ Cilastatin/ Relabactam</b><br><br>Recarbrio®<br><br>SMC2342 | Treatment of:<br>- hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults.<br>- bacteraemia that occurs in association with, or is suspected to be associated with HAP or VAP, in adults.                                                                                                                 | Not routinely available as not recommended for use in NHSScotland | 19/04/2021       |
| <b>Imiquimod</b><br><br>Zyclara®<br><br>SMC2211                          | Topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.                                                                                     | Routinely available in line with national guidance                | 09/12/2019       |
| <b>Imlifidase</b><br><br>Idefirix®<br><br>SMC2445                        | desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. The use of imlifidase should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients. | Routinely available in line with national guidance                | 10/10/2022       |

| Medicine                                                                                            | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                          | NHSGGC Decision                                                                                                                                                            | Date of decision |
|-----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Inclisiran</b><br><br>Leqvio®<br><br>SMC2358                                                     | Treatment for adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:<br>- in combination with a statin or statin with other lipid lowering therapies in patients who are unable to reach LDL-C goals with the maximum tolerated dose of a statin, or<br>- alone or in combination with other lipid lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated. | Routinely available in line with local or regional guidance                                                                                                                | 13/06/2022       |
| <b>Indacaterol / Glycopyrronium / Mometasone furoate</b><br><br>Enerzair Breezhaler®<br><br>SMC2355 | Maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.                                                                                                                                                                                                                    | Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s) | 14/06/2021       |
| <b>Indacaterol / Mometasone furoate</b><br><br>Aectura Breezhaler®<br><br>SMC2356                   | maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonists                                                                                                                                                                                                                                                                                               | Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s) | 14/06/2021       |

| Medicine                                                     | Condition being treated                                                                                                                                                                                                                                                                                              | NHSGGC Decision                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Date of decision |
|--------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Inotersen</b><br><br>Tegsedi®<br><br>SMC2188              | 0 Treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).                                                                                                                                                                                                | Routinely available in line with national guidance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 12/08/2019       |
| <b>Inotuzomab ozogamicin</b><br><br>BESPONSA®<br><br>1328/18 | 0 Monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive relapsed or refractory B cell precursor ALL should have failed treatment with at least one tyrosine kinase inhibitor. | Routinely available in line with local or regional guidance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/06/2018       |
| <b>Insulin aspart</b><br><br>Fiasp®<br><br>1227/17           | 0 Treatment of diabetes mellitus in adults.                                                                                                                                                                                                                                                                          | Routinely available in line with national guidance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 24/04/2017       |
| <b>Insulin degludec</b><br><br>Tresiba®<br><br>856/13        | 0 Treatment of diabetes mellitus in adults                                                                                                                                                                                                                                                                           | Routinely available in line with local or regional guidance<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/insulin_aspart_Fiasp_Abbreviated_FINAL_March_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/insulin_aspart_Fiasp_Abbreviated_FINAL_March_2017_for_website.pdf</a><br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/856_13_insulin_degludec_Tresiba/insulin_degludec_Tresiba_2nd_Resubmission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/856_13_insulin_degludec_Tresiba/insulin_degludec_Tresiba_2nd_Resubmission</a> | 22/08/2016       |



| Medicine                                                                     | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | NHSGGC Decision                                                | Date of decision |
|------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------------------|
| <b>Insulin detemir</b><br><br>Levemir®<br><br>1126/16                        | Treatment of diabetes mellitus in adults,<br>adolescents and children aged 1 year and above.                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Routinely available in line with<br>national guidance          | 26/04/2016       |
| <b>Insulin Glargine 300 units/ml</b><br><br>Toujeo®<br><br>1078/15           | Treatment of type 1 or type 2 diabetes mellitus in<br>adults aged 18 years and above.                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Routinely available in line with local<br>or regional guidance | 12/12/2016       |
| <b>Insulin glargine plus<br/>Lixisenatide</b><br><br>Suliqua®<br><br>SMC2235 | <p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1078_15_insulin_glargine_Toujeo/insulin_glargine_Toujeo_ABB">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1078_15_insulin_glargine_Toujeo/insulin_glargine_Toujeo_ABB</a></p> In combination with metformin for the treatment of<br>adults with type 2 diabetes mellitus, to improve<br>glycaemic control when this has not been provided<br>by metformin alone or metformin combined with<br>another oral glucose-lowering medicinal product or<br>with basal insulin. | Routinely available in line with<br>national guidance          | 06/07/2020       |
| <b>Ipilimumab</b><br><br>Yervoy®<br><br>SMC2094                              | Monotherapy for the treatment of advanced<br>(unresectable or metastatic) melanoma in<br>adolescents 12 years of age and older.                                                                                                                                                                                                                                                                                                                                                                                                                    | Routinely available in line with<br>national guidance          | 18/12/2018       |

| Medicine                                                          | Condition being treated                                                                                                                                                                                                                                                                                             | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>iptacopan</b><br><br>Fabhalta®<br><br>SMC2676                  | 0 Monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.                                                                                                                                                                                       | Routinely available in line with national guidance                | 28/04/2025       |
| <b>Iron (III) isomaltoside 1000</b><br><br>Diafer®<br><br>1177/16 | 0 The treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis, when oral iron preparations are ineffective or cannot be used.                                                                                                                                                          | Not routinely available as not recommended for use in NHSScotland | 10/10/2016       |
|                                                                   | <a href="http://www.scottishmedicines.org.uk/files/advice/iron_isomaltoside_1000_Diafer_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/iron_isomaltoside_1000_Diafer_FINAL_August_2016_for_website.pdf</a>                                                                     |                                                                   |                  |
| <b>Iron III isomaltoside 1000</b><br><br>Diafer®<br><br>1177/16   | 0 Treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis, when oral iron preparations are ineffective or cannot be used.                                                                                                                                                              | Routinely available in line with national guidance                | 20/02/2017       |
|                                                                   | <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1177_16_iron_isomaltoside_1000_Diafer/iron_III_isomaltoside_1000_Diafer_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1177_16_iron_isomaltoside_1000_Diafer/iron_III_isomaltoside_1000_Diafer_Resub</a>                               |                                                                   |                  |
| <b>Isatuximab</b><br><br>Sarclisa®<br><br>SMC2303                 | 0 In combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on the last therapy. | Routinely available in line with local or regional guidance       | 19/04/2021       |

| Medicine                                             | Condition being treated                                                                                                                                                                                                                                                                                    | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Isatuximab</b><br><br>Sarclisa®<br><br>SMC2423    | In combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.                                                                                                                                                 | Not routinely available as not recommended for use in NHSScotland | 18/10/2021       |
| <b>Isavuconazole</b><br><br>Cresemba®<br><br>1129/16 | in adults for the treatment of:<br>-invasive aspergillosis<br>-mucormycosis in patients for whom amphotericin B is inappropriate                                                                                                                                                                           | Routinely available in line with national guidance                | 18/04/2016       |
| <b>Ivacaftor</b><br><br>Kalydeco®<br><br>1193/16     | Treatment of patients with cystic fibrosis (CF) aged 18 years and older who have an R117H mutation in the CF transmembrane conductance regulator (CFTR) gene.                                                                                                                                              | Not routinely available as not recommended for use in NHSScotland | 12/12/2016       |
| <b>Ivacaftor</b><br><br>Kalydeco®<br><br>1134/16     | Treatment of children with cystic fibrosis (CF) aged 2 years and older and weighing less than 25kg who have one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. | Not routinely available as not recommended for use in NHSScotland | 13/06/2016       |

| Medicine                                                                     | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | NHSGGC Decision                                       | Date of decision |
|------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|------------------|
| <b>ivacaftor, lumacaftor</b><br><br>Orkambi®<br><br>SMC2712                  | treatment of cystic fibrosis (CF) in patients aged 1<br>0 year and older (granules in sachet) or 6 years and<br>older (film-coated tablets) who are homozygous for<br>the F508del mutation in the cystic fibrosis<br>transmembrane conductance regulator (CFTR)<br>gene                                                                                                                                                                                                                            | Routinely available in line with<br>national guidance | 07/10/2024       |
| <b>ivacaftor, tezacaftor</b><br><br>Symkevi®<br><br>SMC2711                  | In a combination regimen with ivacaftor tablets for<br>0 the treatment of patients with cystic fibrosis (CF)<br>aged 6 years and older who are homozygous for<br>the F508del mutation or who are heterozygous for<br>the F508del mutation and have one of the following<br>mutations in the cystic fibrosis transmembrane<br>conductance regulator (CFTR) gene: P67L,<br>R117C, L206W, R352Q, A455E, D579G,<br>711+3A→G, S945L, S977F, R1070W, D1152H,<br>2789+5G→A, 3272-26A→G, and 3849+10kbC→T. | Routinely available in line with<br>national guidance | 07/10/2024       |
| <b>ivacaftor, tezacaftor,<br/>elexacaftor</b><br><br>Kaftrio®<br><br>SMC2713 | In a combination regimen with ivacaftor for the<br>0 treatment of cystic fibrosis (CF) in patients aged 2<br>years to less than 6 years (granules in sachet) and<br>6 years and older (film-coated tablets) who have at<br>least one F508del mutation in the cystic fibrosis<br>transmembrane conductance regulator (CFTR)<br>gene.                                                                                                                                                                | Routinely available in line with<br>national guidance | 07/10/2024       |

| Medicine                                         | Condition being treated                                                                                                                                                                                                                                       | NHSGGC Decision                                                                   | Date of decision |
|--------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|------------------|
| <b>ivosidenib</b><br><br>Tibsovo®<br><br>SMC2664 | 0 Monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who were previously treated by at least one prior line of systemic therapy.                  | Routinely available in line with local or regional guidance                       | 17/02/2024       |
| <b>ivosidenib</b><br><br>Tibsovo®<br><br>SMC2615 | 0 In combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.             | Routinely available in line with local or regional guidance                       | 19/08/2024       |
| <b>ixazomib</b><br><br>Ninlaro®<br><br>SMC2099   | 0 In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.                                                                                                  | Not routinely available as not recommended for use in NHSScotland                 | 13/08/2018       |
| <b>ixekizumab</b><br><br>Taltz®<br><br>SMC2097   | 0 Alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies. | Routinely available in line with local or regional guidance<br><br><br>31/12/2018 | 25/02/2019       |

<https://www.scottishmedicines.org.uk/medicines-advice/ixazomib-ninlaro-non-submission-smc2099/>

| Medicine                                                                                                                                                                                                                                  | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Ixekizumab</b><br><br>Taltz®<br><br>SMC2440                                                                                                                                                                                            | Ankylosing spondyloarthritis (radiographic axial spondyloarthritis) Treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy. Non-radiographic axial spondyloarthritis Treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs). | Not routinely available as not recommended for use in NHSScotland | 13/06/2022       |
| <b>Ixekizumab</b><br><br>Taltz®<br><br>1223/17                                                                                                                                                                                            | Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Routinely available in line with national guidance                | 24/04/2017       |
| <b>Lacosamide</b><br><br>Vimpat®<br><br>1301/18                                                                                                                                                                                           | As adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy.                                                                                                                                                                                                                                                                                                                                                               | Routinely available in line with national guidance                | 10/06/2019       |
| <a href="http://www.scottishmedicines.org.uk/files/advice/lacosamide_Vimpat_Abbreviated_FINAL_Jan_2018_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/lacosamide_Vimpat_Abbreviated_FINAL_Jan_2018_for_website.pdf</a> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                   |                  |

| Medicine                                                         | Condition being treated                                                                                                                                                                                                                                                                     | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Lacosamide</b><br><br>Vimpat®<br><br>1324/18                  | Monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy.                                                                                                                              | Not routinely available as not recommended for use in NHSScotland | 23/04/2018       |
|                                                                  | <a href="https://www.scottishmedicines.org.uk/medicines-advice/lacosamide-50mg-100mg-150mg-200mg-tablets-10mgml-syrup-and-10mgml-solution-for-i">https://www.scottishmedicines.org.uk/medicines-advice/lacosamide-50mg-100mg-150mg-200mg-tablets-10mgml-syrup-and-10mgml-solution-for-i</a> |                                                                   |                  |
| <b>Lacosamide</b><br><br>Vimpat®<br><br>1231/17                  | As monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy.                                                                                                                            | Not routinely available as not recommended for use in NHSScotland | 24/04/2017       |
| <b>Lanadelumab</b><br><br>Takhyzyro®<br><br>SMC2206              | For the routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older                                                                                                                                                                          | Routinely available in line with national guidance                | 09/12/2019       |
| <b>Latanoprost &amp; Timolol</b><br><br>Fixapost®<br><br>SMC2159 | Reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.                                                                                                 | Routinely available in line with national guidance                | 10/06/2019       |

| Medicine                                                        | Condition being treated                                                                                                                                                      | NHSGGC Decision                                                          | Date of decision |
|-----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|------------------|
| <b>lebrikizumab</b><br><br>Ebglyss®<br><br>SMC2707              | Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy. | Routinely available in line with local or regional guidance              | 28/04/2025       |
| <b>lecanemab</b><br><br>Leqembi®<br><br>SMC2700                 | Treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε 4 (ApoEε4) heterozygotes or non-carriers.  | Not routinely available as not recommended for use in NHSScotland        | 17/02/2025       |
| <b>lecanemab</b><br><br>Leqembi®<br><br>SMC2811                 | Treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε 4 (ApoEε4) heterozygotes or non-carriers.  | Not routinely available as not recommended for use in NHSScotland        | 18/08/2025       |
| <b>Ledipasvir and Sofosbuvir</b><br><br>Harvoni®<br><br>1343/18 | Treatment of chronic hepatitis C (CHC) in adolescents aged 12 to <18 years.                                                                                                  | Routinely available in line with national guidance<br><br><br>21/08/2018 | 11/06/2018       |



| Medicine                                            | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>lenacapavir</b><br><br>Sunlenca®<br><br>SMC2691  | Film-coated tablets: in combination with other antiretroviral(s) for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen, for oral loading prior to administration of long-acting lenacapavir injection<br>Solution for injection: in combination with other antiretroviral(s) for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.. | Not routinely available as not recommended for use in NHSScotland | 19/08/2024       |
| <b>Lenalidomide</b><br><br>Revlimid®<br><br>1211/16 | Treatment of adult patients with relapsed or refractory mantle cell lymphoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Not routinely available as not recommended for use in NHSScotland | 12/12/2016       |
| <b>Lenalidomide</b><br><br>Revlimid®<br><br>SMC2217 | <p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1211_16_lenalidomide_Revlimid/lenalidomide_Revlimid_non_submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1211_16_lenalidomide_Revlimid/lenalidomide_Revlimid_non_submission</a></p> As combination therapy with bortezomib and dexamethasone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.                                                                                        | Not routinely available as not recommended for use in NHSScotland | 12/08/2019       |

| Medicine                                            | Condition being treated                                                                                                                                                                                                                           | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Lenalidomide</b><br><br>NCMAG103                 | 0 Lenalidomide in combination with dexamethasone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant and are suitable for thalidomide-containing regimens (Routine off-patent use) | Routinely available in line with local or regional guidance       | 20/02/2023       |
| <b>Lenalidomide</b><br><br>Revlimid®<br><br>SMC2281 | 0 In combination with rituximab (anti-CD20 antibody) for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 to 3a).                                                                                             | Routinely available in line with local or regional guidance       | 26/10/2020       |
| <b>Lenalidomide</b><br><br>Revlimid®<br><br>SMC2289 | 0 as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation (ASCT).                                                                            | Routinely available in line with local or regional guidance       | 26/10/2020       |
| <b>Lenalidomide</b><br><br>Revlimid®<br><br>SMC2125 | 0 Monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.                                                                                      | Not routinely available as not recommended for use in NHSScotland | 08/10/2018       |

| Medicine                                                                                                                                                                                                                                                | Condition being treated                                                                                                                                                                           | NHSGGC Decision                                             | Date of decision |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Lenvatinib</b><br><br>Kisplyx®<br><br>SMC2199                                                                                                                                                                                                        | In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy        | Routinely available in line with local or regional guidance | 09/12/2019       |
| <b>Lenvatinib</b><br><br>Lenvima®<br><br>1179/16                                                                                                                                                                                                        | Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). | Routinely available in line with local or regional guidance | 10/10/2016       |
| <a href="http://www.scottishmedicines.org.uk/files/advice/lenvatinib_Lenvima_FINAL_Sept_2016_amended_30.09.16_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/lenvatinib_Lenvima_FINAL_Sept_2016_amended_30.09.16_for_website.pdf</a> |                                                                                                                                                                                                   |                                                             |                  |
| <b>Lenvatinib</b><br><br>Kisplyx®<br><br>SMC2476                                                                                                                                                                                                        | Treatment of adults with advanced renal cell carcinoma (RCC), in combination with pembrolizumab, as first-line treatment                                                                          | Routinely available in line with local or regional guidance | 13/06/2022       |
| <b>Lenvatinib</b><br><br>Lenvima®<br><br>SMC2138                                                                                                                                                                                                        | As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.                                            | Routinely available in line with local or regional guidance | 29/04/2019       |

| Medicine                                                                        | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                 | NHSGGC Decision                                                         | Date of decision |
|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|------------------|
| <b>Ietermovir</b><br><br>Prevmis®<br><br>SMC2853                                | Prophylaxis of cytomegalovirus (CMV) disease in<br>0 CMV-seronegative adults who have received a<br>kidney transplant from a CMV-seropositive donor<br>[D+/R-].                                                                                                                                                                                                                                         | Not routinely available as not<br>recommended for use in<br>NHSScotland | 18/08/2025       |
| <b>Ietermovir</b><br><br>Prevmis®<br><br>SMC1338/18                             | Prophylaxis of cytomegalovirus (CMV) reactivation<br>0 and disease in adult CMV-seropositive recipients<br>[R+] of an allogeneic haematopoietic stem cell<br>transplant (HSCT).                                                                                                                                                                                                                         | Routinely available in line with<br>national guidance                   | 29/04/2019       |
| <b>Leuprorelin acetate</b><br><br>Prostap® 3 DCS, Prostap®<br>SR DCS<br>SMC2320 | 0 Treatment in pre- and perimenopausal women with<br>advanced breast cancer suitable for hormonal<br>manipulation                                                                                                                                                                                                                                                                                       | Routinely available in line with local<br>or regional guidance          | 19/04/2021       |
| <b>Leuprorelin acetate</b><br><br>Prostap® SR DCS, Prostap®<br>3 DCS<br>SMC2319 | 0 as adjuvant treatment in combination with<br>tamoxifen or an aromatase inhibitor, of endocrine<br>responsive early stage breast cancer in pre- and<br>perimenopausal women at higher risk of disease<br>recurrence (young age, high grade tumour, lymph<br>node involvement). In women who have received<br>chemotherapy, premenopausal status must be<br>confirmed after completion of chemotherapy. | Routinely available in line with local<br>or regional guidance          | 19/04/2021       |

| Medicine                                                               | Condition being treated                                                                                                                                                                                              | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>levodopa, carbidopa, entacapone</b><br><br>Lecigon®<br><br>SMC2507  | Treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results.        | Not routinely available as not recommended for use in NHSScotland | 09/12/2024       |
| <b>Levofloxacin</b><br><br>Quinsair®<br><br>1162/16                    | Management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.                                                                                                     | Routinely available in line with national guidance                | 22/08/2016       |
| <b>Levofloxacin with Dexamethasone</b><br><br>Ducressa®<br><br>SMC2511 | Prevention and treatment of inflammation, and prevention of infection associated with cataract surgery in adults. Consideration should be given to official guidance on the appropriate use of antibacterial agents. | Routinely available in line with national guidance                | 12/12/2022       |
| <b>Levonorgestrel</b><br><br>Kyleena®<br><br>1299/18                   | Contraception for up to 5 years.                                                                                                                                                                                     | Routinely available in line with national guidance                | 26/02/2018       |

[http://www.scottishmedicines.org.uk/SMC\\_Advice/Advice/1162\\_16\\_levofloxacin\\_Quinsair/levofloxacin\\_Quinsair](http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1162_16_levofloxacin_Quinsair/levofloxacin_Quinsair)

[http://www.scottishmedicines.org.uk/files/advice/levonorgestrel\\_Kyleena\\_FINAL\\_Jan\\_2018\\_for\\_website.pdf](http://www.scottishmedicines.org.uk/files/advice/levonorgestrel_Kyleena_FINAL_Jan_2018_for_website.pdf)

| Medicine                                                           | Condition being treated                                                                                                                                                                                              | NHSGGC Decision                                                         | Date of decision |
|--------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|------------------|
| linzagolix<br><br>Yselyt®<br><br>SMC2631                           | Treatment of moderate to severe symptoms of<br>uterine fibroids in adult women of reproductive age.                                                                                                                  | Routinely available in line with local<br>or regional guidance          | 18/08/2025       |
| linzagolix<br><br>Yselyt<br><br>SMC2841                            | in adult women of reproductive age for<br>symptomatic treatment of endometriosis in women<br>with a history of previous medical or surgical<br>treatment for their endometriosis                                     | Routinely available in line with local<br>or regional guidance          | 06/10/2025       |
| Liposomal<br>Daunorubicin/Cytarabine<br><br>Vyxeos®<br><br>SMC2130 | The treatment of adults with newly diagnosed,<br>therapy-related acute myeloid leukaemia (AML) or<br>AML with myelodysplasia-related changes.                                                                        | Routinely available in line with local<br>or regional guidance          | 29/04/2019       |
| Liposomal Irinotecan<br><br>Onivyde®<br><br>1217/17                | Treatment of metastatic adenocarcinoma of the<br>pancreas, in combination with fluorouracil(5-FU)<br>and leucovorin (folinic acid), in adult patients who<br>have progressed following gemcitabine based<br>therapy. | Not routinely available as not<br>recommended for use in<br>NHSScotland | 24/04/2017       |

| Medicine                                                                                                                                                                                                                                | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                               | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Liraglutide</b><br><br>Saxenda®<br><br>SMC2378                                                                                                                                                                                       | as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of:<br>- $\geq 30\text{kg/m}^2$ (obese), or<br>- $\geq 27\text{kg/m}^2$ to $< 30\text{kg/m}^2$ (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. | Not routinely available as not recommended for use in NHSScotland | 18/10/2021       |
| <b>Liraglutide</b><br><br>Saxenda®<br><br>SMC2455                                                                                                                                                                                       | as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of:<br>- $\geq 30\text{kg/m}^2$ (obese), or<br>- $\geq 27\text{kg/m}^2$ to $< 30\text{kg/m}^2$ (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. | Routinely available in line with national guidance                | 24/04/2023       |
| <b>Liraglutide</b><br><br>Saxenda®<br><br>1247/17                                                                                                                                                                                       | As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index of $\geq 30\text{kg/m}^2$ (obese), or $\geq 27\text{kg/m}^2$ to $< 30\text{kg/m}^2$ (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.                  | Not routinely available as not recommended for use in NHSScotland | 19/06/2017       |
| <a href="http://www.scottishmedicines.org.uk/SMCAdvice/Advice/1247_17_liraglutide_Saxenda/liraglutide_Saxenda_Non_Sub">http://www.scottishmedicines.org.uk/SMCAdvice/Advice/1247_17_liraglutide_Saxenda/liraglutide_Saxenda_Non_Sub</a> |                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                   |                  |

| Medicine                                                              | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Liraglutide</b><br><br><b>Victoza®</b><br><br>1192/16              | As monotherapy for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance or contraindications.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/liraglutide_Victoza_Non_Sub_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/liraglutide_Victoza_Non_Sub_FINAL_August_2016_for_website.pdf</a> | Not routinely available as not recommended for use in NHSScotland | 10/10/2016       |
| <b>Loncastuximab tesirine</b><br><br><b>Zynlonta®</b><br><br>SMC2609  | monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy                                                                                                                                                                                                                                                                                                                                       | Routinely available in line with local or regional guidance       | 19/08/2024       |
| <b>Lorlatinib</b><br><br><b>Lorviqua®</b><br><br>SMC2239              | Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after:<br>- alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or<br>- crizotinib and at least one other ALK TKI                                                                                                                                                                                                                     | Routinely available in line with local or regional guidance       | 31/08/2020       |
| <b>Lumacaftor and Ivacaftor</b><br><br><b>Orkambi®</b><br><br>SMC2182 | Treatment of cystic fibrosis in patients aged 6 years and older (tablets) and aged 2 to 5 years (granules) who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.                                                                                                                                                                                                                                                                                                             | Not routinely available as not recommended for use in NHSScotland | 12/08/2019       |



| Medicine                                                        | Condition being treated                                                                                                                                                      | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Lumacaftor with ivacaftor</b><br><br>Orkambi®<br><br>1136/16 | Treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CF transmembrane conductance regulator (CFTR) gene. | Not routinely available as not recommended for use in NHSScotland | 13/06/2016       |
| <b>lumasiran</b><br><br>Oxlumo®<br><br>SMC2639                  | Treatment of primary hyperoxaluria type 1 (PH1) in all age groups.                                                                                                           | Not routinely available as not recommended for use in NHSScotland | 11/12/2023       |
| <b>Lurasidone</b><br><br>Latuda®<br><br>SMC 994/14              | Treatment of schizophrenia in adults aged 18 years and over                                                                                                                  | Routinely available in line with local or regional guidance       | 23/10/2017       |
| <b>Lustrombopag</b><br><br>Mulpleo®<br><br>SMC2227              | The treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures                                                         | Routinely available in line with national guidance                | 09/12/2019       |

[http://www.scottishmedicines.org.uk/files/advice/lurasidone\\_Latuda\\_FINAL\\_Sept\\_2014\\_amended\\_15.09.14\\_for\\_website.pdf](http://www.scottishmedicines.org.uk/files/advice/lurasidone_Latuda_FINAL_Sept_2014_amended_15.09.14_for_website.pdf)

| Medicine                                                                      | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Lutetium (177Lu) vipivotide tetraxetan</b><br><br>Pluvicto®<br><br>SMC2517 | Treatment of adult patients with prostate specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.                                                                                                                                                                                                                                                                                                                       | Not routinely available as not recommended for use in NHSScotland | 09/10/2023       |
| <b>Lutetium oxodotreotide</b><br><br>Lutathera®<br><br>1337/18                | Treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.<br><br><a href="https://www.scottishmedicines.org.uk/media/3557/lutetium-177lu-oxodotreotide-lutathera-final-june-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3557/lutetium-177lu-oxodotreotide-lutathera-final-june-2018-for-website.pdf</a>                                                                                                                                                        | Routinely available in line with local or regional guidance       | 13/08/2018       |
| <b>Magnesium glycerophosphate</b><br><br>Neomag®<br><br>1267/17               | as an oral magnesium supplement for the treatment of patients with chronic magnesium loss or hypomagnesaemia as diagnosed by a doctor. Magnesium glycerophosphate is also indicated for adult patients with hypomagnesaemia due to the concomitant administration of loop and thiazide diuretics or other drugs which cause hypomagnesaemia.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/magnesium_glycerophosphate_Neomag_Abb_FINAL_August_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/magnesium_glycerophosphate_Neomag_Abb_FINAL_August_2017_for_website.pdf</a> | Routinely available in line with national guidance                | 23/10/2017       |
| <b>Maraviroc</b><br><br>Celsentri®<br><br>1282/17                             | In combination with other antiretroviral medicinal products for treatment-experienced adolescents and children of 2 years and older and weighing at least 10kg infected with only CCR5-tropic HIV-1 detectable.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/maraviroc_Celsentri_Non_Sub_FINAL_Sept_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/maraviroc_Celsentri_Non_Sub_FINAL_Sept_2017_for_website.pdf</a>                                                                                                                                                      | Not routinely available as not recommended for use in NHSScotland | 23/10/2017       |

| Medicine                                                     | Condition being treated                                                                                                                                                                                                                                                                                                            | NHSGGC Decision                                                                                                                                                            | Date of decision |
|--------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Maribavir</b><br><br>Livtency®<br><br>SMC2576             | Treatment of cytomegalovirus (CMV) infection<br>0 and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT). | Routinely available in line with local or regional guidance                                                                                                                | 09/10/2023       |
| <b>mavacamten</b><br><br>Camzyos®<br><br>SMC2618             | Treatment of symptomatic (New York Heart<br>0 Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.                                                                                                                                                                                | Routinely available in line with national guidance                                                                                                                         | 18/08/2025       |
| <b>Mefenamic acid</b><br><br>Ponstan® and generic<br><br>N/A | Dysmenorrhoea and heavy menstrual bleeding<br>0                                                                                                                                                                                                                                                                                    | Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s) | 28/08/2017       |
| <b>Melatonin</b><br><br>Slenyto®<br><br>SMC2168              | Treatment of insomnia in children and adolescents<br>0 aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.                                                                                                                                      | Not routinely available as not recommended for use in NHSScotland                                                                                                          | 07/10/2019       |

| Medicine                                         | Condition being treated                                                                                                                                                                                                                            | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Mepolizumab</b><br><br>Nucala®<br><br>SMC2139 | as an add-on treatment for severe refractory<br>eosinophilic asthma in adolescents and children<br>aged 6 years and older                                                                                                                          | Routinely available in line with national guidance                | 29/04/2019       |
| <b>Mepolizumab</b><br><br>Nucala®<br><br>SMC2490 | As an add-on treatment for patients aged 6 years<br>and older with relapsing-remitting or refractory<br>eosinophilic granulomatosis with polyangiitis<br>(EGPA).                                                                                   | Not routinely available as not recommended for use in NHSScotland | 13/06/2022       |
| <b>Mepolizumab</b><br><br>Nucala®<br><br>SMC2491 | Add-on therapy with intranasal corticosteroids for<br>the treatment of adult patients with severe chronic<br>rhinosinusitis with nasal polyps for whom therapy<br>with systemic corticosteroids and/or surgery do not<br>provide adequate control. | Not routinely available as not recommended for use in NHSScotland | 13/06/2022       |
| <b>Mepolizumab</b><br><br>Nucala®<br><br>SMC2488 | Add-on treatment for adult patients with<br>inadequately controlled hypereosinophilic<br>syndrome without an identifiable non-haematologic<br>secondary cause.                                                                                     | Not routinely available as not recommended for use in NHSScotland | 13/06/2022       |

| Medicine                                              | Condition being treated                                                                                                                                                                                                                                            | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>mepolizumab</b><br><br>Nucala®<br><br>SMC2765      | Add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.                                                                                                                                             | Routinely available in line with national guidance                | 16/06/2025       |
| <b>Mepolizumab</b><br><br>Nucala®<br><br>1149/16      | Add-on treatment for severe refractory eosinophilic asthma in adult patients.                                                                                                                                                                                      | Routinely available in line with local or regional guidance       | 13/06/2016       |
| <b>Mercaptamine</b><br><br>Cystadrops®<br><br>SMC2343 | Treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.                                                                                                                                                          | Not routinely available as not recommended for use in NHSScotland | 19/04/2021       |
| <b>mercaptamine</b><br><br>Procysbi®<br><br>SMC2571   | treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure. | Not routinely available as not recommended for use in NHSScotland | 11/12/2023       |

| Medicine                                                       | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Mercaptamine</b><br><br>Procysbi®<br><br>SMC2374            | Treatment of proven nephropathic cystinosis<br>0                                                                                                                                                                                                                                                                                                                                                                                                                                                | Not routinely available as not recommended for use in NHSScotland | 18/10/2021       |
| <b>Mercaptamine bitartrate</b><br><br>Procysbi®<br><br>1272/17 | For the treatment of proven nephropathic cystinosis.<br>0                                                                                                                                                                                                                                                                                                                                                                                                                                       | Not routinely available as not recommended for use in NHSScotland | 11/12/2017       |
| <b>Meropenem/vaborbactam</b><br><br>Vaborem®<br><br>SMC2278    | for the treatment of the following infections in adults:<br>0 <ul style="list-style-type: none"> <li>- Complicated urinary tract infection (cUTI), including pyelonephritis</li> <li>- Complicated intra-abdominal infection (cIAI)</li> <li>- Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)</li> </ul> Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. | Routinely available in line with national guidance                | 26/10/2020       |

| Medicine                                              | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Metformin</b><br><br>Glucophage SR®<br><br>1308/18 | Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance and/or impaired fasting glucose, and/or increased HbA1C who are:<br>- at high risk for developing overt type 2 diabetes mellitus and<br>- still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/metformin_hydrochloride_Glucophage_Non_Sub_FINAL_Dec_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/metformin_hydrochloride_Glucophage_Non_Sub_FINAL_Dec_2017_for_website.pdf</a> | Not routinely available as not recommended for use in NHSScotland | 26/02/2018       |
| <b>Metreleptin</b><br><br>Myalepta®<br><br>SMC2559    | As an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients with:<br>- confirmed congenital generalised LD (Berardinelli-Seip syndrome) or acquired generalised LD (Lawrence syndrome) in adults and children 2 years of age and above.<br>- confirmed familial partial LD or acquired partial LD (Barraquer-Simons syndrome), in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control                                                                                                                                                      | Routinely available in line with national guidance                | 11/12/2023       |
| <b>Mexiletine</b><br><br>Namuscla®<br><br>SMC2241     | for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Routinely available in line with national guidance                | 14/12/2020       |

| Medicine                                                         | Condition being treated                                                                                             | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Mexiletine</b><br><br>Namuscla®<br><br>SMC2241                | Symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.                         | Not routinely available as not recommended for use in NHSScotland | 06/07/2020       |
| <b>Micronised progesterone</b><br><br>Utrogestan®<br><br>935/13  | In women for supplementation of the luteal phase during Assisted Reproductive Technology (ART) cycles.              | Routinely available in line with national guidance                | 19/06/2017       |
| <b>Micronised Progesterone</b><br><br>Utrogestan®<br><br>SMC2529 | Adjunctive use with oestrogen in post-menopausal women with an intact uterus, as hormone replacement therapy (HRT). | Routinely available in line with national guidance                | 12/12/2022       |
| <b>Midazolam maleate</b><br><br>Epistatus® PFS<br><br>1279/17    | Treatment of prolonged, acute, convulsive seizures in children and adolescents aged 10 to less than 18 years        | Routinely available in line with national guidance                | 01/01/2018       |



| Medicine                                          | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                         | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Midostaurin</b><br><br>Rydapt®<br><br>SMC2100  | 0 Monotherapy for the treatment of adult patients with aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, or mast cell leukaemia.<br><br><a href="https://www.scottishmedicines.org.uk/medicines-advice/midostaurin-rydapt-non-submission-smc2100/">https://www.scottishmedicines.org.uk/medicines-advice/midostaurin-rydapt-non-submission-smc2100/</a>                          | Not routinely available as not recommended for use in NHSScotland | 13/08/2018       |
| <b>Midostaurin</b><br><br>Rydapt®<br><br>1330/18  | 0 In combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FMS like tyrosine kinase 3 (FLT3) mutation-positive.                                                                    | Routinely available in line with local or regional guidance       | 11/06/2018       |
| <b>Migalastat</b><br><br>Galafold®<br><br>1196/16 | 0 Long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease ( $\alpha$ -galactosidase A deficiency) and who have an amenable mutation.<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1196_16_migalastat_Galafold/migalastat_Galafold">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1196_16_migalastat_Galafold/migalastat_Galafold</a> | Routinely available in line with national guidance                | 12/12/2016       |
| <b>mirikizumab</b><br><br>Omvoh®<br><br>SMC2650   | 0 Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.                                                                                                                                                                                                      | Routinely available in line with local or regional guidance       | 22/04/2024       |

| Medicine                                              | Condition being treated                                                                                                                                                                                                                                     | NHSGGC Decision                                             | Date of decision |
|-------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>mirikizumab</b><br><br>Omvo®<br><br>SMC2822        | Treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.                                       | Routinely available in line with local or regional guidance | 18/08/2025       |
| <b>Mobocertinib</b><br><br>Exkivity®<br><br>SMC2516   | As monotherapy for the treatment of adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received prior platinum-based chemotherapy. | Routinely available in line with local or regional guidance | 20/02/2023       |
| <b>Mogamulizumab</b><br><br>Poteligeo®<br><br>SMC2336 | Treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.                                                                                                                      | Routinely available in line with local or regional guidance | 14/06/2021       |
| <b>molnupiravir</b><br><br>Lagevrio®<br><br>SMC2556   | Treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness.                                                                 | Routinely available in line with local or regional guidance | 16/06/2025       |

| Medicine                                                       | Condition being treated                                                                                                                                                                                                                                                                                                           | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>momelotinib</b><br><br>Omjjara®<br><br>SMC2636              | 0 Treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib. | Routinely available in line with local or regional guidance       | 07/10/2024       |
| <b>Mosunetuzumab</b><br><br>Lunsumio®<br><br>SMC2542           | 0 Monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.                                                                                                                                                                   | Not routinely available as not recommended for use in NHSScotland | 09/10/2023       |
| <b>N/A</b><br><br>Anthelios® XL SPF 50<br><br>Formulary appeal | 0 Skin protection against UVA and UVB rays                                                                                                                                                                                                                                                                                        | Routinely available in line with local or regional guidance       | 18/04/2016       |
| <b>Naldemedine</b><br><br>Rizmoic®<br><br>SMC2242              | 0 Treatment of opioid induced constipation (OIC) in adult patients who have previously been treated with a laxative.                                                                                                                                                                                                              | Routinely available in line with local or regional guidance       | 06/07/2020       |

| Medicine                                                       | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Naltrexone and Bupropion</b><br><br>Mysimba®<br><br>SMC2086 | As an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of ≥ 30 kg/m <sup>2</sup> (obese), or ≥ 27 kg/m <sup>2</sup> to < 30 kg/m <sup>2</sup> (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension)                                                                                                                   | Not routinely available as not recommended for use in NHSScotland | 11/06/2018       |
| <b>Naproxen</b><br><br>Stirlescent®<br><br>1154/16             | Treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal disorders, dysmenorrhoea and acute gout in adults                                                                                                                                                                                                                                                                                                                                                                              | Routinely available in line with national guidance                | 13/06/2016       |
| <b>Necitumumab</b><br><br>Portrazza®<br><br>1184/16            | In combination with gemcitabine and cisplatin chemotherapy for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing squamous non-small cell lung cancer who have not received prior chemotherapy for this condition.<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1184_16_necitumumab_Portrazza/necitumumab_Portrazza">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1184_16_necitumumab_Portrazza/necitumumab_Portrazza</a> | Not routinely available as not recommended for use in NHSScotland | 22/08/2016       |
| <b>Nepafenac</b><br><br>Nevanac®<br><br>1228/17                | Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/nepafenac_Nevanac_Abbreviated_FINAL_March_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/nepafenac_Nevanac_Abbreviated_FINAL_March_2017_for_website.pdf</a>                                                                                                                                                                | Routinely available in line with national guidance                | 24/04/2017       |

| Medicine                                                                                                                                                                                                                                                                | Condition being treated                                                                                                                                                                                                                                                                     | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Neratinib</b><br><br>Nerlynx®<br><br>SMC2251                                                                                                                                                                                                                         | Extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.                                                                            | Routinely available in line with local or regional guidance       | 31/08/2020       |
| <b>netarsudil, latanoprost</b><br><br>Roclanda®<br><br>SMC2720                                                                                                                                                                                                          | Reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.                                                                     | Routinely available in line with national guidance                | 17/02/2025       |
| <b>Netupitant with Palonosetron</b><br><br>Akynzeo®<br><br>1109/15                                                                                                                                                                                                      | Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in adult patients.                                                                                                  | Routinely available in line with local or regional guidance       | 22/02/2016       |
| <b>Nilotinib</b><br><br>Tasigna ®<br><br>1325/18                                                                                                                                                                                                                        | - paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase<br>- paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib | Not routinely available as not recommended for use in NHSScotland | 23/04/2018       |
| <a href="https://www.scottishmedicines.org.uk/medicines-advice/nilotinib-150mg-and-200mg-hard-capsules-tasigna-non-submission-132518/">https://www.scottishmedicines.org.uk/medicines-advice/nilotinib-150mg-and-200mg-hard-capsules-tasigna-non-submission-132518/</a> |                                                                                                                                                                                                                                                                                             |                                                                   |                  |

| Medicine                                                                                                                                                                                                                                                                                | Condition being treated                                                                                                                                                                                                                                                                     | NHSGGC Decision                                             | Date of decision |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Nintedanib</b><br><br>Ofev®<br><br>SMC2513                                                                                                                                                                                                                                           | Treatment of idiopathic pulmonary fibrosis (IPF)<br>0                                                                                                                                                                                                                                       | Routinely available in line with national guidance          | 24/04/2023       |
| <b>Nintedanib</b><br><br>Ofev®<br><br>SMC2331                                                                                                                                                                                                                                           | Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype other than idiopathic pulmonary fibrosis (IPF).<br>0                                                                                                                                          | Routinely available in line with national guidance          | 14/06/2021       |
| <b>Niraparib</b><br><br>Zejula®<br><br>SMC2338                                                                                                                                                                                                                                          | Monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III or IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.<br>0 | Routinely available in line with local or regional guidance | 14/06/2021       |
| <b>Niraparib tosylate monohydrate</b><br><br>Zejula®<br><br>1341/18                                                                                                                                                                                                                     | As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy<br>0                            | Routinely available in line with local or regional guidance | 13/08/2018       |
| <a href="https://www.scottishmedicines.org.uk/media/3650/niraparib-tosylate-monohydrate-zejula-final-july-2018-amended-240718-for-website.pdf">https://www.scottishmedicines.org.uk/media/3650/niraparib-tosylate-monohydrate-zejula-final-july-2018-amended-240718-for-website.pdf</a> |                                                                                                                                                                                                                                                                                             |                                                             |                  |

| Medicine                                                          | Condition being treated                                                                                                                                                                                                                       | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>nirmatrelvir plus ritonavir</b><br><br>Paxlovid<br><br>SMC2557 | Treatment of people with symptomatic coronavirus disease (COVID-19)                                                                                                                                                                           | Routinely available in line with local or regional guidance       | 16/06/2025       |
| <b>Nirmatrelvir, Ritonavir</b><br><br>Paxlovid®<br><br>SMC2557    | Treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19                                                                                                       | Routinely available in line with national guidance                | 24/04/2023       |
| <b>Nitisinone</b><br><br>Orfadin®<br><br>SMC2450                  | Treatment of adult patients with alkaptonuria (AKU).                                                                                                                                                                                          | Not routinely available as not recommended for use in NHSScotland | 13/12/2021       |
| <b>Nivolumab</b><br><br>Opdivo®<br><br>SMC2394                    | in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy. | Routinely available in line with local or regional guidance       | 13/12/2021       |

| Medicine         | Condition being treated                                                                                                                                                                                                                                 | NHSGGC Decision                                             | Date of decision |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Nivolumab</b> | As monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults.                                                                                                                                                        | Routinely available in line with local or regional guidance | 19/06/2017       |
| Opdivo®          |                                                                                                                                                                                                                                                         |                                                             |                  |
| 1188/16          |                                                                                                                                                                                                                                                         |                                                             |                  |
|                  | <a href="http://www.scottishmedicines.org.uk/files/advice/nivolumab%20Opdivo%20RESUBMISSION%20FINAL%20May%202017%20for%20website.pdf">http://www.scottishmedicines.org.uk/files/advice/nivolumab Opdivo RESUBMISSION FINAL May 2017 for website.pdf</a> |                                                             |                  |
| <b>Nivolumab</b> | Treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.                                                                           | Routinely available in line with local or regional guidance | 28/08/2017       |
| Opdivo®          |                                                                                                                                                                                                                                                         |                                                             |                  |
| 1240/17          |                                                                                                                                                                                                                                                         |                                                             |                  |
|                  | <a href="http://www.scottishmedicines.org.uk/files/advice/nivolumab%20Opdivo%20cHL%20FINAL%20June%202017%20for%20website.pdf">http://www.scottishmedicines.org.uk/files/advice/nivolumab Opdivo cHL FINAL June 2017 for website.pdf</a>                 |                                                             |                  |
| <b>Nivolumab</b> | Monotherapy for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression $\geq 1\%$ , who are at high risk of recurrence after undergoing radical resection of MIUC.                         | Routinely available in line with local or regional guidance | 20/02/2023       |
| Opdivo®          |                                                                                                                                                                                                                                                         |                                                             |                  |
| SMC2503          |                                                                                                                                                                                                                                                         |                                                             |                  |
| <b>Nivolumab</b> | In combination with ipilimumab for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).                                                                                                                   | Routinely available in line with local or regional guidance | 21/02/2022       |
| Opdivo®          |                                                                                                                                                                                                                                                         |                                                             |                  |
| SMC2385          |                                                                                                                                                                                                                                                         |                                                             |                  |



| Medicine                                       | Condition being treated                                                                                                                                                                                                           | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Nivolumab</b><br><br>Opdivo®<br><br>1261/17 | As monotherapy, for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy.                                                                                  | Routinely available in line with local or regional guidance       | 23/10/2017       |
|                                                | <a href="http://www.scottishmedicines.org.uk/files/advice/nivolumab%20Opdivo%20FINAL%20August%202017%20for%20website.pdf">http://www.scottishmedicines.org.uk/files/advice/nivolumab Opdivo FINAL August 2017 for website.pdf</a> |                                                                   |                  |
| <b>Nivolumab</b><br><br>Opdivo®<br><br>SMC2112 | Monotherapy for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.                                                                       | Routinely available in line with local or regional guidance       | 10/12/2018       |
| <b>Nivolumab</b><br><br>Opdivo®<br><br>1285/18 | Nivolumab as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.                                         | Not routinely available as not recommended for use in NHSScotland | 26/02/2018       |
|                                                | <a href="http://www.scottishmedicines.org.uk/files/advice/nivolumab%20Opdivo%20FINAL%20Dec%202017%20for%20website.pdf">http://www.scottishmedicines.org.uk/files/advice/nivolumab Opdivo FINAL Dec 2017 for website.pdf</a>       |                                                                   |                  |
| <b>Nivolumab</b><br><br>Opdivo®<br><br>SMC2397 | In combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.  | Not routinely available as not recommended for use in NHSScotland | 21/02/2022       |

| Medicine                                       | Condition being treated                                                                                                                                                                                                                                                                                           | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Nivolumab</b><br><br>Opdivo®<br><br>SMC2458 | In combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥5 | Routinely available in line with local or regional guidance       | 10/10/2022       |
| <b>Nivolumab</b><br><br>Opdivo®<br><br>SMC2362 | Monotherapy for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy.                                                                                                | Routinely available in line with local or regional guidance       | 09/08/2021       |
| <b>Nivolumab</b><br><br>Opdivo®<br><br>SMC2429 | Monotherapy for the adjuvant treatment of adult patients with completely resected oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.                                                                                           | Routinely available in line with local or regional guidance       | 13/06/2022       |
| <b>Nivolumab</b><br><br>Opdivo®<br><br>SMC2620 | In combination with ipilimumab for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell programmed death ligand (PD-L1) expression ≥ 1%                                                                            | Not routinely available as not recommended for use in NHSScotland | 09/10/2023       |

| Medicine         | Condition being treated                                                                                                                                                                                                                                                                                                | NHSGGC Decision                                                   | Date of decision |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Nivolumab</b> | Treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.                                                                                                                                                                                        | Routinely available in line with local or regional guidance       | 10/10/2016       |
| Opdivo®          |                                                                                                                                                                                                                                                                                                                        |                                                                   |                  |
| 1180/16          |                                                                                                                                                                                                                                                                                                                        |                                                                   |                  |
|                  | <a href="http://www.scottishmedicines.org.uk/files/advice/nivolumab%20Opdivo%20FINAL%20Sept%202016%20FINAL%20amended%20150916%20for%20website.pdf">http://www.scottishmedicines.org.uk/files/advice/nivolumab Opdivo FINAL Sept 2016 FINAL amended 150916 for website.pdf</a>                                          |                                                                   |                  |
| <b>Nivolumab</b> | In combination with ipilimumab for the treatment of advanced (unresectable or metastatic) melanoma in adults.                                                                                                                                                                                                          | Routinely available in line with local or regional guidance       | 12/12/2016       |
| Opdivo®          |                                                                                                                                                                                                                                                                                                                        |                                                                   |                  |
| 1187/16          |                                                                                                                                                                                                                                                                                                                        |                                                                   |                  |
|                  | <a href="http://www.scottishmedicines.org.uk/SMCAdvice/Advice/1187%2016%20nivolumab%20Opdivo%20with%20ipilimumab%20for%20melanoma/nivolumab%20Opdivo">http://www.scottishmedicines.org.uk/SMC Advice/Advice/1187 16 nivolumab Opdivo with ipilimumab for melanoma/nivolumab Opdivo</a>                                 |                                                                   |                  |
| <b>nivolumab</b> | in combination with platinum-based chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgical resection, for the treatment of adults with resectable (tumours ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements. | Not routinely available as not recommended for use in NHSScotland | 06/10/2025       |
| Opdivo           |                                                                                                                                                                                                                                                                                                                        |                                                                   |                  |
| SMC2874          |                                                                                                                                                                                                                                                                                                                        |                                                                   |                  |
| <b>Nivolumab</b> | As monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults.                                                                                                                                                                                                                       | Not routinely available as not recommended for use in NHSScotland | 12/12/2016       |
| Opdivo®          |                                                                                                                                                                                                                                                                                                                        |                                                                   |                  |
| 1188/16          |                                                                                                                                                                                                                                                                                                                        |                                                                   |                  |
|                  | <a href="http://www.scottishmedicines.org.uk/SMCAdvice/Advice/1188%2016%20nivolumab%20Opdivo%20for%20renal%20cell%20carcinoma/nivolumab%20Opdivo">http://www.scottishmedicines.org.uk/SMC Advice/Advice/1188 16 nivolumab Opdivo for renal cell carcinoma/nivolumab Opdivo</a>                                         |                                                                   |                  |

| Medicine                                       | Condition being treated                                                                                                                            | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>nivolumab</b><br><br>Opdivo®<br><br>SMC2704 | Adjuvant treatment of adults and adolescents 12 years of age and older with Stage IIB or IIC melanoma                                              | Not routinely available as not recommended for use in NHSScotland | 19/08/2024       |
| <b>nivolumab</b><br><br>Opdivo<br><br>SMC 2726 | In combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. | Not routinely available as not recommended for use in NHSScotland | 07/10/2024       |
| <b>Nivolumab</b><br><br>Opdivo®<br><br>1120/16 | Monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.                                                         | Routinely available in line with local or regional guidance       | 22/08/2016       |
| <b>Nivolumab</b><br><br>Opdivo®<br><br>SMC2153 | In combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).     | Routinely available in line with local or regional guidance       | 10/06/2019       |

[http://www.scottishmedicines.org.uk/SMC\\_Advice/Advice/1120\\_16\\_nivolumab\\_Opdivo/nivolumab\\_Opdivo\\_Resubmission](http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1120_16_nivolumab_Opdivo/nivolumab_Opdivo_Resubmission)

| Medicine         | Condition being treated                                                                                                                                                                                                                                                                            | NHSGGC Decision                                                   | Date of decision |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Nivolumab</b> | Treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.                                                                                                                                                                        | Routinely available in line with local or regional guidance       | 22/08/2016       |
| Opdivo®          |                                                                                                                                                                                                                                                                                                    |                                                                   |                  |
| 1144/16          |                                                                                                                                                                                                                                                                                                    |                                                                   |                  |
|                  | <a href="http://www.scottishmedicines.org.uk/SMCAdvice/Advice/1144_16_nivolumab_Opdivo_for_metastatic_squamous_NSCLC/nivolumab_Opdivo_for">http://www.scottishmedicines.org.uk/SMCAdvice/Advice/1144_16_nivolumab_Opdivo_for_metastatic_squamous_NSCLC/nivolumab_Opdivo_for</a>                    |                                                                   |                  |
| <b>Nivolumab</b> | Monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.                                                                                                                                                                                                         | Not routinely available as not recommended for use in NHSScotland | 18/04/2016       |
| Opdivo®          |                                                                                                                                                                                                                                                                                                    |                                                                   |                  |
| 1120/16          |                                                                                                                                                                                                                                                                                                    |                                                                   |                  |
|                  | <a href="http://www.scottishmedicines.org.uk/SMCAdvice/Advice/1120_16_nivolumab_Opdivo/Briefing_note_nivolumab_Opdivo">http://www.scottishmedicines.org.uk/SMCAdvice/Advice/1120_16_nivolumab_Opdivo/Briefing_note_nivolumab_Opdivo</a>                                                            |                                                                   |                  |
| <b>nivolumab</b> | In combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable (tumours ≥4 cm or node positive) non-small cell lung cancer in adults.                                                                                                                                 | Routinely available in line with local or regional guidance       | 11/12/2023       |
| Opdivo®          |                                                                                                                                                                                                                                                                                                    |                                                                   |                  |
| SMC2619          |                                                                                                                                                                                                                                                                                                    |                                                                   |                  |
| <b>Nivolumab</b> | In combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell programmed death ligand 1 (PD-L1) expression ≥1%. | Routinely available in line with local or regional guidance       | 19/06/2023       |
| Opdivo®          |                                                                                                                                                                                                                                                                                                    |                                                                   |                  |
| SMC2519          |                                                                                                                                                                                                                                                                                                    |                                                                   |                  |

| Medicine                                                     | Condition being treated                                                                                                                        | NHSGGC Decision                                             | Date of decision |
|--------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Nivolumab</b><br><br>NCMAG106                             | Pleural or peritoneal mesothelioma; second or subsequent line in patients whose disease has progressed on or after platinum-based chemotherapy | Routinely available in line with local or regional guidance | 19/02/2024       |
| <b>Nivolumab, ipilimumab</b><br><br>NCMAG121                 | Nivolumab in combination with ipilimumab for the neoadjuvant treatment of resectable stage III melanoma                                        | Routinely available in line with local or regional guidance | 18/08/2025       |
| <b>nivolumab, relatlimab</b><br><br>Opdualag®<br><br>SMC2645 | First-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older.                    | Routinely available in line with local or regional guidance | 09/12/2024       |
| <b>Nusinersen</b><br><br>Spinraza®<br><br>1318/18            | Treatment of 5q spinal muscular atrophy (SMA).                                                                                                 | Routinely available in line with national guidance          | 11/06/2018       |

| Medicine                                               | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | NHSGGC Decision                                                                                                                                                            | Date of decision |
|--------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Nusinersen</b><br><br>Spinraza®<br><br>SMC 1318/18  | Treatment of type II and III (later onset) 5q spinal muscular atrophy (SMA)                                                                                                                                                                                                                                                                                                                                                                                                                                           | Routinely available in line with national guidance                                                                                                                         | 12/08/2019       |
| <b>nusinersen</b><br><br>Spinraza<br><br>SMC2805       | for the treatment of 5q spinal muscular atrophy                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s) | 06/10/2025       |
| <b>Obeticholic acid</b><br><br>Ocaliva®<br><br>1232/17 | Primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid or as monotherapy in adults unable to tolerate ursodeoxycholic acid<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/obeticholic_acid_Ocaliva_FINAL_May_2017_Amended_170517_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/obeticholic_acid_Ocaliva_FINAL_May_2017_Amended_170517_for_website.pdf</a> | Routinely available in line with local or regional guidance                                                                                                                | 19/06/2017       |
| <b>Obinutuzumab</b><br><br>Gazyvaro®<br><br>1219/17    | Obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with rituximab or a rituximab-containing regimen.                                                                                                                                                                                                                             | Routinely available in line with local or regional guidance                                                                                                                | 24/04/2017       |

| Medicine                                     | Condition being treated                                                                                                                                                                                                                                     | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| Obinutuzumab<br><br>Gazyvaro®<br><br>1286/18 | Obinutuzumab in combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma.                                         | Not routinely available as not recommended for use in NHSScotland | 26/02/2018       |
|                                              | <a href="http://www.scottishmedicines.org.uk/files/advice/obinutuzumab_Gazyvaro_FINAL_Dec_2018_Amended_14.12.17_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/obinutuzumab_Gazyvaro_FINAL_Dec_2018_Amended_14.12.17_for_website.pdf</a> |                                                                   |                  |
| Obinutuzumab<br><br>Gazyvaro®<br><br>SMC2015 | In combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma.                                                      | Not routinely available as not recommended for use in NHSScotland | 08/10/2018       |
| Obrelizumab<br><br>Ocrevus®<br><br>1344/18   | Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.                                                                                                                   | Not routinely available as not recommended for use in NHSScotland | 13/08/2018       |
|                                              | <a href="https://www.scottishmedicines.org.uk/media/3603/ocrelizumab-ocrevus-final-june-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3603/ocrelizumab-ocrevus-final-june-2018-for-website.pdf</a>                                       |                                                                   |                  |
| Obrelizumab<br><br>Ocrevus®<br><br>SMC2121   | Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.                                                                                                                   | Routinely available in line with local or regional guidance       | 09/12/2019       |
|                                              |                                                                                                                                                                                                                                                             | 01/06/2019                                                        |                  |



| Medicine                                                                           | Condition being treated                                                                                                                                                                                       | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Ocrelizumab</b><br><br>Ocrevus®<br><br>SMC2223                                  | Treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity. | Routinely available in line with local or regional guidance       | 06/07/2020       |
| <b>Odevixibat</b><br><br>Bylvay®<br><br>SMC2411                                    | Progressive familial intrahepatic cholestasis                                                                                                                                                                 | Routinely available in line with national guidance                | 15/08/2022       |
| <b>Oestrogens, conjugated, bazedoxifene acetate</b><br><br>Duavive®<br><br>1220/17 | Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate.     | Not routinely available as not recommended for use in NHSScotland | 20/02/2017       |
| <b>Ofatumumab</b><br><br>Kesimpta®<br><br>SMC2357                                  | Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.                                                                     | Routinely available in line with local or regional guidance       | 09/08/2021       |

[http://www.scottishmedicines.org.uk/SMC\\_Advice/Advice/1220\\_17\\_oestrogens\\_conjugated\\_Duavive/oestrogens\\_conjugated\\_Duavive\\_Non\\_Sub](http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1220_17_oestrogens_conjugated_Duavive/oestrogens_conjugated_Duavive_Non_Sub)

| Medicine                                         | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Ofatumumab</b><br><br>Arzerra®<br><br>1237/17 | Treatment of adult patients with relapsed CLL in combination with fludarabine and cyclophosphamide.                                                                                                                                                                                                                                                                                                                                                                                                                              | Not routinely available as not recommended for use in NHSScotland | 24/04/2017       |
| <b>olaparib</b><br><br>Lynparza®<br><br>SMC2737  | <p>0</p> Monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy. | Routinely available in line with local or regional guidance       | 28/04/2025       |
| <b>Olaparib</b><br><br>Lynparza®<br><br>SMC2436  | <p>0</p> Monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments.                                                                                                                                                                                | Not routinely available as not recommended for use in NHSScotland | 13/12/2021       |

[http://www.scottishmedicines.org.uk/files/advice/ofatumumab\\_Arzerra\\_Non\\_Sub\\_FINAL\\_March\\_2017\\_for\\_website.pdf](http://www.scottishmedicines.org.uk/files/advice/ofatumumab_Arzerra_Non_Sub_FINAL_March_2017_for_website.pdf)

| Medicine                                        | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Olaparib</b><br><br>Lynparza®<br><br>1047/15 | 0 Monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1047_15_olaparib_Lynparza/olaparib_Lynparza_Resubmission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1047_15_olaparib_Lynparza/olaparib_Lynparza_Resubmission</a> | Routinely available in line with local or regional guidance       | 12/12/2016       |
| <b>Olaparib</b><br><br>Lynparza®<br><br>SMC2435 | 0 Monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.                                                                                                                                                                                                                                                                                                    | Not routinely available as not recommended for use in NHSScotland | 13/12/2021       |
| <b>olaparib</b><br><br>Lynparza®<br><br>SMC2617 | 0 In combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.                                                                                                                                                                                                                                                                                                                                                     | Routinely available in line with local or regional guidance       | 19/08/2024       |
| <b>Olaparib</b><br><br>Lynparza®<br><br>SMC2209 | 0 Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.                                                                                                                                                                                                                                                         | Routinely available in line with local or regional guidance       | 09/12/2019       |

| Medicine                                    | Condition being treated                                                                                                                                                                                                                                                                               | NHSGGC Decision                                                                   | Date of decision |
|---------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|------------------|
| <b>Olaparib</b><br><br>Lynparza®<br>SMC2366 | 0 Monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent                                                                 | Routinely available in line with local or regional guidance<br><br><br>28/02/2022 | 21/02/2022       |
| <b>Olaparib</b><br><br>Lynparza<br>SMC2518  | 0 As monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have human epidermal growth factor receptor 2 (HER2)-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. | Routinely available in line with local or regional guidance                       | 09/10/2023       |
| <b>Olaparib</b><br><br>Lynparza®<br>SMC     | 0 Monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.                                                          | Routinely available in line with local or regional guidance                       | 09/08/2021       |

| Medicine                                               | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | NHSGGC Decision                                             | Date of decision |
|--------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Olaparib</b><br><br>Lynparza®<br><br>SMC2368        | In combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability. | Routinely available in line with local or regional guidance | 13/12/2021       |
| <b>Olaratumab</b><br><br>Lartruvo®<br><br>1273/17      | In combination with doxorubicin for the treatment of adult patients with advanced soft-tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin.                                                                                                                                                                                                                                                                  | Routinely available in line with local or regional guidance | 11/12/2017       |
| <b>Olipudase alfa</b><br><br>Xenpozyme®<br><br>SMC2560 | As an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B                                                                                                                                                                                                                                                                                                 | Routinely available in line with national guidance          | 22/04/2024       |

| Medicine                                                                                                                                                                                                                              | Condition being treated                                                                                                                                                                                                            | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Olopatadine with Mometasone</b><br><br>Ryaltris®<br><br>SMC2418                                                                                                                                                                    | in adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis.                                                                                      | Routinely available in line with national guidance                | 13/12/2021       |
| <b>Omalizumab</b><br><br>Xolair®<br><br>SMC2344                                                                                                                                                                                       | As add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe chronic rhinosinusitis with nasal polyps for whom therapy with INC does not provide adequate disease control. | Not routinely available as not recommended for use in NHSScotland | 19/04/2021       |
| <b>Opicapone</b><br><br>Ongentys®<br><br>SMC2430                                                                                                                                                                                      | As adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations                | Routinely available in line with national guidance                | 21/02/2022       |
| <b>Opicapone</b><br><br>Ongentys®<br><br>1281/17                                                                                                                                                                                      | Adjunctive therapy to preparations of levodopa / DOPA decarboxylase inhibitors in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations                        | Not routinely available as not recommended for use in NHSScotland | 23/10/2017       |
| <a href="http://www.scottishmedicines.org.uk/files/advice/opicapone_Ongentys_Non_Sub_FINAL_Sept_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/opicapone_Ongentys_Non_Sub_FINAL_Sept_2017_for_website.pdf</a> |                                                                                                                                                                                                                                    |                                                                   |                  |

| Medicine                                            | Condition being treated                                                                                                                                                                                                                                                                        | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Oritavancin</b><br><br>Tenkasi®<br><br>SMC2285   | Treatment of acute bacterial skin and skin structure<br>0 infections (ABSSSI) in adults.                                                                                                                                                                                                       | Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s)            | 13/06/2022       |
| <b>Oseltamivir</b><br><br>Tamiflu®<br><br>1127/16   | Treatment of influenza in children aged <1 year<br>0 including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms. | Routinely available in line with national guidance                                                                                                                                    | 26/04/2016       |
| <b>osilodrostat</b><br><br>Isturisa®<br><br>SMC2640 | Treatment of endogenous Cushing's syndrome in<br>0 adults                                                                                                                                                                                                                                      | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 11/12/2023       |
| <b>osimertinib</b><br><br>Tagrisso®<br><br>SMC2736  | In combination with pemetrexed and platinum-<br>0 based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.   | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>08/12/2025 | 06/10/2025       |

| Medicine                                                                                                                                                                                                                      | Condition being treated                                                                                                                                                                                                                                                          | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Osimertinib</b><br><br>Tagrisso®<br><br>SMC2382                                                                                                                                                                            | As monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.                                                                          | Routinely available in line with local or regional guidance       | 21/02/2022       |
| <b>Osimertinib</b><br><br>Tagrisso®<br><br>SMC2383                                                                                                                                                                            | Monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations. | Routinely available in line with local or regional guidance       | 13/12/2021       |
| <b>Osimertinib</b><br><br>Tagrisso®<br><br>SMC2171                                                                                                                                                                            | Monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations                                                                              | Not routinely available as not recommended for use in NHSScotland | 07/10/2019       |
| <b>Osimertinib</b><br><br>Tagrisso®<br><br>1214/17                                                                                                                                                                            | Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC).                                                                                                              | Routinely available in line with local or regional guidance       | 20/02/2017       |
| <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1214_17_osimertinib_Tagrisso/osimertinib_Tagrisso">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1214_17_osimertinib_Tagrisso/osimertinib_Tagrisso</a> |                                                                                                                                                                                                                                                                                  |                                                                   |                  |



| Medicine                                          | Condition being treated                                                                                                                                                                                                                                                                                                                                                       | NHSGGC Decision                                             | Date of decision |
|---------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Ospemifene</b><br><br>Senshio®<br><br>SMC2170  | Treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy.                                                                                                                                                                                                             | Routinely available in line with national guidance          | 07/10/2019       |
| <b>Ozanimod</b><br><br>Zeposia®<br><br>SMC2478    | for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.                                                                                                                                                     | Routinely available in line with national guidance          | 10/10/2022       |
| <b>Ozanimod</b><br><br>Zeposia®<br><br>SMC2309    | Treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.                                                                                                                                                                                                                                | Routinely available in line with national guidance          | 19/04/2021       |
| <b>Palbociclib</b><br><br>Ibrance®<br><br>SMC2149 | Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist. | Routinely available in line with local or regional guidance | 12/08/2019       |

| Medicine                                                             | Condition being treated                                                                                                                                                                                                                                 | NHSGGC Decision                                                                                                                                                                           | Date of decision |
|----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Palbociclib</b><br><br><b>Ibrance®</b><br><br>1276/17             | Treatment of hormone receptor (HR)-positive,<br>human epidermal growth factor receptor 2 (HER2)-<br>negative locally advanced or metastatic breast<br>cancer (refer to SMC advice for full details of<br>indication).                                   | Routinely available in line with local<br>or regional guidance                                                                                                                            | 11/12/2017       |
| <b>Paliperidone palmitate</b><br><br><b>Trevicta®</b><br><br>1181/16 | Maintenance treatment of schizophrenia in adult<br>patients who are clinically stable on one-monthly<br>paliperidone palmitate injectable product                                                                                                       | Not routinely available as local<br>clinical experts do not wish to add<br>the medicine to the Formulary at<br>this time or there is a local<br>preference for alternative<br>medicine(s) | 10/10/2016       |
| <b>Panitumumab</b><br><br><b>Vectibix®</b><br><br>439                | 1st line metastatic colorectal cancer in combination<br>with either FOLFOX or FOLFIRI:<br>- cetuximab for EGFR-expressing, RAS wild-type<br>- panitumumab for RAS wild-type in                                                                          | Routinely available in line with local<br>or regional guidance                                                                                                                            | 19/06/2017       |
| <b>Panobinostat</b><br><br><b>Farydak®</b><br><br>1122/16            | In combination with bortezomib and<br>dexamethasone, for the treatment of adult patients<br>with relapsed and/or refractory multiple myeloma<br>who have received at least two prior regimens<br>including bortezomib and an immunomodulatory<br>agent. | Routinely available in line with local<br>or regional guidance                                                                                                                            | 22/02/2016       |

[http://www.scottishmedicines.org.uk/files/advice/paliperidone\\_palmitate Trevicta Abb FINAL August 2016 for website.pdf](http://www.scottishmedicines.org.uk/files/advice/paliperidone_palmitate_Trevicta_Abb_FINAL_August_2016_for_website.pdf)

<https://www.nice.org.uk/guidance/ta439>

| Medicine                   | Condition being treated                                                                                                                                                                                                                             | NHSGGC Decision                                                   | Date of decision |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Parathyroid hormone</b> | As adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.                                                                                                          | Not routinely available as not recommended for use in NHSScotland | 23/04/2018       |
| Natpar ®                   |                                                                                                                                                                                                                                                     |                                                                   |                  |
| 1334/18                    |                                                                                                                                                                                                                                                     |                                                                   |                  |
|                            | <a href="https://www.scottishmedicines.org.uk/medicines-advice/parathyroid-hormone-natpar-nonsub-133418/">https://www.scottishmedicines.org.uk/medicines-advice/parathyroid-hormone-natpar-nonsub-133418/</a>                                       |                                                                   |                  |
| <b>Pasireotide</b>         | Treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed.                                                                                                                                | Not routinely available as not recommended for use in NHSScotland | 26/02/2018       |
| Signifor®                  |                                                                                                                                                                                                                                                     |                                                                   |                  |
| 1311/18                    |                                                                                                                                                                                                                                                     |                                                                   |                  |
|                            | <a href="http://www.scottishmedicines.org.uk/files/advice/pasireotide_Signifor_Non_Sub_FINAL_Jan_2018_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/pasireotide Signifor Non Sub FINAL Jan 2018 for website.pdf</a>             |                                                                   |                  |
| <b>Patiomer</b>            | The treatment of hyperkalaemia in adults                                                                                                                                                                                                            | Not routinely available as not recommended for use in NHSScotland | 13/08/2018       |
| Veltassa®                  |                                                                                                                                                                                                                                                     |                                                                   |                  |
| 2084                       |                                                                                                                                                                                                                                                     |                                                                   |                  |
|                            | <a href="https://www.scottishmedicines.org.uk/media/3651/patiomer-sorbitex-calcium-veltassa-final-july-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3651/patiomer-sorbitex-calcium-veltassa-final-july-2018-for-website.pdf</a> |                                                                   |                  |
| <b>Patiomer</b>            | Treatment of hyperkalaemia in adults                                                                                                                                                                                                                | Not routinely available as not recommended for use in NHSScotland | 14/12/2020       |
| Veltassa®                  |                                                                                                                                                                                                                                                     |                                                                   |                  |
| SMC2264                    |                                                                                                                                                                                                                                                     |                                                                   |                  |

| Medicine                                                         | Condition being treated                                                                                                                                                                         | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Patiomer</b><br><br>Veltassa®<br><br>SMC2381                  | Hyperkalaemia in adults<br>0                                                                                                                                                                    | Routinely available in line with national guidance                | 09/08/2021       |
| <b>Patiomer sorbitex calcium</b><br><br>Veltassa®<br><br>SMC2568 | Treatment of hyperkalaemia in adults.<br>0                                                                                                                                                      | Routinely available in line with national guidance                | 24/04/2023       |
| <b>Patisiran</b><br><br>Onpattro®<br><br>SMC2157                 | Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.<br>0                                                   | Routinely available in line with national guidance                | 10/06/2019       |
| <b>pazopanib</b><br><br>NCMAG112                                 | Second line treatment of poor or intermediate risk advanced/metastatic renal cell carcinoma in patients who have received nivolumab in combination with ipilimumab as first line treatment<br>0 | Not routinely available as not recommended for use in NHSScotland | 19/02/2024       |

| Medicine                                                    | Condition being treated                                                                                                                                                                                                                                   | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Pegaspargase</b><br><br>Oncaspar®<br><br>1197/16         | As a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.                                                                                            | Routinely available in line with local or regional guidance       | 12/12/2016       |
|                                                             | <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1197_16_pegaspargase_Oncaspar_/pegaspargase_Oncaspar">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1197_16_pegaspargase_Oncaspar_/pegaspargase_Oncaspar</a>                       |                                                                   |                  |
| <b>pegcetacoplan</b><br><br>Aspaveli®<br><br>SMC2715        | Monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.                                                                                                                               | Not routinely available as not recommended for use in NHSScotland | 07/10/2024       |
| <b>Pegcetacoplan</b><br><br>Aspaveli®<br><br>SMC2451        | Treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months.                                                                                                    | Routinely available in line with national guidance                | 15/08/2022       |
| <b>Peginterferon alfa-2a</b><br><br>Pegasys®<br><br>1312/18 | Treatment of hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels.                          | Not routinely available as not recommended for use in NHSScotland | 26/02/2018       |
|                                                             | <a href="http://www.scottishmedicines.org.uk/files/advice/peginterferon_alfa-2a_Pegasys_Non_Sub_FINAL_Jan_2018_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/peginterferon_alfa-2a_Pegasys_Non_Sub_FINAL_Jan_2018_for_website.pdf</a> |                                                                   |                  |

| Medicine                                                             | Condition being treated                                                                                                                                                                                                                                                                             | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>pegunigalsidase alfa</b><br><br>Elfabrio®<br><br>SMC2591          | Long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry Disease (deficiency of alpha-galactosidase).<br><br>0                                                                                                                                                    | Not routinely available as not recommended for use in NHSScotland | 11/12/2023       |
| <b>pegunigalsidase alfa</b><br><br>Elfabrio®<br><br>SMC2665          | for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).<br><br>0                                                                                                                                                | Routinely available in line with national guidance                | 18/08/2025       |
| <b>Pegvisomant</b><br><br>Somavert®<br><br>158/05                    | Treatment of adult patients with acromegaly who have had an inadequate response to surgery and / or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-1 [insulin-like growth factor 1] concentrations or was not tolerated.<br><br>0 | Routinely available in line with national guidance                | 11/12/2017       |
| <b>pegylated liposomal irinotecan</b><br><br>Onivyde®<br><br>SMC2812 | In combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.<br><br>0                                                                                                                  | Not routinely available as not recommended for use in NHSScotland | 16/06/2025       |

| Medicine                                                                                                                                                                                                                    | Condition being treated                                                                                                                                                                                                                                                                                       | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>pegzilarginase</b><br><br>Loargys®<br><br>SMC2813                                                                                                                                                                        | 0 Treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older.                                                                                                                                                                    | Not routinely available as not recommended for use in NHSScotland | 16/06/2025       |
| <b>Pembrolizumab</b><br><br>Keytruda®<br><br>SMC2420                                                                                                                                                                        | 0 In combination with platinum and fluoropyrimidine based chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS≥10. | Routinely available in line with local or regional guidance       | 13/06/2022       |
| <b>Pembrolizumab</b><br><br>Keytruda®<br><br>SMC2375                                                                                                                                                                        | 0 Monotherapy for the first-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults.                                                                                                                                             | Routinely available in line with local or regional guidance       | 18/10/2021       |
| <b>Pembrolizumab</b><br><br>Keytruda®<br><br>1291/18                                                                                                                                                                        | 0 Monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.                                                                                                                                                    | Routinely available in line with local or regional guidance       | 26/02/2018       |
| <a href="http://www.scottishmedicines.org.uk/files/advice/pembrolizumab_Keytruda_FINAL_Jan_2018_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/pembrolizumab_Keytruda_FINAL_Jan_2018_for_website.pdf</a> |                                                                                                                                                                                                                                                                                                               |                                                                   |                  |

| Medicine                                                    | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | NHSGGC Decision                                                          | Date of decision  |
|-------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|-------------------|
| <p><b>pembrolizumab</b></p> <p>Keytruda®</p> <p>SMC2589</p> | <p>As monotherapy for adults with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in the following settings:</p> <ul style="list-style-type: none"> <li>- treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine-based combination therapy.</li> </ul> <p>As monotherapy for the treatment of the following MSI-H or dMMR tumours in adults with:</p> <ul style="list-style-type: none"> <li>- advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation;</li> <li>- unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.</li> </ul> | <p>Routinely available in line with local or regional guidance</p>       | <p>19/08/2024</p> |
| <p><b>Pembrolizumab</b></p> <p>Keytruda®</p> <p>1087/15</p> | <p>Monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.</p> <p>This submission relates to use in adults previously treated with ipilimumab.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <p>Not routinely available as not recommended for use in NHSScotland</p> | <p>12/12/2016</p> |
| <p><b>Pembrolizumab</b></p> <p>Keytruda®</p> <p>SMC2143</p> | <p>Monotherapy for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a ≥50% TPS and progressing on or after platinum-containing chemotherapy</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | <p>Not routinely available as not recommended for use in NHSScotland</p> | <p>10/12/2018</p> |

[http://www.scottishmedicines.org.uk/SMC\\_Advice/Advice/1087\\_15\\_pembrolizumab\\_Keytruda/pembrolizumab\\_Keytruda\\_Resub](http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1087_15_pembrolizumab_Keytruda/pembrolizumab_Keytruda_Resub)



| Medicine                                                    | Condition being treated                                                                                                                                                                                                                                                             | NHSGGC Decision                                                          | Date of decision  |
|-------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|-------------------|
| <p><b>pembrolizumab</b></p> <p>Keytruda®</p> <p>SMC2767</p> | <p>In combination with carboplatin and paclitaxel, for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults.</p>                                                                                                                               | <p>Routinely available in line with local or regional guidance</p>       | <p>06/10/2025</p> |
| <p><b>Pembrolizumab</b></p> <p>Keytruda®</p> <p>SMC2479</p> | <p>As monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC) at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.</p>                                                                     | <p>Routinely available in line with local or regional guidance</p>       | <p>10/10/2022</p> |
| <p><b>Pembrolizumab</b></p> <p>Keytruda®</p> <p>SMC2127</p> | <p>In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma (NSCLC) in adults whose tumours have no EGFR or ALK positive mutations.</p>                                                      | <p>Not routinely available as not recommended for use in NHSScotland</p> | <p>25/02/2019</p> |
| <p><b>Pembrolizumab</b></p> <p>Keytruda®</p> <p>SMC2460</p> | <p>in combination with chemotherapy, for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS <math>\geq 10</math> and who have not received prior chemotherapy for metastatic disease.</p> | <p>Routinely available in line with local or regional guidance</p>       | <p>10/10/2022</p> |

| Medicine                                             | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Pembrolizumab</b><br><br>Keytruda®<br><br>1296/18 | 0 Monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin.<br><br><a href="https://www.scottishmedicines.org.uk/medicines-advice/pembrolizumab-keytruda-chl-fullsubmission-129618/">https://www.scottishmedicines.org.uk/medicines-advice/pembrolizumab-keytruda-chl-fullsubmission-129618/</a> | Routinely available in line with local or regional guidance       | 23/04/2018       |
| <b>pembrolizumab</b><br><br>Keytruda®<br><br>SMC2660 | 0 in combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) ≥ 1.                                                                                                                   | Routinely available in line with local or regional guidance       | 28/04/2025       |
| <b>pembrolizumab</b><br><br>Keytruda®<br><br>SMC2644 | 0 in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1.                                                                                                                                                                                               | Not routinely available as not recommended for use in NHSScotland | 19/08/2024       |
| <b>Pembrolizumab</b><br><br>Keytruda®<br><br>SMC2207 | 0 In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma (NSCLC) in adults whose tumours have no EGFR or ALK positive mutations.                                                                                                                                                                                                                                                                    | Routinely available in line with local or regional guidance       | 07/10/2019       |

| Medicine                                             | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | NHSGGC Decision                                             | Date of decision |
|------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Pembrolizumab</b><br><br>Keytruda®<br><br>1204/17 | Treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express programmed death ligand 1 (PD-L1) and who have received at least one prior chemotherapy regimen.<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1204_17_pembrolizumab_Keytruda/pembrolizumab_Keytruda">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1204_17_pembrolizumab_Keytruda/pembrolizumab_Keytruda</a>                                                                                                 | Routinely available in line with local or regional guidance | 20/02/2017       |
| <b>Pembrolizumab</b><br><br>Keytruda®<br><br>SMC2501 | In combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express programmed death ligand 1 (PD-L1) with a combined positive score (CPS)≥1.                                                                                                                                                                                                                                                                                                              | Routinely available in line with local or regional guidance | 20/02/2023       |
| <b>Pembrolizumab</b><br><br>Keytruda<br><br>1239/17  | As monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express programmed death ligand 1 (PD-L1) with a ≥50% tumour proportion score (TPS) with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) positive tumour mutations.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/pembrolizumab_Keytruda_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/pembrolizumab_Keytruda_FINAL_June_2017_for_website.pdf</a> | Routinely available in line with local or regional guidance | 28/08/2017       |
| <b>Pembrolizumab</b><br><br>Keytruda®<br><br>SMC2144 | Monotherapy for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.                                                                                                                                                                                                                                                                                                                                                                                                                      | Routinely available in line with local or regional guidance | 10/06/2019       |

| Medicine                                             | Condition being treated                                                                                                                                                                                                                                                                                           | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Pembrolizumab</b><br><br>Keytruda®<br><br>SMC2526 | 0 Monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB or IIC melanoma and who have undergone complete resection.                                                                                                                                              | Routinely available in line with local or regional guidance       | 24/04/2023       |
| <b>pembrolizumab</b><br><br>Keytruda®<br><br>SMC2683 | 0 In combination with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults.                                                                                                                                                    | Not routinely available as not recommended for use in NHSScotland | 17/06/2024       |
| <b>pembrolizumab</b><br><br><br><br>NCMAG122         | 0 For the neoadjuvant treatment of stage IIIB to IIID or oligometastatic resectable stage IV melanoma                                                                                                                                                                                                             | Routinely available in line with local or regional guidance       | 18/08/2025       |
| <b>Pembrolizumab</b><br><br>Keytruda®<br><br>SMC2257 | 0 as monotherapy or in combination with platinum and fluorouracil chemotherapy, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express programmed cell death ligand-1 (PD-L1) with a combined positive score (CPS)≥1. | Routinely available in line with local or regional guidance       | 31/08/2020       |

| Medicine                                             | Condition being treated                                                                                                                                                                                                                                                                                  | NHSGGC Decision                                                | Date of decision |
|------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------------------|
| <b>Pembrolizumab</b><br><br>Keytruda®<br><br>SMC2187 | In combination with carboplatin and either<br>0 paclitaxel or nab-paclitaxel, for the first-line<br>treatment of metastatic squamous non-small cell<br>lung cancer (NSCLC) in adults.                                                                                                                    | Routinely available in line with local<br>or regional guidance | 07/10/2019       |
| <b>Pembrolizumab</b><br><br>Keytruda®<br><br>SMC2538 | In combination with chemotherapy as neoadjuvant<br>0 treatment, and then continued as monotherapy as<br>adjuvant treatment after surgery, for the treatment<br>of adults with locally advanced, or early stage triple-<br>negative breast cancer (TNBC) at high risk of<br>recurrence.                   | Routinely available in line with local<br>or regional guidance | 19/06/2023       |
| <b>Pembrolizumab</b><br><br>Keytruda®<br><br>SMC2247 | in combination with axitinib, for the first-line<br>0 treatment of advanced renal cell carcinoma in<br>adults.                                                                                                                                                                                           | Routinely available in line with local<br>or regional guidance | 31/08/2020       |
| <b>Pembrolizumab</b><br><br>Keytruda®<br><br>SMC2474 | In combination with lenvatinib, for the treatment of<br>0 advanced or recurrent endometrial carcinoma in<br>adults who have disease progression on or<br>following prior treatment with a platinum-containing<br>therapy in any setting and who are not candidates<br>for curative surgery or radiation. | Routinely available in line with local<br>or regional guidance | 10/10/2022       |

| Medicine                                                    | Condition being treated                                                                                                                                                                                                                                                                   | NHSGGC Decision                                                          | Date of decision  |
|-------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|-------------------|
| <p><b>pembrolizumab</b></p> <p>Keytruda</p> <p>SMC 2689</p> | <p>As monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy.</p>                                                                                            | <p>Routinely available in line with local or regional guidance</p>       | <p>28/04/2025</p> |
| <p><b>pembrolizumab</b></p> <p>Keytruda®</p> <p>SMC2688</p> | <p>In combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, for the treatment of resectable non-small cell lung carcinoma at high risk of recurrence in adults.</p>                                        | <p>Not routinely available as not recommended for use in NHSScotland</p> | <p>09/12/2024</p> |
| <p><b>Pembrolizumab</b></p> <p>Keytruda®</p> <p>SMC2380</p> | <p>Monotherapy for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.</p> | <p>Routinely available in line with local or regional guidance</p>       | <p>13/12/2021</p> |
| <p><b>Pembrolizumab</b></p> <p>Keytruda®</p> <p>1339/18</p> | <p>As monotherapy, for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy and whose tumours express PD-L1 with a combined positive score (CPS)≥10.</p>                                             | <p>Not routinely available as not recommended for use in NHSScotland</p> | <p>08/10/2018</p> |

| Medicine                                                      | Condition being treated                                                                                                                                                                                                       | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Pemetrexed</b><br><br>NCMAG109                             | Pemetrexed in combination with cisplatin as adjuvant treatment for patients with completely resected stage IIA to IIIA non-squamous, non-small-cell lung cancer                                                               | Routinely available in line with national guidance                | 21/08/2023       |
| <b>Pemigatinib</b><br><br>Pemazyre®<br>SMC2399                | Treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. | Routinely available in line with local or regional guidance       | 21/02/2022       |
| <b>Pentosan Polysulfate Sodium</b><br><br>Elmiron®<br>SMC2194 | Treatment of bladder pain syndrome characterised by either glomerulations or Hunner's lesions in adults with moderate to severe pain, urgency and frequency of micturition.                                                   | Routinely available in line with local or regional guidance       | 09/12/2019       |
| <b>Perampanel</b><br><br>Fycompa®<br>SMC2218                  | The adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.                                                             | Not routinely available as not recommended for use in NHSScotland | 12/08/2019       |

| Medicine                                                                                                                                                                                                                                | Condition being treated                                                                                                                                                                                                                                              | NHSGGC Decision                                                         | Date of decision |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|------------------|
| <b>Perampanel</b><br><br>Fycompa®<br><br>SMC2172                                                                                                                                                                                        | for the adjunctive treatment of partial-onset<br>seizures with or without secondarily generalised<br>seizures in adult and adolescent patients from 12<br>years of age with epilepsy.                                                                                | Routinely available in line with<br>national guidance                   | 12/08/2019       |
| <b>Perampanel</b><br><br>Fycompa®<br><br>1200/16                                                                                                                                                                                        | Adjunctive treatment of primary generalised tonic-<br>clonic seizures in adult and adolescent patients<br>from 12 years of age with idiopathic generalised<br>epilepsy                                                                                               | Not routinely available as not<br>recommended for use in<br>NHSScotland | 10/10/2016       |
| <b>Pertuzumab</b><br><br>Perjeta®<br><br>SMC2120                                                                                                                                                                                        | In combination with trastuzumab and docetaxel, in<br>adult patients with HER2 positive metastatic or<br>locally recurrent unresectable breast cancer, who<br>have not received previous anti HER2 therapy or<br>chemotherapy for their metastatic disease.           | Routinely available in line with local<br>or regional guidance          | 25/02/2019       |
| <b>Pertuzumab</b><br><br>Perjeta®<br><br>897/13                                                                                                                                                                                         | for use in combination with trastuzumab and<br>docetaxel in adult patients with HER2-positive<br>metastatic or locally recurrent unresectable breast<br>cancer, who have not received previous anti-HER2<br>therapy or chemotherapy for their metastatic<br>disease. | Not routinely available as not<br>recommended for use in<br>NHSScotland | 19/06/2017       |
| <a href="http://www.scottishmedicines.org.uk/files/advice/perampanel_Fycompa_Non_Sub_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/perampanel_Fycompa_Non_Sub_FINAL_Sept_2016_for_website.pdf</a>   |                                                                                                                                                                                                                                                                      |                                                                         |                  |
| <a href="http://www.scottishmedicines.org.uk/files/advice/pertuzumab_Perjeta_2nd_Resub_FINAL_May_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/pertuzumab_Perjeta_2nd_Resub_FINAL_May_2017_for_website.pdf</a> |                                                                                                                                                                                                                                                                      |                                                                         |                  |



| Medicine                                         | Condition being treated                                                                                                                                                                                                                                  | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Pertuzumab</b><br><br>Perjeta®<br><br>SMC2284 | for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.                                                                                  | Routinely available in line with local or regional guidance       | 31/08/2020       |
| <b>Pertuzumab</b><br><br>Perjeta®<br><br>SMC2119 | In combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2 positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.                                             | Routinely available in line with local or regional guidance       | 10/12/2018       |
| <b>Pertuzumab</b><br><br>Perjeta®<br><br>1121/16 | In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. | Not routinely available as not recommended for use in NHSScotland | 12/12/2016       |
| <b>Pertuzumab</b><br><br>Perjeta®<br><br>SMC2197 | For use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.                                                                                  | Not routinely available as not recommended for use in NHSScotland | 07/10/2019       |

[http://www.scottishmedicines.org.uk/SMC\\_Advice/Advice/1121\\_16\\_pertuzumab\\_Perjeta/pertuzumab\\_Perjeta\\_Resub](http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1121_16_pertuzumab_Perjeta/pertuzumab_Perjeta_Resub)

| Medicine                                                                                  | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Pertuzumab</b><br><br>Perjeta®<br><br>1121/16                                          | In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.<br><br><a href="http://www.scottishmedicines.org.uk/SMCAdvice/Advice/1121_16_pertuzumab_Perjeta/Briefing_note_pertuzumab_Perjeta">http://www.scottishmedicines.org.uk/SMCAdvice/Advice/1121_16_pertuzumab_Perjeta/Briefing_note_pertuzumab_Perjeta</a>                                                                                                      | Not routinely available as not recommended for use in NHSScotland | 18/04/2016       |
| <b>Pertuzumab and trastuzumab</b><br><br>Phesgo®<br><br>SMC2364                           | 1) Early breast cancer (EBC) In combination with chemotherapy in:<br>- the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence<br>- the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence<br>2) Metastatic breast cancer (MBC)<br>In combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. | Routinely available in line with local or regional guidance       | 09/08/2021       |
| <b>Phenylephrine hydrochloride, tropicamide</b><br><br>Mydriaser®<br><br>Formulary appeal | For use in adult patients to obtain pre-operative mydriasis or for diagnostic purposes when monotherapy is known to be insufficient.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Routinely available in line with local or regional guidance       | 18/04/2016       |

| Medicine                                                | Condition being treated                                                                                                                                                                                                                                                              | NHSGGC Decision                                                                      | Date of decision  |
|---------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------|
| <p><b>pitolisant</b></p> <p>Wakix®</p> <p>SMC2662</p>   | <p>Improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by, or who have not tolerated, OSA primary therapy, such as continuous positive airway pressure (CPAP).</p> | <p>Not routinely available as not recommended for use in NHSScotland</p>             | <p>22/04/2024</p> |
| <p><b>Pitolisant</b></p> <p>Wakix®</p> <p>1229/17</p>   | <p>Treatment of narcolepsy with or without cataplexy in adults</p>                                                                                                                                                                                                                   | <p>Not routinely available as not recommended for use in NHSScotland</p>             | <p>20/02/2017</p> |
| <p><b>Pixantrone</b></p> <p>Pixuvri®</p> <p>1138/16</p> | <p>Monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non Hodgkin B-cell Lymphomas</p>                                                                                                                                                  | <p>Not routinely available as not recommended for use in NHSScotland</p>             | <p>22/02/2016</p> |
| <p><b>Polatuzumab</b></p> <p>Polivy®</p> <p>SMC2525</p> | <p>In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).</p>                                                                                     | <p>Routinely available in line with local or regional guidance</p> <p>31/08/2023</p> | <p>19/06/2023</p> |

| Medicine                                                                                         | Condition being treated                                                                                                                                                                                                                 | NHSGGC Decision                                                         | Date of decision |
|--------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|------------------|
| <b>polatuzumab vedotin</b><br><br>Polivy®<br><br>SMC2524                                         | In combination with bendamustine and rituximab<br>for the treatment of adult patients with relapsed or<br>refractory diffuse large B-cell lymphoma (DLBCL)<br>who are not candidates for haematopoietic stem<br>cell transplant (HSCT). | Routinely available in line with local<br>or regional guidance          | 21/08/2023       |
| <b>Polatuzumab vedotin</b><br><br>Polivy®<br><br>SMC2282                                         | in combination with bendamustine and rituximab<br>for the treatment of adult patients with relapsed or<br>refractory diffuse large B-cell lymphoma who are<br>not candidates for haematopoietic stem cell<br>transplant.                | Routinely available in line with local<br>or regional guidance          | 31/08/2020       |
| <b>Pomalidomide</b><br><br>Imnovid®<br><br>SMC2219                                               | In combination with bortezomib and<br>dexamethasone for the treatment of adult patients<br>with multiple myeloma who have received at least<br>one prior treatment regimen including lenalidomide.                                      | Not routinely available as not<br>recommended for use in<br>NHSScotland | 12/08/2019       |
| <b>Pomalidomide in<br/>combination with<br/>bortezomib and<br/>dexamethasone</b><br><br>NCMAG120 | Treatment of adult patients with multiple myeloma<br>who have received at least one prior treatment<br>regimen including lenalidomide                                                                                                   | Routinely available in line with local<br>or regional guidance          | 28/04/2025       |

| Medicine                                                                                                                     | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | NHSGGC Decision                                                                                                                                                                 | Date of decision                               |
|------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|
| <b>Pomalidomide in combination with dexamethasone</b><br><br>NCMAG119<br><br><b>Ponesimod</b><br><br>Ponvory®<br><br>SMC2384 | Treatment of adult patients with multiple myeloma who have received one prior treatment regimen including lenalidomide, and where more effective alternatives are not suitable.<br><br>0<br><br>Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.<br><br>0<br><br>for the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children aged one year and older.<br><br>0 | Routinely available in line with local or regional guidance<br><br>Routinely available in line with national guidance<br><br>Routinely available in line with national guidance | 28/04/2025<br><br>13/06/2022<br><br>15/08/2022 |
| <b>Potassium citrate and potassium hydrogen carbonate</b><br><br>Sibnaya®<br><br>SMC2409                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                 |                                                |

| Medicine                                                    | Condition being treated                                                                                                                                                                             | NHSGGC Decision                                                                                                                                                            | Date of decision |
|-------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Pralsetinib</b><br><br>Gavreto®<br><br>SMC2496           | 0 Monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor | Routinely available in line with local or regional guidance                                                                                                                | 24/04/2023       |
| <b>Prasterone</b><br><br>Intrarosa®<br><br>SMC2255          | 0 Treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms.                                                                                               | Not routinely available as not recommended for use in NHSScotland                                                                                                          | 09/12/2019       |
| <b>Prednisolone</b><br><br>Predfoam® and generic<br><br>N/A | 0 Treatment of inflammatory bowel conditions                                                                                                                                                        | Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s) | 28/08/2017       |
| <b>progesterone</b><br><br>Utrogestan®<br><br>SMC2630       | 0 Prevention of preterm birth in women with a singleton pregnancy who have a short cervix (mid-trimester sonographic cervix ≤25 mm) and/or a history of spontaneous preterm birth.                  | Not routinely available as not recommended for use in NHSScotland                                                                                                          | 11/12/2023       |

| Medicine            | Condition being treated                                                                                                                                                                                                                                                           | NHSGGC Decision                                                                                                                                                     | Date of decision |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Progesterone</b> | Luteal support as part of an assisted reproductive technology (ART) treatment program for infertile women                                                                                                                                                                         | Routinely available in line with national guidance                                                                                                                  | 10/10/2016       |
| Lutigest®           |                                                                                                                                                                                                                                                                                   |                                                                                                                                                                     |                  |
| 1185/16             |                                                                                                                                                                                                                                                                                   |                                                                                                                                                                     |                  |
|                     | <a href="http://www.scottishmedicines.org.uk/files/advice/progesterone_Lutigest_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/progesterone_Lutigest_FINAL_Sept_2016_for_website.pdf</a>                                                       |                                                                                                                                                                     |                  |
| <b>Progesterone</b> | In adults for luteal support as part of an Assisted Reproductive Technology (ART) treatment program in infertile women who are unable to use or tolerate vaginal preparations.                                                                                                    | Routinely available in line with national guidance                                                                                                                  | 13/08/2018       |
| Lubion®             |                                                                                                                                                                                                                                                                                   |                                                                                                                                                                     |                  |
| SMC2017             |                                                                                                                                                                                                                                                                                   |                                                                                                                                                                     |                  |
|                     | <a href="https://www.scottishmedicines.org.uk/media/3560/progesterone-lubion-abbreviated-final-june-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3560/progesterone-lubion-abbreviated-final-june-2018-for-website.pdf</a>                                     |                                                                                                                                                                     |                  |
| <b>quizartinib</b>  | In combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive. | Routinely available in line with local or regional guidance                                                                                                         | 28/04/2025       |
| Vanflyta®           |                                                                                                                                                                                                                                                                                   |                                                                                                                                                                     |                  |
| SMC2699             |                                                                                                                                                                                                                                                                                   |                                                                                                                                                                     |                  |
| <b>raloxifene</b>   | Primary prevention of breast cancer in post-menopausal people at moderate or high risk who are not suitable for on-label alternatives.                                                                                                                                            | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: | 28/04/2025       |
| NCMAG114            |                                                                                                                                                                                                                                                                                   | 25/08/2025                                                                                                                                                          |                  |

| Medicine                                            | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                             | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Raltegravir</b><br><br>Isentress®<br><br>1280/17 | In combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults and paediatric patients weighing at least 40kg.                                                                                                                                                                                                                          | Routinely available in line with national guidance                | 11/12/2017       |
| <b>Raltegravir</b><br><br>Isentress®<br><br>SMC2101 | In combination with other anti-retroviral medicinal products in the treatment of human immunodeficiency virus in neonates.                                                                                                                                                                                                                                                                                          | Not routinely available as not recommended for use in NHSScotland | 13/08/2018       |
| <b>Ramucirumab</b><br><br>Cyramza®<br><br>SMC2291   | <a href="https://www.scottishmedicines.org.uk/medicines-advice/raltegravir-isentress-non-submission-smc2101/">https://www.scottishmedicines.org.uk/medicines-advice/raltegravir-isentress-non-submission-smc2101/</a><br>In combination with erlotinib for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations. | Not routinely available as not recommended for use in NHSScotland | 14/06/2021       |



| Medicine                                         | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Ramucirumab</b><br><br>Cymaza®<br><br>1176/16 | <p>- In combination with paclitaxel for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy</p> <p>- As monotherapy for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate</p> <p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1176_16_ramucirumab_Cymaza/ramucirumab_Cymaza">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1176_16_ramucirumab_Cymaza/ramucirumab_Cymaza</a></p> | Not routinely available as not recommended for use in NHSScotland | 22/08/2016       |
| <b>Ramucirumab</b><br><br>Cymaza®<br><br>1165/16 | <p>In combination with docetaxel for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.</p> <p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1165_16_ramucirumab_Cymaza/ramucirumb_Cymaza">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1165_16_ramucirumab_Cymaza/ramucirumb_Cymaza</a></p>                                                                                                                                                                                                                                                                                                                                  | Not routinely available as not recommended for use in NHSScotland | 13/06/2016       |
| <b>Ramucirumab</b><br><br>Cymaza®<br><br>1156/16 | <p>In combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) for the treatment of adult patients with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Not routinely available as not recommended for use in NHSScotland | 13/06/2016       |

| Medicine                                            | Condition being treated                                                                                                                                                                                               | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Ramucirumab</b><br><br>Cynamza®<br><br>SMC2246   | As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein of $\geq$ 400 ng/mL and who have been previously treated with sorafenib. | Not routinely available as not recommended for use in NHSScotland | 09/12/2019       |
| <b>Ranibizumab</b><br><br>Lucentis®<br><br>SMC2270  | Treatment of proliferative diabetic retinopathy in adults.                                                                                                                                                            | Not routinely available as not recommended for use in NHSScotland | 24/02/2020       |
| <b>Ranibizumab</b><br><br>Lucentis®<br><br>SMC2274  | In preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.                                        | Not routinely available as not recommended for use in NHSScotland | 06/07/2020       |
| <b>ravulizumab</b><br><br>Ultomiris®<br><br>SMC2658 | treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin 4 (AQP4) antibody-positive                                                                                     | Not routinely available as not recommended for use in NHSScotland | 19/02/2024       |

| Medicine                                            | Condition being treated                                                                                                                                                                                                                                                                         | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Ravulizumab</b><br><br>Ultomiris®<br><br>SMC2305 | Treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH):<br>- In patients with haemolysis with clinical symptom(s) indicative of high disease activity<br>- In patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. | Routinely available in line with national guidance                | 14/06/2021       |
| <b>Ravulizumab</b><br><br>Ultomiris®<br><br>SMC2330 | Treatment of patients with a body weight of 10kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.                                           | Routinely available in line with national guidance                | 14/06/2021       |
| <b>ravulizumab</b><br><br>Ultomiris®<br><br>SMC2657 | Add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.                                                                                                                           | Not routinely available as not recommended for use in NHSScotland | 19/02/2024       |
| <b>Regorafenib</b><br><br>Stivarga®<br><br>1316/18  | Monotherapy for the treatment of adult patients with hepatocellular carcinoma who have been previously treated with sorafenib.                                                                                                                                                                  | Routinely available in line with local or regional guidance       | 11/06/2018       |

| Medicine                                                             | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                  | NHSGGC Decision                                             | Date of decision |
|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Regorafenib</b><br><br>SMC2562                                    | 0 <p>Monotherapy for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.</p>                                                                                                                                           | Routinely available in line with local or regional guidance | 09/10/2023       |
| <b>Relugolix</b><br><br>Orgovyx<br>SMC 2678                          | 0 <ul style="list-style-type: none"> <li>•For the treatment of adult patients with advanced hormone-sensitive prostate cancer</li> <li>•for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy</li> <li>•as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer</li> </ul> | Routinely available in line with local or regional guidance | 28/04/2025       |
| <b>Relugolix, estradiol, norethisterone</b><br><br>Ryeqo®<br>SMC2442 | 0 <p>Treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.</p>                                                                                                                                                                                                                                                                                                                                | Routinely available in line with national guidance          | 10/10/2022       |

| Medicine                                                                         | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                  | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>relugolix, estradiol, norethisterone acetate</b><br><br>Ryeqo®<br><br>SMC2666 | In adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.                                                                                                                                                                                                                                                 | Routinely available in line with local or regional guidance       | 17/02/2025       |
| <b>remdesivir</b><br><br>Veklury®<br><br>SMC2550                                 | treatment of COVID-19 in:<br>- adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).<br>- adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19 | Routinely available in line with local or regional guidance       | 19/08/2024       |
| <b>Remimazolam</b><br><br>Byfavo®<br><br>SMC2454                                 | in adults for procedural sedation.                                                                                                                                                                                                                                                                                                                                                                                       | Not routinely available as not recommended for use in NHSScotland | 15/08/2022       |

| Medicine                                          | Condition being treated                                                                                                                                                                                                                                                                                   | NHSGGC Decision                                                         | Date of decision |
|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|------------------|
| <b>remimazolam</b><br><br>Byfavo®<br><br>SMC2692  | Adults for intravenous induction and maintenance<br>of general anaesthesia.                                                                                                                                                                                                                               | Not routinely available as not<br>recommended for use in<br>NHSScotland | 19/08/2024       |
| <b>Reslizumab</b><br><br>Cinqaero®<br><br>1233/17 | As add-on therapy in adult patients with severe<br>eosinophilic asthma inadequately controlled<br>despite high-dose inhaled corticosteroids plus<br>another medicinal product for maintenance<br>treatment.                                                                                               | Not routinely available as not<br>recommended for use in<br>NHSScotland | 11/12/2017       |
| <b>Rezafungin</b><br><br>Rezzayo<br><br>SMC 2659  | Treatment of invasive candidiasis in adults                                                                                                                                                                                                                                                               | Routinely available in line with local<br>or regional guidance          | 07/10/2024       |
| <b>Ribociclib</b><br><br>Kisqali®<br><br>SMC2198  | Treatment of women with hormone receptor (HR)-<br>positive, human epidermal growth factor receptor 2<br>(HER2)-negative locally advanced or metastatic<br>breast cancer in combination with fulvestrant* as<br>initial endocrine-based therapy, or in women who<br>have received prior endocrine therapy. | Routinely available in line with local<br>or regional guidance          | 09/12/2019       |

| Medicine                                                                                                                                                                                                                                                                          | Condition being treated                                                                                                                                                                                                                                                                                                                                        | NHSGGC Decision                                             | Date of decision |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Ribociclib</b>                                                                                                                                                                                                                                                                 | In combination with an aromatase inhibitor, for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.                                                                                           | Routinely available in line with local or regional guidance | 23/04/2018       |
| Kisqali®                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                |                                                             |                  |
| 1295/18                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                |                                                             |                  |
| <a href="https://www.scottishmedicines.org.uk/medicines-advice/ribociclib-kisqali-fullsubmission-129518/">https://www.scottishmedicines.org.uk/medicines-advice/ribociclib-kisqali-fullsubmission-129518/</a>                                                                     |                                                                                                                                                                                                                                                                                                                                                                |                                                             |                  |
| <b>Rilpivirine</b>                                                                                                                                                                                                                                                                | In combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients aged 12 to 18 years of age and older with a viral load (VL) ≤ 100,000 HIV-1 RNA copies/mL.                                                                                  | Routinely available in line with national guidance          | 22/08/2016       |
| Edurant®                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                |                                                             |                  |
| 1168/16                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                |                                                             |                  |
| <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1168_16_rilpivirine_hydrochloride_Edurant/rilpivirine_hydrochloride_Edurant">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1168_16_rilpivirine_hydrochloride_Edurant/rilpivirine_hydrochloride_Edurant</a> |                                                                                                                                                                                                                                                                                                                                                                |                                                             |                  |
| <b>Rilpivirine, Emtricitabine, Tenofovir alafenamide</b>                                                                                                                                                                                                                          | Treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg), infected with human immunodeficiency virus type 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load HIV 1 RNA ≤100,000 copies/mL. | Routinely available in line with national guidance          | 10/10/2016       |
| Odefsey®                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                |                                                             |                  |
| 1189/16                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                |                                                             |                  |
| <a href="http://www.scottishmedicines.org.uk/files/advice/rilpivirine_emtricitabine_Odefsey_Abbreviated_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/rilpivirine_emtricitabine_Odefsey_Abbreviated_FINAL_Sept_2016_for_website.pdf</a>       |                                                                                                                                                                                                                                                                                                                                                                |                                                             |                  |
| <b>Rimegepant</b>                                                                                                                                                                                                                                                                 | Preventive treatment of episodic migraine in adults who have at least four migraine attacks per month                                                                                                                                                                                                                                                          | Routinely available in line with local or regional guidance | 09/10/2023       |
| Vydura®                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                |                                                             |                  |
| SMC2603                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                |                                                             |                  |

| Medicine                                         | Condition being treated                                                                                                                                                      | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|--------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Rimegepant</b><br><br>Vydura®<br><br>SMC2567  | The preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.                                                                   | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 19/06/2023       |
| <b>Rimegepant</b><br><br>Vydura®<br><br>SMC2521  | For the acute treatment of migraine with or without aura in adults.                                                                                                          | Routinely available in line with national guidance                                                                                                                                    | 19/06/2023       |
| <b>ripretinib</b><br><br>Qinlock®<br><br>SMC2722 | Treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 28/04/2025       |
| <b>ripretinib</b><br><br>Qinlock®<br><br>SMC2821 | Treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>08/12/2025 | 06/10/2025       |



| Medicine                                           | Condition being treated                                                                                                                                                                                                                                         | NHSGGC Decision                                                          | Date of decision |
|----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|------------------|
| <b>risankizumab</b><br><br>Skyrizi®<br><br>SMC2686 | treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy                                                    | Routinely available in line with local or regional guidance              | 17/02/2025       |
| <b>risankizumab</b><br><br>Skyrizi®<br><br>SMC2534 | Treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable. | Routinely available in line with local or regional guidance              | 11/12/2023       |
| <b>Risankizumab</b><br><br>Skyrizi®<br><br>SMC2459 | Alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).          | Routinely available in line with national guidance                       | 13/06/2022       |
| <b>Risankizumab</b><br><br>Skyrizi®<br><br>SMC2196 | The treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.                                                                                                                                                         | Routinely available in line with national guidance<br><br><br>31/12/2019 | 09/12/2019       |

| Medicine                                           | Condition being treated                                                                                                                                                                                      | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Risdiplam</b><br><br>Evrysdi®<br><br>SMC2401    | Treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA type 1, type 2 or type 3 or with one to four SMN2 [survival of motor neuron 2] copies. | Routinely available in line with national guidance                | 21/02/2022       |
| <b>ritlecitinib</b><br><br>Litfulo®<br><br>SMC2610 | Treatment of severe alopecia areata in adults and adolescents 12 years of age and older.                                                                                                                     | Routinely available in line with national guidance                | 22/04/2024       |
| <b>Rituximab</b><br><br>MabThera®<br><br>SMC2165   | In combination with glucocorticoids, for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA).                          | Not routinely available as not recommended for use in NHSScotland | 29/04/2019       |
| <b>Rituximab</b><br><br>MabThera®<br><br>SMC2193   | Treatment of patients with moderate to severe pemphigus vulgaris.                                                                                                                                            | Not routinely available as not recommended for use in NHSScotland | 10/06/2019       |

| Medicine                                          | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Rivaroxaban</b><br><br>Xarelto®<br><br>SMC2128 | 0 Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with coronary artery disease at high risk of ischaemic events                                                                                                                                                                                                                                                                                                                                                                                                   | Routinely available in line with local or regional guidance       | 25/02/2019       |
| <b>Roflumilast</b><br><br>Daxas®<br><br>635/10    | 0 For maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (forced expiratory volume in one second [FEV1] post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/roflumilast_Daxas_Resubmission_FINAL_August_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/roflumilast_Daxas_Resubmission_FINAL_August_2017_for_website.pdf</a> | Not routinely available as not recommended for use in NHSScotland | 23/10/2017       |
| <b>Rolapitant</b><br><br>Varuby®<br><br>1266/17   | 0 Prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults. Rolapitant is given as part of combination therapy.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/rolapitant_Varuby_FINAL_August_2017_amended_030917_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/rolapitant_Varuby_FINAL_August_2017_amended_030917_for_website.pdf</a>                                                                                                                                | Routinely available in line with local or regional guidance       | 23/10/2017       |
| <b>Romiplostim</b><br><br>Nplate®<br><br>SMC2126  | 0 Chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins)                                                                                                                                                                                                                                                                                                                                                                                              | Routinely available in line with national guidance                | 29/04/2019       |

| Medicine                                                      | Condition being treated                                                                                  | NHSGGC Decision                                                         | Date of decision |
|---------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|------------------|
| <b>Romosozumab</b><br><br>Evenity®<br><br>SMC2280             | Treatment of severe osteoporosis in<br>postmenopausal women at high risk of fracture.                    | Routinely available in line with<br>national guidance                   | 14/12/2020       |
| <b>ropeginterferon alfa-2b</b><br><br>Besremi®<br><br>SMC2563 | Monotherapy in adults for the treatment of<br>polycythaemia vera without symptomatic<br>splenomegaly     | Not routinely available as not<br>recommended for use in<br>NHSScotland | 21/08/2023       |
| <b>Ropeginterferon alfa-2b</b><br><br>Besremi®<br><br>SMC2421 | Monotherapy in adults for the treatment of<br>polycythaemia vera without symptomatic<br>splenomegaly.    | Not routinely available as not<br>recommended for use in<br>NHSScotland | 13/06/2022       |
| <b>Roxadustat</b><br><br>Evrenzo®<br><br>SMC2461              | treatment of adult patients with symptomatic<br>anaemia associated with chronic kidney disease<br>(CKD). | Routinely available in line with local<br>or regional guidance          | 15/08/2022       |

| Medicine                                               | Condition being treated                                                                                                                                                                                                                                                                                                                                                                         | NHSGGC Decision                                                                                                                                                                                   | Date of decision |
|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>rozanolixizumab</b><br><br>Rystiggo®<br><br>SMC2761 | Add-on to standard therapy for the treatment of<br>0 generalised myasthenia gravis (gMG) in adult<br>patients who are anti-acetylcholine receptor<br>(AChR) or anti-muscle-specific tyrosine kinase<br>(MuSK) antibody positive                                                                                                                                                                 | Not routinely available as not<br>recommended for use in<br>NHSScotland                                                                                                                           | 17/02/2025       |
| <b>Rucaparib</b><br><br>Rubraca®<br><br>SMC2221        | as monotherapy treatment of adult patients with<br>0 platinum sensitive, relapsed or progressive, BRCA<br>mutated (germline and/or somatic), high-grade<br>epithelial ovarian, fallopian tube, or primary<br>peritoneal cancer, who have been treated with two<br>or more prior lines of platinum based<br>chemotherapy, and who are unable to tolerate<br>further platinum based chemotherapy. | Not routinely available as not<br>recommended for use in<br>NHSScotland                                                                                                                           | 12/08/2019       |
| <b>Rucaparib</b><br><br>Rubraca®<br><br>SMC2224        | As monotherapy for the maintenance treatment of<br>0 adult patients with platinum-sensitive relapsed high-<br>grade epithelial ovarian, fallopian tube, or primary<br>peritoneal cancer who are in response (complete or<br>partial) to platinum-based chemotherapy.                                                                                                                            | Routinely available in line with local<br>or regional guidance                                                                                                                                    | 06/07/2020       |
| <b>rucaparib</b><br><br>Rubraca®<br><br>SMC2799        | Monotherapy for the maintenance treatment of<br>0 adult patients with advanced (FIGO Stages III and<br>IV) high-grade epithelial ovarian, fallopian tube, or<br>primary peritoneal cancer who are in response<br>(complete or partial) following completion of first-<br>line platinum-based chemotherapy.                                                                                      | Not routinely available as local<br>implementation plans are being<br>developed or ADTC is waiting for<br>further advice from local clinical<br>experts - Decision expected by:<br><br>08/12/2025 | 06/10/2025       |

| Medicine                                           | Condition being treated                                                                                                                                                                                                                                                 | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Rufinamide</b><br><br>Inovelon®<br><br>SMC2146  | 0 As adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 years to ≤4 years.                                                                                                                                           | Routinely available in line with national guidance                | 29/04/2019       |
| <b>Ruxolitinib</b><br><br>Jakavi®<br><br>SMC2498   | 0 treatment of:<br>- patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids<br>- patients aged 12 years and older with chronic graft versus host disease who have inadequate response to corticosteroids | Not routinely available as not recommended for use in NHSScotland | 13/06/2022       |
| <b>Ruxolitinib</b><br><br>Jakavi®<br><br>SMC2213   | 0 The treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea (hydroxycarbamide).                                                                                                                                         | Routinely available in line with local or regional guidance       | 09/12/2019       |
| <b>ruxolitinib</b><br><br>Opzelura®<br><br>SMC2634 | 0 Treatment of non-segmental vitiligo (NSV) with facial involvement in adults and adolescents from 12 years of age.                                                                                                                                                     | Not routinely available as not recommended for use in NHSScotland | 17/06/2024       |

| Medicine                                                                                                                                                                                                                                                                                | Condition being treated                                                                                                                                                                                                                                                 | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>ruxolitinib</b><br><br>Jakavi®<br><br>SMC2750                                                                                                                                                                                                                                        | Treatment of patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids.                                                                                                                                     | Routinely available in line with national guidance                | 16/06/2025       |
| <b>Ruxolitinib phosphate</b><br><br>Jakavi®<br><br>1166/16                                                                                                                                                                                                                              | Treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.                                                                                                                                                                  | Not routinely available as not recommended for use in NHSScotland | 13/06/2016       |
| <a href="http://www.scottishmedicines.org.uk/SMCAdvice/Advice/1166_16_ruxolitinib_as_phosphate_Jakavi/ruxolitinib_Jakavi_Non_submission">http://www.scottishmedicines.org.uk/SMCAdvice/Advice/1166_16_ruxolitinib_as_phosphate_Jakavi/ruxolitinib_Jakavi_Non_submission</a>             |                                                                                                                                                                                                                                                                         |                                                                   |                  |
| <b>Sacituzumab</b><br><br>Trodelvy®<br><br>SMC2446                                                                                                                                                                                                                                      | Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior lines of systemic therapies, at least one of them given for unresectable locally advanced or metastatic disease. | Routinely available in line with local or regional guidance       | 13/06/2022       |
| <b>Sacubitril/Valsartan</b><br><br>Entresto®<br><br>1132/16                                                                                                                                                                                                                             | In adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.                                                                                                                                                                    | Routinely available in line with local or regional guidance       | 18/04/2016       |
| <a href="http://www.scottishmedicines.org.uk/SMCAdvice/Advice/1132_16_sacubitril_valartan_Entresto/Briefing_note_sacubitril_valartan_Entresto">http://www.scottishmedicines.org.uk/SMCAdvice/Advice/1132_16_sacubitril_valartan_Entresto/Briefing_note_sacubitril_valartan_Entresto</a> |                                                                                                                                                                                                                                                                         |                                                                   |                  |

| Medicine                           | Condition being treated                                                                                                                                                                                                                                                                                                                | NHSGGC Decision                        | Date of decision |
|------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|------------------|
| <b>Safinamide</b>                  | Treatment of adult patients with idiopathic                                                                                                                                                                                                                                                                                            | Not routinely available as not         | 19/06/2017       |
| <b>Xadago®</b>                     | 0 Parkinson's disease (PD) as add-on therapy to a stable dose of Levodopa alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.                                                                                                                                                          | recommended for use in NHSScotland     |                  |
| 1259/17                            | <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1259_17_safinamide_Xadago/safinamide_Xadago_Non-submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1259_17_safinamide_Xadago/safinamide_Xadago_Non-submission</a>                                                                                        |                                        |                  |
| <b>Sapropterin Dihydrochloride</b> | The treatment of hyperphenylalaninaemia (HPA) in                                                                                                                                                                                                                                                                                       | Not routinely available as not         | 13/08/2018       |
| <b>Kuvan®</b>                      | 0 adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment.                                                                                                                                                                                                        | recommended for use in NHSScotland     |                  |
| 558/09                             | <a href="https://www.scottishmedicines.org.uk/media/3652/sapropterin-kuvan-final-july-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3652/sapropterin-kuvan-final-july-2018-for-website.pdf</a>                                                                                                                      |                                        |                  |
| <b>sarilumab</b>                   | Treatment of polymyalgia rheumatica (PMR) in                                                                                                                                                                                                                                                                                           | Not routinely available as not         | 16/06/2025       |
| <b>Kevzara®</b>                    | 0 adult patients who have had an inadequate response to corticosteroids or who experience a relapse during corticosteroid taper.                                                                                                                                                                                                       | recommended for use in NHSScotland     |                  |
| SMC2810                            |                                                                                                                                                                                                                                                                                                                                        |                                        |                  |
| <b>Sarilumab</b>                   | In combination with methotrexate for the treatment                                                                                                                                                                                                                                                                                     | Routinely available in line with local | 23/04/2018       |
| <b>Kevzara®</b>                    | 0 of moderately to severely active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Sarilumab can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate. | or regional guidance                   |                  |
| 1314/18                            | <a href="https://www.scottishmedicines.org.uk/medicines-advice/sarilumab-kevzara-fullsubmission-131418/">https://www.scottishmedicines.org.uk/medicines-advice/sarilumab-kevzara-fullsubmission-131418/</a>                                                                                                                            |                                        |                  |



| Medicine                                                          | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>satralizumab</b><br><br>Enspryng®<br><br>SMC2663               | 0 Monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive.                                                                                                                                                                                                                                                                                                                                              | Not routinely available as not recommended for use in NHSScotland | 22/04/2024       |
| <b>Saxagliptin with Dapagliflozin</b><br><br>Qtern<br><br>1255/17 | 0 in adults aged 18 years and older with type 2 diabetes mellitus 1) to improve glycaemic control when metformin and/or sulphonylurea and one of the monocomponents of Qtern® do not provide adequate glycaemic control or 2) when already being treated with the free combination of dapagliflozin and saxagliptin<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/saxagliptin-dapagliflozin_Qtern_Abbreviated_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/saxagliptin-dapagliflozin_Qtern_Abbreviated_FINAL_June_2017_for_website.pdf</a> | Routinely available in line with national guidance                | 28/08/2017       |
| <b>Sebelipase alfa</b><br><br>Kanuma®<br><br>SMC2437              | 0 Long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Not routinely available as not recommended for use in NHSScotland | 13/12/2021       |
| <b>Secukinumab</b><br><br>Cosentyx®<br><br>1167/16                | 0 alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1167_16_secukinumab_Cosentyx/secukinumab_Cosentyx">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1167_16_secukinumab_Cosentyx/secukinumab_Cosentyx</a>                                                                                                                                       | Routinely available in line with national guidance                | 22/08/2016       |

| Medicine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Condition being treated                                                                                                                                                                                                                                                                                                                                                           | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>secukinumab</b><br><br>Cosentyx®<br><br>SMC2592                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0 Treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.                                                                                                                                                                                                                  | Routinely available in line with national guidance                | 19/02/2024       |
| <b>Secukinumab</b><br><br>Cosentyx®<br><br>SMC2308                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0 Treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs.                                                                                                    | Routinely available in line with national guidance                | 19/04/2021       |
| <b>Secukinumab</b><br><br>Cosentyx®<br><br>1159/16                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0 Treatment of active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy.                                                                                                                                                                                                                                                              | Routinely available in line with national guidance                | 22/08/2016       |
| <b>Selexipag</b><br><br>Uptravi<br><br>1235/17                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0 For the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II to III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies | Not routinely available as not recommended for use in NHSScotland | 28/08/2017       |
| <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1159_16_secukinumab_Cosentyx_AS/secukinumab_Cosentyx">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1159_16_secukinumab_Cosentyx_AS/secukinumab_Cosentyx</a><br><a href="http://www.scottishmedicines.org.uk/files/advice/selexipag_Uptravi_FINAL_June_2017_for_website_amended_10.08.17.pdf">http://www.scottishmedicines.org.uk/files/advice/selexipag_Uptravi_FINAL_June_2017_for_website_amended_10.08.17.pdf</a> |                                                                                                                                                                                                                                                                                                                                                                                   |                                                                   |                  |

| Medicine                                             | Condition being treated                                                                                                                                                                                                                                                                                                                                                  | NHSGGC Decision                                             | Date of decision |
|------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Selexipag</b><br><br>Uptravi®<br><br>1235/17      | Long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II to III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. | Routinely available in line with national guidance          | 11/06/2018       |
| <b>Selinexor</b><br><br>Nexpovio<br><br>SMC 2673     | In combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.                    | Routinely available in line with local or regional guidance | 17/02/2025       |
| <b>Selinexor</b><br><br>Nexpovio<br><br>SMC 2674     | In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.                                                                                                                                                                                                                 | Routinely available in line with local or regional guidance | 17/02/2025       |
| <b>Selpercatinib</b><br><br>Retsevmo®<br><br>SMC2370 | Monotherapy is indicated for the treatment of adults with advanced RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and/or lenvatinib.                                                                                                                                                                           | Routinely available in line with local or regional guidance | 18/10/2021       |

| Medicine                                             | Condition being treated                                                                                                                                                                                                     | NHSGGC Decision                                                                   | Date of decision |
|------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|------------------|
| <b>Selpercatinib</b><br><br>Retsevmo®<br><br>SMC2371 | 0 Monotherapy for the treatment of adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy | Not routinely available as not recommended for use in NHSScotland                 | 13/12/2021       |
| <b>selpercatinib</b><br><br>Retsevmo®<br><br>SMC2573 | 0 Monotherapy for the treatment of adults with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.                                | Routinely available in line with local or regional guidance                       | 11/12/2023       |
| <b>selpercatinib</b><br><br>Retsevmo®<br><br>SMC2733 | 0 Monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).                 | Routinely available in line with local or regional guidance                       | 18/08/2025       |
| <b>selpercatinib</b><br><br>Retsevmo®<br><br>SMC2732 | 0 Monotherapy for the treatment of adults and adolescents 12 years and older with advanced rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC).                                                      | Routinely available in line with local or regional guidance<br><br><br>18/08/2025 | 18/08/2025       |

| Medicine                                           | Condition being treated                                                                                                                                                                                                                                                                                                                                         | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Selumetinib</b><br><br>Koselugo®<br><br>SMC2540 | as monotherapy for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above.                                                                                                                                                                                     | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 21/08/2023       |
| <b>Semaglutide</b><br><br>Rybelsus®<br><br>SMC2287 | for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise<br>-As monotherapy when metformin is considered inappropriate due to intolerance or contraindications<br>-In combination with other medicinal products for the treatment of diabetes.                       | Routinely available in line with national guidance                                                                                                                                    | 26/10/2020       |
| <b>Semaglutide</b><br><br>Ozempic®<br><br>SMC2092  | Treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise:<br>- As monotherapy when metformin is considered inappropriate due to intolerance or contraindications<br>- In addition to other medicinal products for the treatment of diabetes.                                                       | Routinely available in line with national guidance                                                                                                                                    | 25/02/2019       |
| <b>Semaglutide</b><br><br>Wegovy<br><br>SMC2497    | An adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of<br>• ≥30kg/m <sup>2</sup> (obesity), or<br>• ≥27kg/m <sup>2</sup> to <30kg/m <sup>2</sup> (overweight) in the presence of at least one weight-related comorbidity. | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>16/02/2026 | 06/10/2025       |

| Medicine                                                  | Condition being treated                                                                                                                                                                                                                                                    | NHSGGC Decision                                                                                                                                                                                                                                                                                                     | Date of decision |
|-----------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>setmelanotide</b><br><br>Imcivree®<br><br>SMC2647      | 0 Treatment of obesity and the control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adults and children 6 years of age and above.                                                                                                        | Not routinely available as not recommended for use in NHSScotland                                                                                                                                                                                                                                                   | 19/02/2024       |
| <b>Setmelanotide</b><br><br>Imcivree®<br><br>SMC2565      | 0 Treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. | Not routinely available as not recommended for use in NHSScotland                                                                                                                                                                                                                                                   | 20/02/2023       |
| <b>Sevelamer carbonate</b><br><br>Renvela®<br><br>1304/18 | 0 Control of hyperphosphataemia in paediatric patients (>6 years of age and a Body Surface Area of >0.75m <sup>2</sup> ) with chronic kidney disease.                                                                                                                      | Routinely available in line with national guidance                                                                                                                                                                                                                                                                  | 12/02/2018       |
| <b>Siponimod</b><br><br>Mayzent®<br><br>SMC2265           | 0 Treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.                                                                                                 | <a href="http://www.scottishmedicines.org.uk/files/advice/sevelamer_carbonate_Renvela_Abbreviated_FINAL_Jan_2018_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/sevelamer_carbonate_Renvela_Abbreviated_FINAL_Jan_2018_for_website.pdf</a><br>Routinely available in line with national guidance | 14/06/2021       |

| Medicine                                                                             | Condition being treated                                                                                                                              | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Sirolimus</b><br><br><a href="#">Rapamune®</a><br><br>SMC2173                     | 0 Treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function                                 | Not routinely available as not recommended for use in NHSScotland | 08/10/2018       |
| <b>sirolimus</b><br><br><a href="#">Hyftor®</a><br><br>SMC2710                       | 0 Treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.              | Routinely available in line with national guidance                | 17/02/2025       |
| <b>sodium thiosulfate</b><br><br><a href="#">Pedmarqsi®</a><br><br>SMC2730           | 0 Prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours. | Routinely available in line with local or regional guidance       | 18/08/2025       |
| <b>Sodium zirconium cyclosilicate</b><br><br><a href="#">Lokelma®</a><br><br>SMC2288 | 0 Treatment of hyperkalaemia in adult patients.                                                                                                      | Routinely available in line with national guidance                | 26/10/2020       |

| Medicine                                                                                                                                                                                                                                                          | Condition being treated                                                                                                             | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Sodium Zirconium Cyclosilicate</b><br><br>Lokelma®<br><br>SMC2233                                                                                                                                                                                              | treatment of hyperkalaemia in adult patients<br><br>0                                                                               | Not routinely available as not recommended for use in NHSScotland | 24/02/2020       |
| <b>Sodium zirconium cyclosilicate</b><br><br>Lokelma®<br><br>SMC2515                                                                                                                                                                                              | Treatment of hyperkalaemia in adult patients<br><br>0                                                                               | Routinely available in line with national guidance                | 12/12/2022       |
| <b>Sofosbuvir</b><br><br>Sovaldi ®<br><br>1326/18                                                                                                                                                                                                                 | In combination with other medicinal products for the treatment of chronic hepatitis C in adolescents aged 12 to <18 years.<br><br>0 | Not routinely available as not recommended for use in NHSScotland | 23/04/2018       |
| <b>Sofosbuvir and Velpatasvir</b><br><br>Epclusa®<br><br>1271/17                                                                                                                                                                                                  | Treatment of chronic hepatitis C virus (HCV) infection in adults.<br><br>0                                                          | Routinely available in line with local or regional guidance       | 23/04/2018       |
| <a href="https://www.scottishmedicines.org.uk/medicines-advice/sofosbuvir-400mg-film-coated-tablets-sovaldi-non-submission-132618/">https://www.scottishmedicines.org.uk/medicines-advice/sofosbuvir-400mg-film-coated-tablets-sovaldi-non-submission-132618/</a> |                                                                                                                                     |                                                                   |                  |
| <a href="https://www.scottishmedicines.org.uk/medicines-advice/sofosbuvirvelpatasvir-epclusa-fullsubmission-127117/">https://www.scottishmedicines.org.uk/medicines-advice/sofosbuvirvelpatasvir-epclusa-fullsubmission-127117/</a>                               |                                                                                                                                     |                                                                   |                  |



| Medicine                                        | Condition being treated                                                                                                                                                                                                                                                         | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Sofosbuvir and Velpatasvir</b>               | Treatment of chronic hepatitis C virus (HCV) infection in adults.                                                                                                                                                                                                               | Routinely available in line with national guidance                | 12/12/2016       |
| Epclusa®                                        |                                                                                                                                                                                                                                                                                 |                                                                   |                  |
| 1195/16                                         |                                                                                                                                                                                                                                                                                 |                                                                   |                  |
|                                                 | <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1195_16_sofosbuvir_velpatasvir_Epclusa/sofosbuvir_velpatasvir_Epclusa">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1195_16_sofosbuvir_velpatasvir_Epclusa/sofosbuvir_velpatasvir_Epclusa</a>           |                                                                   |                  |
| <b>Sofosbuvir with Velpatasvir</b>              | Treatment of chronic hepatitis C virus (HCV) infection in adults                                                                                                                                                                                                                | Routinely available in line with national guidance                | 23/10/2017       |
| Epclusa®                                        |                                                                                                                                                                                                                                                                                 |                                                                   |                  |
| 1271/17                                         |                                                                                                                                                                                                                                                                                 |                                                                   |                  |
|                                                 | <a href="http://www.scottishmedicines.org.uk/files/advice/sofosbuvir_velpatasvir_Epclusa_FINAL_Sept_2017_05.10.17_amended_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/sofosbuvir_velpatasvir_Epclusa_FINAL_Sept_2017_05.10.17_amended_for_website.pdf</a> |                                                                   |                  |
| <b>Sofosbuvir, Velpatasvir and Voxilaprevir</b> | Treatment of chronic hepatitis C virus (HCV) infection in adults.                                                                                                                                                                                                               | Routinely available in line with national guidance                | 23/04/2018       |
| Vosevi®                                         |                                                                                                                                                                                                                                                                                 |                                                                   |                  |
| 1317/18                                         |                                                                                                                                                                                                                                                                                 |                                                                   |                  |
|                                                 | <a href="https://www.scottishmedicines.org.uk/medicines-advice/sofosbuvirvelpatasvirvoxilprevir-vosevi-fullsubmission-131718/">https://www.scottishmedicines.org.uk/medicines-advice/sofosbuvirvelpatasvirvoxilprevir-vosevi-fullsubmission-131718/</a>                         |                                                                   |                  |
| <b>Solriamfetol</b>                             | To improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).                            | Not routinely available as not recommended for use in NHSScotland | 13/06/2022       |
| Sunosi®                                         |                                                                                                                                                                                                                                                                                 |                                                                   |                  |
| SMC2419                                         |                                                                                                                                                                                                                                                                                 |                                                                   |                  |

| Medicine                                          | Condition being treated                                                                                                                                                                                                                                         | NHSGGC Decision                                             | Date of decision |
|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Solriamfetol</b><br><br>Sunosi®<br><br>SMC2439 | To improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy).<br>0                                                                                                                              | Routinely available in line with national guidance          | 15/08/2022       |
| <b>Sorafenib</b><br><br>Nexavar®<br><br>482/08    | Treatment of hepatocellular carcinoma<br>0                                                                                                                                                                                                                      | Routinely available in line with local or regional guidance | 22/02/2016       |
| <b>Sotorasib</b><br><br>Lumykras®<br><br>SMC2443  | Monotherapy for the treatment of adult patients with KRAS G12C-mutated, locally advanced or metastatic, non-small cell lung cancer (NSCLC), who have progressed on, or are intolerant to platinum-based chemotherapy and/or anti PD-1/PD-L1 immunotherapy.<br>0 | Routinely available in line with local or regional guidance | 13/06/2022       |
| <b>Sotrovimab</b><br><br>Xevudy®<br><br>SMC2555   | Treatment of symptomatic adults and adolescents (aged 12 years and over and weighing at least 40kg) with acute COVID-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID infection<br>0         | Routinely available in line with local or regional guidance | 24/04/2023       |

| Medicine                                                   | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>spesolimab</b><br><br>Spevigo®<br><br>SMC2729           | 0 Treatment of flares in adult patients with generalised pustular psoriasis (GPP) as monotherapy.                                                                                                                                                                                                                                                                                                                                                                                                                                           | Not routinely available as not recommended for use in NHSScotland | 28/04/2025       |
| <b>Stiripentol</b><br><br>Diacomit®<br><br>524/08          | 0 In conjunction with clobazam and valproate as adjunctive therapy of refractory generalised tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI; Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/stiripentol_Diacomit_Resubmission_FINAL_August_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/stiripentol_Diacomit_Resubmission_FINAL_August_2017_for_website.pdf</a> | Routinely available in line with national guidance                | 23/10/2017       |
| <b>Sufentanil citrate</b><br><br>Zalviso®<br><br>1270/17   | 0 Management of acute moderate to severe post-operative pain in adult patients.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/sufentanil_Zalviso_Non_Sub_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/sufentanil_Zalviso_Non_Sub_FINAL_July_2017_for_website.pdf</a>                                                                                                                                                                                                                | Not routinely available as not recommended for use in NHSScotland | 28/08/2017       |
| <b>sumatriptan, naproxen</b><br><br>Suvexx®<br><br>SMC2756 | 0 treatment of the headache phase of migraine attacks with or without aura in adults where treatment with a mono-entity product has been insufficient.                                                                                                                                                                                                                                                                                                                                                                                      | Not routinely available as not recommended for use in NHSScotland | 16/06/2025       |

| Medicine                                         | Condition being treated                                                                                                                                                                                  | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>sunitinib</b><br><br>NCMAG111                 | Sunitinib as second line treatment of poor or intermediate risk advanced/metastatic renal cell carcinoma in patients who have received nivolumab in combination with ipilimumab as first line treatment. | Routinely available in line with local or regional guidance       | 19/02/2024       |
| <b>Tafamidis</b><br><br>Vyndaqel®<br><br>SMC2354 | Treatment of wild-type and hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).                                                                                         | Not routinely available as not recommended for use in NHSScotland | 09/08/2021       |
| <b>Tafamidis</b><br><br>Vyndaqel®<br><br>SMC2426 | for the treatment of wild-type and hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).                                                                                 | Not routinely available as not recommended for use in NHSScotland | 13/12/2021       |
| <b>tafamidis</b><br><br>Vyndaqel®<br><br>SMC2585 | Treatment of wild-type and hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).                                                                                         | Routinely available in line with local or regional guidance       | 11/12/2023       |

| Medicine                                           | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Tafasitamab</b><br><br>Minjuvi®<br><br>SMC2522  | In combination with lenalidomide followed by tafasitamab monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).                                                                                                                                                                                                                                                                                                      | Not routinely available as not recommended for use in NHSScotland | 19/06/2023       |
| <b>talazoparib</b><br><br>Talzenna®<br><br>SMC2753 | In combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.                                                                                                                                                                                                                                                                                                                                                              | Routinely available in line with local or regional guidance       | 16/06/2025       |
| <b>talazoparib</b><br><br>Talzenna®<br><br>SMC2607 | Monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy. | Routinely available in line with local or regional guidance       | 19/08/2024       |

| Medicine                                                   | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | NHSGGC Decision                                                   | Date of decision |
|------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Talazoparib</b><br><br>Talzena®<br>SMC2325              | As monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo) adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments.<br>Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy. | Not routinely available as not recommended for use in NHSScotland | 19/04/2021       |
| <b>Talimogene laherparepvec</b><br><br>Imlygic®<br>1248/17 | Treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.                                                                                                                                                                                                                                                                                                                                                                             | Not routinely available as not recommended for use in NHSScotland | 19/06/2017       |
| <b>talquetamab</b><br><br>Talvey®<br>SMC2705               | Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy                                                                                                                                                                                                                                                       | Not routinely available as not recommended for use in NHSScotland | 19/08/2024       |

[http://www.scottishmedicines.org.uk/SMC\\_Advice/Advice/1248\\_17\\_talimogene\\_laherparepvec\\_Imlygic/talimogene\\_laherparepvec\\_Imlygic\\_Non\\_S](http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1248_17_talimogene_laherparepvec_Imlygic/talimogene_laherparepvec_Imlygic_Non_S)

| Medicine                                            | Condition being treated                                                                                                                                                                                                                                                                                | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|-----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>tamoxifen</b><br><br>NCMAG115                    | Primary prevention of breast cancer in people at moderate or high risk                                                                                                                                                                                                                                 | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>25/08/2025 | 28/04/2025       |
| <b>tebentafusp</b><br><br>Kimmtrak®<br><br>SMC2746  | Monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.                                                                                                                                                         | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 28/04/2025       |
| <b>teclistamab</b><br><br>Tecvayli®<br><br>SMC2668  | Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. | Routinely available in line with local or regional guidance                                                                                                                           | 28/04/2025       |
| <b>Teduglutide</b><br><br>Revestive®<br><br>1139/16 | Treatment of patients aged one year and above with short bowel syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.                                                                                                                                    | Routinely available in line with national guidance                                                                                                                                    | 23/04/2018       |

| Medicine                                            | Condition being treated                                                                                                                                                  | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Teduglutide</b><br><br>Revestive®<br><br>SMC2225 | for the treatment of patients age 1 year and above with short bowel syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery. | Routinely available in line with local or regional guidance       | 24/02/2020       |
| <b>Teduglutide</b><br><br>Revestive®<br><br>1139/16 | Treatment of adult patients with Short Bowel Syndrome                                                                                                                    | Not routinely available as not recommended for use in NHSScotland | 22/02/2016       |
| <b>Telotristat</b><br><br>Xermelo®<br><br>1327/18   | Treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue therapy in adults inadequately controlled by somatostatin analogue therapy.          | Routinely available in line with local or regional guidance       | 11/06/2018       |
| <b>tenecteplase</b><br><br>Metalyse®<br><br>SMC2697 | In adults for the thrombolytic treatment of acute ischaemic stroke within 4.5 hours from last known well and after exclusion of intracranial haemorrhage.                | Routinely available in line with local or regional guidance       | 09/12/2024       |



| Medicine                                                    | Condition being treated                                                                                                                                                                                                                                                                                                                                                                    | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Tenofovir alafenamide</b><br><br>Vemlidy®<br><br>1238/17 | Treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg).<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/tenofovir_alafenamide_Vemlidy_Non_Sub_FINAL_March_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/tenofovir_alafenamide_Vemlidy_Non_Sub_FINAL_March_2017_for_website.pdf</a> | Not routinely available as not recommended for use in NHSScotland | 24/04/2017       |
| <b>Tepotinib</b><br><br>Tepmetko®<br><br>SMC2535            | Treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.                                                                                                                                                                                                        | Routinely available in line with local or regional guidance       | 20/02/2023       |
| <b>Tepotinib</b><br><br>Tepmetko®<br><br>SMC2457            | treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.                                                                                                                                                                                                        | Not routinely available as not recommended for use in NHSScotland | 13/06/2022       |
| <b>Tepotinib</b><br><br>Tepmetko®<br><br>SMC2457            | Treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.                                                                                                                                                                                                        | Not routinely available as not recommended for use in NHSScotland | 15/08/2022       |

| Medicine                                                      | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                      | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Testosterone</b><br><br>Testavan®<br><br>SMC2152           | Testosterone replacement therapy for adult male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests.                                                                                                                                                                                                                                                                                                                    | Routinely available in line with national guidance                | 29/04/2019       |
| <b>Tezacaftor and Ivacaftor</b><br><br>Symkevi<br><br>SMC2183 | In a combination regimen with ivacaftor 150mg tablets for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T. | Not routinely available as not recommended for use in NHSScotland | 12/08/2019       |
| <b>tezepelumab</b><br><br>Tezspire®<br><br>SMC2541            | as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.                                                                                                                                                                                                                                       | Routinely available in line with local or regional guidance       | 21/08/2023       |

| Medicine                                                   | Condition being treated                                                                                                                                                                                    | NHSGGC Decision                                                          | Date of decision |
|------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|------------------|
| <b>Ticagrelor</b><br><br>Brilique®<br><br>1224/17          | Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction and a high risk of developing an atherothrombotic event. | Not routinely available as not recommended for use in NHSScotland        | 24/04/2017       |
| <b>Tildrakizumab</b><br><br>Ilumetri®<br><br>SMC2167       | The treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.                                                                                                  | Routinely available in line with national guidance<br><br><br>31/12/2019 | 09/12/2019       |
| <b>Tiotropium</b><br><br>Spiriva® Respimat®<br><br>SMC2118 | Add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.                           | Routinely available in line with national guidance                       | 25/02/2019       |
| <b>Tiotropium</b><br><br>Spiriva Respimat®<br><br>411/07   | As a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).                                                                               | Routinely available in line with national guidance                       | 11/12/2017       |

| Medicine                                           | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Tirbanibulin</b><br><br>Klisyri®<br><br>SMC2395 | field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.                                                                                                                                                                                                                                                                                                                                                                                        | Routinely available in line with national guidance                                                                                                                                    | 13/12/2021       |
| <b>tirzepatide</b><br><br>Mounjaro®<br><br>SMC2633 | Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:<br>- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications<br>- in addition to other medicinal products for the treatment of diabetes.                                                                                                                                                                                                               | Routinely available in line with local or regional guidance                                                                                                                           | 22/04/2024       |
| <b>tirzepatide</b><br><br>Mounjaro®<br><br>SMC2653 | For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of $\geq 30$ kg/m <sup>2</sup> (obesity) or $\geq 27$ kg/m <sup>2</sup> to $< 30$ kg/m <sup>2</sup> (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus). | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>16/02/2026 | 06/10/2025       |

| Medicine                                               | Condition being treated                                                                                                                                                                                          | NHSGGC Decision                                                         | Date of decision |
|--------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|------------------|
| <b>Tisagenlecleucel</b><br><br>Kymriah®<br><br>SMC2566 | Treatment of adult patients with relapsed or<br>refractory follicular lymphoma after two or more<br>lines of systemic therapy.                                                                                   | Not routinely available as not<br>recommended for use in<br>NHSScotland | 20/02/2023       |
| <b>Tisagenlecleucel</b><br><br>Kymriah®<br><br>SMC2141 | For adult patients with relapsed or refractory<br>diffuse large B-cell lymphoma (DLBCL) after two or<br>more lines of systemic therapy.                                                                          | Not routinely available as not<br>recommended for use in<br>NHSScotland | 29/04/2019       |
| <b>Tisagenlecleucel</b><br><br>Kymriah®<br><br>SMC2129 | Treatment of paediatric and young adult patients<br>up to 25 years of age with B-cell acute<br>lymphoblastic leukaemia (ALL) that is refractory, in<br>relapse post-transplant or in second or later<br>relapse. | Routinely available in line with<br>national guidance                   | 11/12/2023       |
| <b>Tisagenlecleucel</b><br><br>Kymriah®<br><br>SMC2200 | Adult patients with relapsed or refractory diffuse<br>large B-cell lymphoma (DLBCL) after two or more<br>lines of systemic therapy.                                                                              | Routinely available in line with local<br>or regional guidance          | 07/10/2019       |

| Medicine                                                                                                                                                                                                                                    | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Tivozanib</b><br><br>Fotivda®<br><br>1335/18                                                                                                                                                                                             | First-line treatment of adult patients with advanced renal cell carcinoma and for adult patients who are vascular endothelial growth factor receptor and mammalian target of rapamycin pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced renal cell carcinoma (RCC).<br><br><a href="https://www.scottishmedicines.org.uk/media/3562/tivozanib-fotivda-final-june-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3562/tivozanib-fotivda-final-june-2018-for-website.pdf</a> | Routinely available in line with local or regional guidance       | 13/08/2018       |
| <b>tixagevimab plus cilgavimab</b><br><br>Evusheld®<br><br>SMC2580                                                                                                                                                                          | Pre-exposure prophylaxis of COVID-19 in adults who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and:<br>- who are unlikely to mount an adequate immune response to COVID-19 vaccination or<br>- for whom COVID-19 vaccination is not recommended.                                                                                                                                                                                                                         | Not routinely available as not recommended for use in NHSScotland | 21/08/2023       |
| <b>tixagevimab, cilgavimab</b><br><br>Evusheld®<br><br>SMC2558                                                                                                                                                                              | Treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.                                                                                                                                                                                                                                                                                                                                                                                                                        | Not routinely available as not recommended for use in NHSScotland | 17/06/2024       |
| <b>Tocilizumab</b><br><br>RoActemra®<br><br>1201/16                                                                                                                                                                                         | Treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.                                                                                                                                                                                                                                                                                                                                                                                                                                           | Not routinely available as not recommended for use in NHSScotland | 10/10/2016       |
| <a href="http://www.scottishmedicines.org.uk/files/advice/tocilizumab_RoActemra_Non_Sub_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/tocilizumab_RoActemra_Non_Sub_FINAL_Sept_2016_for_website.pdf</a> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                   |                  |

| Medicine           | Condition being treated                                                                                                                                                                                                             | NHSGGC Decision                                             | Date of decision |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Tocilizumab</b> | The treatment of Giant Cell Arteritis (GCA) in adult patients                                                                                                                                                                       | Routinely available in line with local or regional guidance | 07/10/2019       |
| RoActemra®         |                                                                                                                                                                                                                                     |                                                             |                  |
| SMC2014            |                                                                                                                                                                                                                                     |                                                             |                  |
| <b>Tocilizumab</b> | Treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation                                                                     | Routinely available in line with local or regional guidance | 24/04/2023       |
| RoActemra®         |                                                                                                                                                                                                                                     |                                                             |                  |
| SMC2552            |                                                                                                                                                                                                                                     |                                                             |                  |
| <b>Tofacitinib</b> | In combination with methotrexate for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy. | Routinely available in line with local or regional guidance | 25/02/2019       |
| Xeljanz®           |                                                                                                                                                                                                                                     |                                                             |                  |
| SMC2116            |                                                                                                                                                                                                                                     |                                                             |                  |
| <b>Tofacitinib</b> | Treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy                                                                                                         | Routinely available in line with local or regional guidance | 10/10/2022       |
| Xeljanz®           |                                                                                                                                                                                                                                     |                                                             |                  |
| SMC2463            |                                                                                                                                                                                                                                     |                                                             |                  |

| Medicine                                                                           | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | NHSGGC Decision                                             | Date of decision |
|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Tofacitinib</b><br><br>Xeljanz®<br><br>SMC2122                                  | 0 Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.                                                                                                                                                                                                                                                                                                                                                                                                | Routinely available in line with local or regional guidance | 25/02/2019       |
| <b>Tofacitinib</b><br><br>Xeljanz®<br><br>1298/18                                  | 0 In combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Tofacitinib can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/tofacitinib_Xeljanz_FINAL_Jan_2018_Amended_05.02.17_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/tofacitinib_Xeljanz_FINAL_Jan_2018_Amended_05.02.17_for_website.pdf</a> | Routinely available in line with local or regional guidance | 26/02/2018       |
| <b>Tolvaptan</b><br><br>Jinarc®<br><br>1114/15                                     | 0 To slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.                                                                                                                                                                                                                                                                                                                                                     | Routinely available in line with national guidance          | 22/02/2016       |
| <b>Topotecan,Caelyx,paclitaxel,t<br/>rabectedin,gemcitabin</b><br><br>NICE MTA 389 | 0 Recurrent ovarian cancer<br><br><a href="https://www.nice.org.uk/guidance/ta389">https://www.nice.org.uk/guidance/ta389</a>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Routinely available in line with national guidance          | 13/06/2016       |



| Medicine                                            | Condition being treated                                                                                                                                                                                                               | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Trabectedin</b><br><br>Yondelis®<br><br>SMC2210  | The treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents.                                                                       | Not routinely available as not recommended for use in NHSScotland | 09/12/2019       |
| <b>Trabectedin</b><br><br>Yondelis®<br><br>SMC2283  | Treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients | Routinely available in line with local or regional guidance       | 14/12/2020       |
| <b>Tralokinumab</b><br><br>Adtralza®<br><br>SMC2403 | Treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.                                                                                                                          | Routinely available in line with national guidance                | 21/02/2022       |
| <b>Trametinib</b><br><br>Mekinist®<br><br>1161/16   | In combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation                                                                                                 | Routinely available in line with local or regional guidance       | 10/10/2016       |

[http://www.scottishmedicines.org.uk/files/advice/trametinib\\_0\\_5mg\\_and\\_2mg\\_Mekinist\\_FINAL\\_August\\_2016\\_Amended\\_02.09.16\\_for\\_website.pdf](http://www.scottishmedicines.org.uk/files/advice/trametinib_0_5mg_and_2mg_Mekinist_FINAL_August_2016_Amended_02.09.16_for_website.pdf)

| Medicine                            | Condition being treated                                                                                                                                                                                                                               | NHSGGC Decision                                                   | Date of decision |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Trametinib</b>                   | In combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.                                                                                                                | Routinely available in line with local or regional guidance       | 19/04/2021       |
| Mekinist®                           |                                                                                                                                                                                                                                                       |                                                                   |                  |
| SMC2328                             |                                                                                                                                                                                                                                                       |                                                                   |                  |
| <b>trametinib</b>                   | Treatment of low grade serous ovarian cancer after at least one line of platinum-based chemotherapy                                                                                                                                                   | Routinely available in line with local or regional guidance       | 17/02/2025       |
| NCMAG118                            |                                                                                                                                                                                                                                                       |                                                                   |                  |
| <b>Trametinib (with dabrafenib)</b> | in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation                                                                                                                 | Not routinely available as not recommended for use in NHSScotland | 28/08/2017       |
| Mekinist®                           |                                                                                                                                                                                                                                                       |                                                                   |                  |
| 1264/17                             |                                                                                                                                                                                                                                                       |                                                                   |                  |
|                                     | <a href="http://www.scottishmedicines.org.uk/files/advice/trametinib_Mekinist_Non_Submission_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/trametinib_Mekinist_Non_Submission_FINAL_June_2017_for_website.pdf</a> |                                                                   |                  |
| <b>Trastuzumab</b>                  | for treatment of adult patients with human epidermal growth factor receptor 2 (HER2) positive early breast cancer: Reduced treatment duration of 6-months, or 9 cycles, for patients categorised as lower risk (off-label duration)                   | Routinely available in line with local or regional guidance       | 20/02/2023       |
| NCMAG105                            |                                                                                                                                                                                                                                                       |                                                                   |                  |

| Medicine                                                     | Condition being treated                                                                                                                                                                                                                                         | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Trastuzumab deruxtecan</b><br><br>Enhertu®<br><br>SMC2545 | 0 Monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.                                                                                     | Routinely available in line with local or regional guidance       | 24/04/2023       |
| <b>trastuzumab deruxtecan</b><br><br>Enhertu®<br><br>SMC2854 | 0 Treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumours who have received prior treatment or who have no satisfactory alternative treatment options                                                                   | Not routinely available as not recommended for use in NHSScotland | 18/08/2025       |
| <b>Trastuzumab deruxtecan</b><br><br>Enhertu®<br><br>SMC2388 | 0 As monotherapy for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received two or more prior anti-HER2-based regimens.                                       | Routinely available in line with local or regional guidance       | 21/02/2022       |
| <b>trastuzumab deruxtecan</b><br><br>Enhertu®<br><br>SMC2706 | 0 Monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. | Not routinely available as not recommended for use in NHSScotland | 19/08/2024       |

| Medicine                                                     | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                | NHSGGC Decision                                                   | Date of decision |
|--------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>trastuzumab deruxtecan</b><br><br>Enhertu®<br><br>SMC2608 | As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.                                                                                                                                                                                | Routinely available in line with local or regional guidance       | 19/02/2024       |
| <b>trastuzumab deruxtecan</b><br><br>Enhertu®<br><br>SMC2693 | Monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.                                                                                                                                                                                                                                                             | Not routinely available as not recommended for use in NHSScotland | 19/08/2024       |
| <b>Trastuzumab emtansine</b><br><br>Kadcyla ®<br><br>990/14  | As a single agent, for the treatment of adult patients with human epidermal growth factor type 2 (HER2)-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. | Routinely available in line with local or regional guidance       | 24/04/2017       |
| <b>Trastuzumab emtansine</b><br><br>Kadcyla®<br><br>SMC2298  | As a single agent, for the adjuvant treatment of adult patients with human epidermal growth factor-2 (HER2) positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2 targeted therapy.                                                                                                                                                                               | Routinely available in line with local or regional guidance       | 14/12/2020       |

| Medicine                                                           | Condition being treated                                                                                                                                                                                                                                                                         | NHSGGC Decision                                             | Date of decision |
|--------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Treosulfan</b><br><br>Trecondi®<br><br>SMC2527                  | In combination with fludarabine as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non-malignant diseases, and in paediatric patients older than one month with malignant diseases.                 | Routinely available in line with local or regional guidance | 19/06/2023       |
| <b>Trientine tetrahydrochloride</b><br><br>Cuprior®<br><br>SMC2222 | Treatment of Wilson's disease in adults, adolescents and children ≥5 years intolerant to D-penicillamine therapy                                                                                                                                                                                | Routinely available in line with national guidance          | 09/12/2019       |
| <b>Trifarotene</b><br><br>Akliel®<br><br>SMC2441                   | Cutaneous treatment of acne vulgaris of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present.                                                                                                                            | Routinely available in line with national guidance          | 10/10/2022       |
| <b>trifluridine, tipiracil</b><br><br>Lonsurf®<br><br>SMC2654      | In combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents. | Routinely available in line with local or regional guidance | 09/12/2024       |

| Medicine                                                                   | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | NHSGGC Decision                                             | Date of decision |
|----------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Trifluridine/Tipiracil</b><br><br>Lonsurf®<br><br>SMC2329               | 0 Monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease                                                                                                                                                                                                                                                                                                                                                                                                                                    | Routinely available in line with local or regional guidance | 14/06/2021       |
| <b>Trifluridine/tipiracil hydrochloride</b><br><br>Lonsurf®<br><br>1221/17 | 0 Treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti vascular endothelial growth factor agents, and anti-epidermal growth factor receptor agents.<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1221_17_trifluridine_tipiracil_as_hydrochloride_Lonsurf/trifluridine_tipiracil_as_hydrochloride">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1221_17_trifluridine_tipiracil_as_hydrochloride_Lonsurf/trifluridine_tipiracil_as_hydrochloride</a> | Routinely available in line with local or regional guidance | 20/02/2017       |
| <b>Triptorelin</b><br><br>Decapeptyl SR®<br><br>SMC2186                    | 0 As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as premenopausal after completion of chemotherapy.                                                                                                                                                                                                                                                                                                                                                                                                                                              | Routinely available in line with local or regional guidance | 07/10/2019       |
| <b>Tucatinib</b><br><br>Tukysa®<br><br>SMC2398                             | 0 In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Routinely available in line with local or regional guidance | 21/02/2022       |

| Medicine                                               | Condition being treated                                                                                                                                                                                                                                                                          | NHSGGC Decision                                             | Date of decision |
|--------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>ublituximab</b><br><br>Briumvi®<br><br>SMC2731      | Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.                                                                                                                                                        | Routinely available in line with local or regional guidance | 17/02/2025       |
| <b>Ulipristal acetate</b><br><br>Esmya®<br><br>1128/16 | Intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.                                                                                                                                                                                    | Routinely available in line with national guidance          | 22/02/2016       |
| <b>Upadacitinib</b><br><br>Rinvoq®<br><br>SMC2510      | Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.                                                                                      | Routinely available in line with national guidance          | 10/10/2022       |
| <b>Upadacitinib</b><br><br>Rinvoq®<br><br>SMC2532      | Treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs). | Routinely available in line with national guidance          | 20/02/2023       |

| Medicine                                          | Condition being treated                                                                                                                                                                                                                                                                   | NHSGGC Decision                                             | Date of decision |
|---------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Upadacitinib</b><br><br>Rinvoq®<br><br>SMC2575 | Treatment of adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent, or for whom such therapies are not advisable.                               | Routinely available in line with national guidance          | 19/06/2023       |
| <b>Upadacitinib</b><br><br>Rinvoq®<br><br>SMC2315 | Treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate. | Routinely available in line with national guidance          | 19/04/2021       |
| <b>Upadacitinib</b><br><br>Rinvoq®<br><br>SMC2417 | Treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.                                                                                                                                                   | Routinely available in line with national guidance          | 13/06/2022       |
| <b>Upadacitinib</b><br><br>Rinvoq®<br><br>SMC2361 | Treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Upadacitinib may be used as monotherapy or in combination with methotrexate                                                                    | Routinely available in line with local or regional guidance | 14/06/2021       |



| Medicine                                                                                                                                                                                                                | Condition being treated                                                                                                                                                                                                                                                                                       | NHSGGC Decision                                    | Date of decision |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|------------------|
| <b>Upadacitinib</b><br><br>Rinvoq®<br><br>SMC2480                                                                                                                                                                       | Treatment of active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy.                                                                                                                                                                                    | Routinely available in line with national guidance | 12/12/2022       |
| <b>Upadacitinib</b><br><br>Rinvoq®<br><br>SMC2495                                                                                                                                                                       | Treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate.                     | Routinely available in line with national guidance | 12/12/2022       |
| <b>Ustekinumab</b><br><br>Stelara®<br><br>1115/15                                                                                                                                                                       | Treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.                                                                                             | Routinely available in line with national guidance | 22/02/2016       |
| <b>Ustekinumab</b><br><br>Stelara®<br><br>1250/17                                                                                                                                                                       | for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist or have medical contraindications to such therapies. | Routinely available in line with national guidance | 28/08/2017       |
| <a href="http://www.scottishmedicines.org.uk/files/advice/ustekinumab_Stelara_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/ustekinumab Stelara FINAL June 2017 for website.pdf</a> |                                                                                                                                                                                                                                                                                                               |                                                    |                  |

| Medicine                                          | Condition being treated                                                                                                                                                                                                                                            | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Ustekinumab</b><br><br>Stelara®<br><br>SMC2250 | Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies. | Routinely available in line with national guidance                | 06/07/2020       |
| <b>vamorolone</b><br><br>Agamree®<br><br>SMC2721  | Treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older.                                                                                                                                                                                 | Routinely available in line with national guidance                | 17/02/2025       |
| <b>Vedolizumab</b><br><br>Entyvio®<br><br>SMC2276 | Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.               | Routinely available in line with local or regional guidance       | 31/08/2020       |
| <b>Vedolizumab</b><br><br>Entyvio®<br><br>SMC2506 | Treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.     | Not routinely available as not recommended for use in NHSScotland | 15/08/2022       |

| Medicine                                            | Condition being treated                                                                                                                                                                                                                           | NHSGGC Decision                                             | Date of decision |
|-----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------|
| <b>Vedolizumab</b><br><br>Entyvio®<br><br>SMC2277   | Treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. | Routinely available in line with local or regional guidance | 31/08/2020       |
| <b>Velmanase alfa</b><br><br>Lamzed®<br><br>SMC2466 | Enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis                                                                                                              | Routinely available in line with national guidance          | 24/04/2023       |
| <b>Venetoclax</b><br><br>Venclyxto®<br><br>SMC2412  | In combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.                                                                 | Routinely available in line with local or regional guidance | 13/06/2022       |
| <b>Venetoclax</b><br><br>Venclyxto®<br><br>SMC2166  | in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.                                                                                          | Routinely available in line with local or regional guidance | 12/08/2019       |

| Medicine                                           | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | NHSGGC Decision                                                   | Date of decision |
|----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>Venetoclax</b><br><br>Venclyxto®<br><br>SMC2509 | In combination with low-dose cytarabine for the treatment of adult patients with newly-diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.                                                                                                                                                                                                                                                                                                                                                                                                                                       | Not routinely available as not recommended for use in NHSScotland | 12/12/2022       |
| <b>Venetoclax</b><br><br>Venclyxto®<br><br>SMC2293 | In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Routinely available in line with local or regional guidance       | 14/12/2020       |
| <b>Venetoclax</b><br><br>Venclyxto®<br><br>1249/17 | as monotherapy for the treatment of chronic lymphocytic leukaemia (CLL) either in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.<br><br><a href="http://www.scottishmedicines.org.uk/files/advice/venetoclax_Venclyxto_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/venetoclax_Venclyxto_FINAL_July_2017_for_website.pdf</a> | Routinely available in line with local or regional guidance       | 28/08/2017       |
| <b>Venetoclax</b><br><br>Venclyxto®<br><br>SMC2427 | In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Routinely available in line with local or regional guidance       | 13/06/2022       |

| Medicine                                            | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                                                    | NHSGGC Decision                                                                                                                                                            | Date of decision |
|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Vericiguat</b><br><br>Verquvo®<br><br>SMC2425    | Treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy.                                                                                                                                                                                                                                                                                               | Not routinely available as not recommended for use in NHSScotland                                                                                                          | 18/10/2021       |
| <b>Vernakalant</b><br><br>Brinavess®<br><br>1222/17 | Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults<br>- For non-surgery patients: atrial fibrillation ≤ 7 days duration<br>- For post-cardiac surgery patients: atrial fibrillation ≤ 3 days duration<br><br><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1222_17_vernakalant_Brinavess/vernakalant_Brinavess">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1222_17_vernakalant_Brinavess/vernakalant_Brinavess</a> | Not routinely available as not recommended for use in NHSScotland                                                                                                          | 20/02/2017       |
| <b>vibegron</b><br><br>Obgemsa®<br><br>SMC2696      | Symptomatic treatment of adult patients with overactive bladder (OAB) syndrome.                                                                                                                                                                                                                                                                                                                                                                                            | Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s) | 28/04/2025       |
| <b>Vinorelbine</b><br><br>NCMAG108                  | As a second- or subsequent-line treatment of patients with malignant pleural mesothelioma whose disease has progressed on or after platinum-based chemotherapy, with or without immunotherapy                                                                                                                                                                                                                                                                              | Not routinely available as not recommended for use in NHSScotland                                                                                                          | 24/04/2023       |

| Medicine                                                                     | Condition being treated                                                                                                                                                                                                        | NHSGGC Decision                                                      | Date of decision |
|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|------------------|
| <b>Voclosporin</b><br><br><a href="#">Lupkynis®</a><br><br>SMC2570           | In combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis.                                                           | Routinely available in line with local or regional guidance          | 09/10/2023       |
| <b>volanesorsen</b><br><br><a href="#">Waylivra®</a><br><br>SMC2716          | As an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate. | Not routinely available as not recommended for use in NHSScotland    | 07/10/2024       |
| <b>Volanesorsen</b><br><br><a href="#">Waylivra®</a><br><br>SMC2299          | As an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate. | Routinely available in line with national guidance                   | 09/08/2021       |
| <b>voretigene neparvovec</b><br><br><a href="#">Luxturna®</a><br><br>SMC2641 | Treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.                                     | Routinely available from a specialist centre in another health board | 19/08/2024       |

| Medicine                                                     | Condition being treated                                                                                                                                                                         | NHSGGC Decision                                                                                                                                                            | Date of decision |
|--------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Voretigene neparvovec</b><br><br>Luxturna®<br><br>SMC2228 | Treatment of adult and paediatric patients with<br>0 vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells. | Routinely available in line with national guidance                                                                                                                         | 26/10/2020       |
| <b>Vortioxetine</b><br><br>Brintellix®<br><br>1158/16        | Treatment of major depressive episodes in adults.<br>0                                                                                                                                          | Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s) | 22/08/2016       |
| <b>voxelotor</b><br><br>Oxbryta®<br><br>SMC2626              | Treatment of haemolytic anaemia due to sickle cell<br>0 disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.       | Routinely available in line with national guidance                                                                                                                         | 17/06/2024       |
| <b>Vutrisiran</b><br><br>Amvuttra®<br><br>SMC2596            | Treatment of hereditary transthyretin-mediated<br>0 amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.                                                   | Routinely available in line with local or regional guidance                                                                                                                | 09/10/2023       |

| Medicine                                                                              | Condition being treated                                                                                                                                                                                                                                                                                                                                                                                                                       | NHSGGC Decision                                                   | Date of decision |
|---------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>White birch betula verrucosa extract</b><br><br>Itulazax 12 SQ-Bet®<br><br>SMC2471 | In adult patients for the treatment of moderate-to-severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch homologous group.<br>ITULAZAX is indicated in patients with a clinical history of symptoms despite use of symptom-relieving medication and a positive test of sensitisation to a member of the birch homologous group (skin prick test and/or specific IgE).                                               | Not routinely available as not recommended for use in NHSScotland | 13/06/2022       |
| <b>Zanamivir</b><br><br>Dectova®<br><br>SMC2204                                       | Treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥ 6 months) when:<br>- the patient's influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or<br>- other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient. | Routinely available in line with national guidance                | 09/12/2019       |
| <b>zanubrutinib</b><br><br>Brukinsa®<br><br>SMC2671                                   | In combination with obinutuzumab for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.                                                                                                                                                                                                                                                            | Not routinely available as not recommended for use in NHSScotland | 17/06/2024       |



| Medicine                                            | Condition being treated                                                                                                                                                                                              | NHSGGC Decision                                                                                                                                                                       | Date of decision |
|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| <b>Zanubrutinib</b><br><br>Brukinsa®<br><br>SMC2528 | Monotherapy for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. | Routinely available in line with local or regional guidance                                                                                                                           | 12/12/2022       |
| <b>Zanubrutinib</b><br><br>Brukinsa®<br><br>SMC2600 | As monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL)                                                                                                                          | Routinely available in line with local or regional guidance                                                                                                                           | 09/10/2023       |
| <b>Zanubrutinib</b><br><br>Brukinsa®<br><br>SMC2452 | Monotherapy for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. | Not routinely available as not recommended for use in NHSScotland                                                                                                                     | 10/10/2022       |
| <b>zanubrutinib</b><br><br>Brukinsa®<br><br>SMC2819 | Monotherapy for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy                                                                                         | Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:<br><br>08/12/2025 | 06/10/2025       |

| Medicine                                            | Condition being treated                                                                                                                                                     | NHSGGC Decision                                                   | Date of decision |
|-----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------|
| <b>zanubrutinib</b><br><br>Brukinsa®<br><br>SMC2684 | 0 Monotherapy for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.                           | Routinely available in line with local or regional guidance       | 28/04/2025       |
| <b>zilucoplan</b><br><br>Zilbrysq®<br><br>SMC 2717  | 0 As an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. | Not routinely available as not recommended for use in NHSScotland | 07/10/2024       |